




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


(51) International Patent Classification ⁶ : C07C 323/60, C07D 209/86, 333/16, 333/24, 307/54, 409/06, 307/91, 307/12, 213/30, A61K 31/195, 31/40, 31/38, 31/41, 31/415, 31/34, 31/44		A1	(11) International Publication Number: WO 98/17639
			(43) International Publication Date: 30 April 1998 (30.04.98)
(21) International Application Number: PCT/EP97/05709		Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). WITTY, David, R. [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB).	
(22) International Filing Date: 10 October 1997 (10.10.97)			
(30) Priority Data:			
9621692.4 17 October 1996 (17.10.96) GB 9704581.9 5 March 1997 (05.03.97) GB 9716212.7 31 July 1997 (31.07.97) GB			
(71) Applicant (for all designated States except US): SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).		(74) Agent: VALENTINE, Jill, Barbara; SmithKline Beecham plc, Corporate Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).	
(72) Inventors; and		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(75) Inventors/Applicants (for US only): BATESON, John, Hargreaves [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). BEST, Desmond, John [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). CLARKE, Brian, Peter [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). GILPIN, Martin, Leonard [GB/GB]; SmithKline Beecham		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	

(54) Title: BETA-THIOPROPIONYL-AMINO ACID DERIVATIVES AND THEIR USE AS BETA-LACTAMASE INHIBITORS



(a)

(I)



(b)

(57) Abstract

Mercapto amino acid derivatives of formula (I), wherein R is hydrogen, a salt-forming cation of an *in vivo* hydrolysable ester-forming group; R₁ is selected from (a) and (b) in which A is a monocyclic aryl or heteroaryl ring and B is a monocyclic aryl, alicyclic or heterocyclic ring, C and D are independently -Z_p-(CR₈CR₉)_q- or -(CR₈CR₉)_q-Z_p- where p is 0 or 1, q is 0 to 3 provided that p + q in C is not 0, R₈ and R₉ are independently hydrogen or (C₁₋₆)alkyl or together represent oxo and Z is O, NR₁₀ or S(O)_x where R₁₀ is hydrogen, (C₁₋₆)alkyl or aryl(C₁₋₆)alkyl and x is 0-2, and wherein C and D are linked ortho to one another on each of the rings A and B in formula (b); R₂ is hydrogen, (C₁₋₆)alkyl or aryl(C₁₋₆)alkyl; R₃ is hydrogen, (C₁₋₆)alkyl optionally substituted by up to three halogen atoms, (C₃₋₇)cycloalkyl, fused aryl(C₃₋₇)cycloalkyl, (C₃₋₇)cycloalkyl(C₂₋₆)alkyl, (C₂₋₆)alkenyl, (C₂₋₆)alkynyl, aryl, aryl-(CH₂)_m-X-(CH₂)_n, heterocyclyl or heterocyclyl-(CH₂)_m-X-(CH₂)_n, where m is 0 to 3, n is 1 to 3 and X is O or S(O)_x where x is 0-2 or a bond; R₄ is hydrogen or an *in vivo* hydrolysable acyl group; and R₅ and R₆ are independently hydrogen and (C₁₋₆)alkyl or together represent (CH₂)_r, where r is 2 to 5; for use in treatment of bacterial infections in humans or animals by administration in combination with a β-lactam antibiotic.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

BETA-THIOPROPIONYL-AMINO ACID DERIVATIVES AND THEIR USE AS BETA-LACTAMASE INHIBITORS

This invention relates to chemical compounds having metallo- β -lactamase inhibitory and antibacterial properties. The invention also relates to methods for the preparation of such compounds, to pharmaceutical compositions containing them, and to uses thereof.

Metallo- β -lactamases confer resistance to the vast majority of β -lactam based therapies, including carbapenems and jeopardise the future use of all such agents. As a result of the increased use of carbapenems and other β -lactam antibiotics the clinical climate is becoming more favourable for the survival of clinical strains which produce metallo- β -lactamases, and metallo- β -lactamases have now been identified in common pathogens such as *Bacillus fragilis*, *Klebsiella*, *Pseudomonas aeruginosa* and *Serratia marcescens*. Emerging knowledge emphasises that metallo- β -lactamases have the potential to present a crisis situation for antimicrobial chemotherapy.

US4513009 discloses amino acid derivatives including thiorphan having enkephalinase-inhibiting, antalgic, antidiarrhea and hypotensive. Analgesic effects are disclosed for thiorphan (B.P. Roques *et al*, *Nature*, 1980, 288, 286) and for other mercapto amino acid derivatives (JO 3002-117-A). Mercapto amino acid derivatives are disclosed as inhibitors of angiotensin-converting enzyme (ACE) (J.L. Stanton, *et al*, *J. Med. Chem.*, 1983, 26, 1257, US 4053-651 and GB 2090-591); as conferring antihypotensive effects (WO 9308162); as enkephalinase (neutral endopeptidase (NEP)) inhibitors (US 4474-799 and Mimura *et al*, *J. Med. Chem.*, 1992, 35, 602 and references cited therein); as dual inhibitors of ACE and NEP (Fournie-Zaluski *et al*, *J. Med. Chem.*, 1994, 37(8), 1070, WO 9417036 and *Bioorg. Med. Chem. Lett.*, 1996, 6(17), 2097); as inhibitors of endothelin-converting enzyme (ECE) (WO 9311154, Burtenshaw, *et al*, *Bioorg. Med. Chem. Lett.*, 1993, 3(10), 1953 and Deprez *et al*, *Bioorg. Med. Chem. Lett.*, 1996, 6(19)); as metalloproteinase inhibitors (WO 9425435); and having radioprotective action and cytotoxicity (M. Hikita *et al*, *J. Radiat. Res.*, 1975, 16(3), 162 and DE2,349, 707). DE3819539 (Squibb) discloses amino acids and peptide derivatives as inhibitors of neutral endopeptidase and their use as antihypertensives and diuretics.

Other references to amino acid derivatives having the abovementioned activities include: Gordon *et al*, *Life Sciences* 1983, 33 (Supp. I), 113-6; Waller *et al*, *J. Med. Chem.* 1993, 36, 2390-2403; Saunders *et al*, *J. Comp. Aided Mole. Des.* 1987, 1, 133-42; Gomez-Monterrey *et al*, *J. Med. Chem.* 1993, 36, 87-94; Oya *et al*, *Chem. Pharm. Bull.* 1981, 29(4), 940-7; Trapani *et al*, *Biochem. Mol. Biol. Int* 1993, 31(5), 861-7; Baxter *et al*, *J. Med. Chem.* 1992, 35(20), 3718-20; Condon *et al*, *J. Med. Chem.* 1982, 25(3), 250-8; Cheung *et al*, *J. Biol. Chem.* 1980, 255(2), 401-7; Cushman *et al*,

Biochemistry 1977, 16(25), 5484-91; EP0539848, EP0419327, EP0254032, EP0355784, EP0449523, EP0153755, US5061710, US4339600, US4401677, US4199512, DE2717548, DE2711225, JP54052073, JP54063017, JP54092937, JP55055165, JP54063017, WO9407481, WO8202890, BE890398, and WO97/24341 and WO97/24342


5 both published 10 July 1997.

Other amino acid derivatives are described by: Fuchs et al., *Arzneim.-Forsch.* 1985, 35(9)1394-402, having mitochondrial dysfunction and postischemic myocardial damage activity; Rajkovic et al., *Biochem. Pharmacol.* 1984, 33(8), 1249-50, having enhancement of neutrophil response and modulation of superoxide and hydrogen peroxide production; Sakurai et al., *Chem. Pharam. Bull.* 1979, 27(12), 3022-8 forming a peptide/cytochrome P-450 heme system; and Sugiura et al., *J. Am. Chem. Soc.* 1977, 99(5), 1581-5, forming copper(II) and nickel(II) complexes.

WO97/30027 published 21 August 1997 discloses certain amino acid derivatives which have metallo- β -lactamase inhibitory properties.

15 A novel series of amino acid derivatives have now been discovered, which compounds have metallo- β -lactamase inhibitory properties, and are useful for the treatment of infections in animals.


According to the present invention there is provided a compound of formula (I) or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof:



wherein:

R is hydrogen, a salt forming cation or an *in vivo* hydrolysable ester-forming group;

25 R_1 is selected from



30 in which A is a monocyclic aryl or heteroaryl ring and B is a monocyclic aryl, alicyclic or heterocyclic ring, C and D are independently $-Z_p-(CR_8R_9)_q-$ or $-(CR_8R_9)_q-Z_p$ where p is 0 or 1, q is 0 to 3 provided that p + q in C is not 0, R_8 and R_9 are independently hydrogen or (C_{1-6}) alkyl or together represent oxo and Z is O, NR_{10} or $S(O)_x$ where R_{10}

is hydrogen, (C₁₋₆)alkyl or aryl(C₁₋₆)alkyl and x is 0-2, and wherein C and D are linked ortho to one another on each of rings A and B in formula (b);

R₂ is hydrogen, (C₁₋₆)alkyl or aryl(C₁₋₆)alkyl;

5 R₃ is hydrogen, (C₁₋₆)alkyl optionally substituted by up to three halogen atoms, (C₃₋₇)cycloalkyl, fused aryl(C₃₋₇)cycloalkyl, (C₃₋₇)cycloalkyl(C₂₋₆)alkyl, (C₂₋₆)alkenyl, (C₂₋₆)alkynyl, aryl, aryl-(CH₂)_m-X-(CH₂)_n, heterocyclyl or heterocyclyl-(CH₂)_m-X-(CH₂)_n, where m is 0 to 3, n is 1 to 3 and X is O, S(O)_x where x is 0-2 or a bond;

R₄ is hydrogen, or an *in vivo* hydrolysable acyl group; and

10 R₅ and R₆ are independently hydrogen and (C₁₋₆)alkyl or together represent (CH₂)_r where r is 2 to 5.

The compound of formula (I) may exist in a number of isomeric forms, all of which, including racemic and diastereoisomeric forms, are encompassed within the scope of the present invention.

15 It is preferred that the stereochemistry at the carbon atom marked * is D-.

The preferred stereochemistry at the carbon atom marked (+) is S.

The term 'aryl' includes phenyl and naphthyl, each optionally substituted with up to five, preferably up to three, groups selected from halogen, mercapto, (C₁₋₆)alkyl optionally substituted by 1-3 halo, phenyl, phenyl(C₁₋₆)alkyl, phenyl(C₁₋₆)alkoxy, (C₁₋₆)alkoxy optionally substituted by 1-3 halo, hydroxy(C₁₋₆)alkyl, mercapto(C₁₋₆)alkyl, hydroxy, CO₂R₇, N(R₇)₂ or CON(R₇)₂ where each R₇ is independently hydrogen, (C₁₋₆)alkyl or (C₁₋₆)alkanoyl, OCONH₂, nitro, (C₁₋₆)alkylcarbonyloxy, (C₁₋₆)alkoxycarbonyl(C₁₋₆)alkyl, formyl and (C₁₋₆)alkylcarbonyl groups.

Each alicyclic ring suitably has from 4 to 7, preferably 5 or 6, ring carbon atoms.

25 Alicyclic rings may be unsubstituted or substituted by, for example, up to five, preferably up to three, groups selected from those mentioned above for substitution on aryl.

The terms 'heterocyclyl' and 'heterocyclic' as used herein include aromatic and non-aromatic, single and fused, rings suitably containing up to four hetero-atoms in each ring selected from oxygen, nitrogen and sulphur, which rings may be unsubstituted or substituted by, for example, up to three groups selected from those mentioned above for substitution on aryl and, for non-aromatic heterocyclic rings, oxo groups. Each heterocyclic ring suitably has from 4 to 7, preferably 5 or 6, ring atoms. The term 'heteroaryl' refers to heteroaromatic heterocyclic ring or ring system, suitably having 5 or 30 6 ring atoms in each ring. A fused heterocyclic ring system may include alicyclic rings and need include only one heterocyclic ring. Examples of heterocyclyl groups include pyridyl, triazolyl, tetrazolyl, indolyl, thienyl, isoimidazolyl, thiazolyl, furanyl,

tetrahydrofuranyl, quinolinyl, imidazolidinyl and benzothienyl. Compounds within the invention containing a heterocyclyl group may occur in two or more tautomeric forms depending on the nature of the heterocyclyl group; all such tautomeric forms are included within the scope of the invention.

5 When used herein the terms 'lower alkyl', 'lower alkenyl', 'lower alkynyl' and 'alkoxy' include straight and branched chain groups containing from 1 to 6 carbon atoms, such as methyl, ethyl, propyl and butyl. A particular alkyl group is methyl.

When used herein the term 'halogen' refers to fluorine, chlorine, bromine and iodine.

10 In a preferred aspect, when R_1 is formula (a), ring A is selected from 2,5-thienyl, 2,5-furyl, 1,2-phenyl, 1,3-phenyl and 1,4-phenyl, ring B is selected from phenyl optionally substituted by one or two hydroxy or by methoxy, dimethylamino, carboxy, nitro, amino, acetylamino, trifluoromethoxy or benzyloxy, 2-furyl, 2-, 3- or 4-pyridyl, 1-tetrazolyl, 2-tetrazolyl, 1-triazolyl, 2-triazolyl, 2 thienyl and imidazolin-2,5-dione-1-yl
15 and C is selected from CH_2 , O or OCH_2 . In a more preferred aspect R_1 is 4-benzyloxyphenyl 3- or 4-substituted in the benzyl group by a substituent listed above for phenyl or naphthyl. Preferred substituents are carboxy and dimethylamino.

In another preferred aspect, when R_1 is formula (b), rings A and B are both phenyl, C is O, CH_2 or NR_{10} and D is a bond ($p+q=0$).

20 Preferred examples of R_1 include (5-benzyl)thien-2-yl, (5-benzyl)furan-2-yl, 5-(1-tetrazolylmethyl)thien-2-yl, 5-(2-tetrazolylmethyl)thien-2-yl, 5-(imidazolin-2,5-dione-1-ylmethyl)thien-2-yl, 5-(1-triazolylmethyl)thien-2-yl, 5-(2-triazolylmethyl)thien-2-yl, 3-phenoxyphenyl, 2-phenoxyphenyl, 4-phenoxyphenyl, 3-(4-hydroxybenzyl)phenyl, 3-(4-methoxybenzyl)phenyl, 4-benzyloxyphenyl, 4-(2-thienylmethoxy)phenyl, 1-fluorenyl,
25 3-(N-ethylcarbazolyl), 4-hydroxybenzyloxy-4-phenyl, 4-methoxybenzyloxy-4-phenyl, 4-dimethylaminobenzyloxy-4-phenyl, 4-carboxybenzyloxy-4-phenyl, 3-carboxybenzyloxy-4-phenyl, (2-pyridyl)-methoxy-4-phenyl, (4-pyridyl)-methoxy-4-phenyl, 5-[1-(4-carbamoyltriazolyl)-methyl]-thien-2-yl, 5-[1-(4-carboxytriazolyl)-methyl]-thien-2-yl, (2-furyl)-methoxy-4-phenyl, dibenzofuranyl, 4-(4-acetamidobenzyloxy)phenyl, 3-(3-carboxybenzyloxy)phenyl, 3-(4-carboxybenzyloxy)phenyl, 4-(3-aminobenzyloxy)phenyl,
30 4-(4-dimethylaminobenzyloxy)phenyl, 4-(4-benzyloxybenzyloxy)phenyl and 4-(4-trifluoromethoxybenzyloxy)phenyl.

Suitable examples of R_2 include hydrogen, methyl and benzyl.

R_2 is preferably hydrogen.

35 Examples of R_3 include methyl, isobutyl, phenyl- $(CH_2)_{1-5}$, phenoxyethyl, 1-indanyl, 3,4-dihydroxybenzyl, 4-hydroxycarbonyl-phenylethyl, 2-

trifluoromethylquinolin-6-yl, 4-difluoromethoxy-phenylethyl, 3-difluoromethoxy-phenylethyl and 3-methyl-2,4,5-tricarbonylimidazol-1-yl.

- Preferably R_3 is aryl-(CH₂)_m-X-(CH₂)_n, such as benzyl, 2-phenethyl or 3-phenylpropyl wherein the aryl moiety is preferably unsubstituted or substituted by (C₁₋₆) alkoxy optionally substituted by 1-3 halo. When X is S(O)_x, x is preferably 0. R_3 is most preferably 2-phenethyl.

Examples of R_4 include hydrogen, lower alkylcarbonyl, optionally substituted benzoyl or optionally substituted phenyl lower alkyl carbonyl, more preferably hydrogen and acetyl.

- R_4 is preferably hydrogen.


R_5 and R_6 are preferably independently hydrogen or methyl.

- Suitable pharmaceutically acceptable salts of the carboxylic acid group of the compound of formula (I) (or of other carboxylic acid groups which may be present as optional substituents) include those in which R is a metal ion e.g. aluminium salts, alkali metal salts (e.g. sodium, lithium or potassium salts), alkaline earth metal salts (e.g. calcium or magnesium salts), ammonium salts, and substituted ammonium salts, for example those with lower alkylamines (e.g. triethylamine), hydroxy-lower alkylamines (e.g. 2-hydroxyethylamine), bis-(2-hydroxyethyl)amine, tris-(2-hydroxyethyl)amine, lower-cycloalkylamines (e.g. dicyclohexyl-amine), or with procaine, dibenzylamine, *N,N*-dibenzyl-ethylenediamine, 1-phenamine, *N*-methylmorpholine, *N*-ethylpiperidine, *N*-benzyl-β-phenethylamine, dehydroabietylamine, ethylenediamine, *N,N'*-bishydroabietyl-ethylenediamine, bases of the pyridine type (e.g. pyridine, collidine and quinoline), and other amines which have been or can be used to form quaternary ammonium salts.

- Pharmaceutically acceptable salts may also be acid addition salts of any amino or substituted amino group(s) that may be present as optional substituents on the compound of formula (I), or of a heterocyclic group ring nitrogen atom. Suitable salts include for example hydrochlorides, sulphates, hydrogen sulphates, acetates, phosphates etc. and other pharmaceutically acceptable salts will be apparent to those skilled in the art.
- Suitable addition salts are the hydrochlorides and hydrogen sulphates.

Preferred salts are sodium salts.

- Examples of suitable pharmaceutically acceptable *in vivo* hydrolysable ester-forming groups R include those forming esters which break down readily in the human body to leave the parent acid or its salt. Suitable groups of this type include those of part formulae (i), (ii), (iii), (iv) and (v):




5

wherein R^a is hydrogen, (C₁₋₆) alkyl, (C₃₋₇) cycloalkyl, methyl, or phenyl, R^b is (C₁₋₆) alkyl, (C₁₋₆) alkoxy, phenyl, benzyl, (C₃₋₇) cycloalkyl, (C₃₋₇) cycloalkyloxy, (C₁₋₆) alkyl (C₃₋₇) cycloalkyl, 1-amino (C₁₋₆) alkyl, or 1-(C₁₋₆ alkyl)amino (C₁₋₆) alkyl; or R^a and R^b together form a 1,2-phenylene group optionally substituted by one or two methoxy groups; R^c represents (C₁₋₆) alkylene optionally substituted with a methyl or ethyl group and R^d and R^e independently represent (C₁₋₆) alkyl; R^f represents (C₁₋₆) alkyl; R^g represents hydrogen or phenyl optionally substituted by up to three groups selected from halogen, (C₁₋₆) alkyl, or (C₁₋₆) alkoxy; Q is oxygen or NH; R^h is hydrogen or (C₁₋₆) alkyl; R^i is hydrogen, (C₁₋₆) alkyl optionally substituted by halogen, (C₂₋₆) alkenyl, (C₁₋₆) alkoxy, carbonyl, aryl or heteroaryl; or R^h and R^i together form (C₁₋₆) alkylene; R^j represents hydrogen, (C₁₋₆) alkyl or (C₁₋₆) alkoxy, carbonyl; and R^k represents (C₁₋₈) alkyl, (C₁₋₈) alkoxy, (C₁₋₆) alkoxy(C₁₋₆)alkoxy or aryl.

Examples of suitable *in vivo* hydrolysable ester-forming groups include, for example, acyloxyalkyl groups such as acetoxymethyl, pivaloyloxymethyl, α -acetoxylethyl, α -pivaloyloxyethyl, 1-(cyclohexylcarbonyloxy)prop-1-yl, and (1-aminoethyl)carbonyloxymethyl; alkoxy, carbonyloxyalkyl groups, such as ethoxycarbonyloxymethyl, α -ethoxycarbonyloxyethyl and propoxycarbonyloxyethyl; dialkylaminoalkyl especially di-loweralkylamino alkyl groups such as

dimethylaminomethyl, dimethylaminoethyl, diethylaminomethyl or diethylaminoethyl; 2-(alkoxycarbonyl)-2-alkenyl groups such as 2-(isobutoxycarbonyl)pent-2-enyl and 2-(ethoxycarbonyl)but-2-enyl; and lactone groups such as phthalidyl and dimethoxyphthalidyl.

- 5 A further suitable pharmaceutically acceptable *in vivo* hydrolysable ester-forming group is that of the formula:



wherein R^k is hydrogen, C_{1-6} alkyl or phenyl.

- 10 R is preferably hydrogen.

It will be appreciated that also included within the scope of the invention are pharmaceutically acceptable salts and pharmaceutically acceptable esters, including *in vivo* hydrolysable esters, of any carboxy groups that may be present as optional substituents in compounds of formula (I).

- 15 Some compounds of formula (I) may be crystallised or recrystallised from solvents such as organic solvents. In such cases solvates may be formed. This invention includes within its scope stoichiometric solvates including hydrates as well as compounds containing variable amounts of solvents such as water that may be produced by processes such as lyophilisation. Compounds of formula (I) may be prepared in crystalline form by
20 for example dissolution of the compound in water, preferably in the minimum quantity thereof, followed by admixing of this aqueous solution with a water miscible organic solvent such as a lower aliphatic ketone such as a di- (C_{1-6}) alkyl ketone, or a (C_{1-6}) alcohol, such as acetone or ethanol.


- The compounds of formula (I) are metallo- β -lactamase inhibitors and are
25 intended for use in pharmaceutical compositions. Therefore it will readily be understood that they are preferably each provided in substantially pure form, for example at least 60% pure, more suitably at least 75% pure and preferably at least 85% pure, especially at least 95% pure particularly at least 98% pure (% are on a weight for weight basis). Impure preparations of the compounds may be used for preparing the more pure forms
30 used in the pharmaceutical compositions; these less pure preparations of the compounds should contain at least 1%, more suitably at least 5% and preferably from 10 to 59% of a compound of the formula (I) or salt, solvate or *in vivo* hydrolysable ester thereof.

The present invention also provides a process for the preparation of a compound of formula (I) as defined above, which comprises reacting a compound of formula (II)



(II)

with a compound of formula (III)



(III)

wherein W is a leaving group, Y is Y' where Y' is R₄'S or a group convertible thereto and R₁₁ is H, or Y and R₁₁ together form a bond, R^X is R or a carboxylate protecting group, X¹ is N₃ or NHR₂' and R₁', R₂', R₃', R₄', R₅' and R₆' are R₁, R₂, R₃, R₄, R₅ and R₆ or groups convertible thereto, wherein R, R₁, R₂, R₃, R₄, R₅ and R₆ are as defined in formula (I), and thereafter, where Y and R₁₁ form a bond, reacting the product with a nucleophilic sulphur reagent Y'H, where necessary, converting Y' into R₄'S, R^X, R₁', R₂', R₃' R₄', R₅' and/or R₆' into R, R₁, R₂, R₃, R₄, R₅ and/or R₆ and optionally inter-converting R, R₁, R₂, R₃, R₄, R₅ and/or R₆.

Suitable ester-forming carboxyl-protecting groups R^X other than *in vivo* hydrolysable ester forming groups are those which may be removed under conventional conditions. Such groups for R^X include methyl, ethyl, benzyl, p-methoxybenzyl, benzoylmethyl, p-nitrobenzyl, 4-pyridylmethyl, 2,2,2-trichloroethyl, 2,2,2-tribromoethyl, t-butyl, t-amyl, allyl, diphenylmethyl, triphenylmethyl, adamantyl, 2-benzyloxyphenyl, 4-methylthiophenyl, tetrahydrofur-2-yl, tetrahydropyran-2-yl, pentachlorophenyl, acetonyl, p-toluenesulphonylethyl, methoxymethyl, a silyl (such as trimethylsilyl), stannyl or phosphorus-containing group or an oxime radical of formula -N=CHR₁₂ where R₁₂ is aryl or heterocyclyl, or an *in vivo* hydrolysable ester radical such as defined above.

Certain compounds of formulae (II) and (III) may include an amino group which may be protected. Suitable amino protecting groups are those well known in the art which may be removed under conventional conditions if required without disruption of the remainder of the molecule.

Examples of amino protecting groups include (C₁₋₆) alkanoyl; benzoyl; benzyl optionally substituted in the phenyl ring by one or two substituents selected from (C₁₋₄) alkyl, (C₁₋₄) alkoxy, trifluoromethyl, halogen, or nitro; (C₁₋₄) alkoxycarbonyl; benzyloxycarbonyl or trityl substituted as for benzyl above; allyloxycarbonyl, trichloroethoxycarbonyl or chloroacetyl.

When X¹ in the compound of formula (III) is NHR₂', the compound is preferably presented as the anion prepared by treatment of the amine with an organic base such as triethylamine, pyridine or morpholine, and suitable examples of the leaving W group in

the compound of formula (II) include halo such as chloro and mixed sulphonic anhydrides such as those where W is methanesulphonyloxy, toluene-p-sulphonyloxy or trifluoromethanesulphonyloxy in mixed sulphonic anhydrides. The compound of formula (III) may be presented as the trimethylsilyl ester hydrochloride.

5 The reaction of the compounds of formula (II) and (III) is preferably carried out at ambient temperature, for example 15-25°C, in an inert solvent such as chloroform tetrahydrofuran, dichloromethane, dioxan or dimethylformamide.

When X in the compound of formula (III) is N₃, the leaving group W in the compound of formula (II) is preferably SH and the reaction is carried out at elevated
10 temperature, such as at reflux, in an inert solvent such as toluene.

Examples of Y' convertible into R₄'S include halo such as bromo which may be displaced by thiobenzoic acid or thioacetic acid.


Where R₁₁ and Y together represent a bond, the group R₄'S may be introduced by addition of a nucleophilic sulphur reagent Y'H. Y' is R₄'S or a group convertible
15 thereto. Thiolacetic acid is a suitable sulphur reagent.

Examples of groups R₁', R₂', R₃', R₄' convertible to R₁, R₂, R₃ and R₄ include those where any carboxy or amino group is protected by carboxy or amino protecting groups. Additionally, examples of R₁' convertible to R₁ include those containing ring A substituted by hydroxy which can generate R₁ groups of formula (a) where linker C is of
20 the form -O-(CR₈R₉)_q- and where ring B is an aromatic ring or heterocycle, optionally substituted. This may be effected, for example, by alkylation of the hydroxy substituent with a benzyl bromide derivative or with a heterocyclylalkyl bromide derivative. Alternatively, the hydroxy group may be coupled with a benzyl alcohol derivative or with a heterocyclylalkyl alcohol derivative in established ways, for example in the
25 presence of diethyl azodicarboxylate and triphenylphosphine (Mitsunobo et al, *Bull. Chem. Soc. Jpn.*, 1967, 40, 2380).

R₄' in the compound of formula (II) is preferably other than hydrogen, such as an acyl protecting group as described above for carboxy protecting groups, for example acetyl.

30 The acid derivative of formula (II) is preferably prepared from the corresponding free acid by treatment with strong base such as sodium hydride followed by a source of the anion leaving group W, such as oxalyl chloride where W is Cl, or hydrogen sulphide where W is SH.

The initial product of the reaction of compounds of formulae (II) and (III) is a
35 compound of formula (IV):



wherein the variables are as defined in formulae (II) and (III). Novel intermediates of formula (IV) wherein R^x is other than R when R_1' , R_2' , R_3' , R_4' , R_5' and R_6' are R_1 , R_2 , R_3 , R_4 , R_5 and R_6 also form part of the invention.

5 Compounds of formula (IV) where R_1' is $-(A)-OH$ or $-(A)-CH_2OH$ may be converted to compounds with R_1 as defined in (a) where C is $-OCH_2-$ or $-CH_2O-$ using alcohols of formula $(B')-CH_2OH$ or $(B')-OH$, respectively under Mitsunobu conditions (Synthesis 1981, 1), using a coupling reagent such as triphenyl phosphine and diethyl azodicarboxylate. B' is B or a group convertible thereto, for example where a carboxy or
10 amino substituent on B is protected.

When R^x is other than hydrogen, the carboxy group $-COOR^x$ may be deprotected, that is to say, converted to a free carboxy, carboxy salt or carboxy ester group $-COOR$ in a conventional manner, for example as described in EP0232966A.

15 Simultaneous deprotection of $-COOR^x$ and $R_4'S$ and any protecting group in R_1' may be achieved by treatment with sodium sulphide nonahydrate in water/methanol.

When it is desired to obtain a free acid or salt of the preferred isomer of the formula (I) from an isomeric mixture, this may be effected by chromatographic separation of the diastereomers of the product. Where this is an ester and/or where R_4' is other than hydrogen, the desired isomer may then be deprotected to give the
20 corresponding free acid or salt. In some cases, however, it has been found particularly convenient first to deprotect the isomeric mixture to give an isomeric mixture of the free acid or salt of formula (I), followed by fractional recrystallisation to give the desired acid or salt isomer. Where $*D$ isomer of formula (I) is desired, it is preferred to use the corresponding $*D$ isomer of the intermediate of formula (III).

25 When an enantiomerically pure form of (III) is used in the preparation of (I), the preferred diastereomer at position (+) of (I) can also be separated by chromatography. An enantiomerically pure form of (II) may also be used.


A carboxyl group may be regenerated from any of the above esters by usual methods appropriate to the particular R^x group, for example, acid- and base-catalysed
30 hydrolysis, or by enzymically-catalysed hydrolysis, or by hydrogenolysis under conditions wherein the remainder of the molecule is substantially unaffected. For example, in the case of acetonyl, by hydrolysis in acetonitrile with 0.1M aqueous potassium hydroxide solution.

35 Pharmaceutically acceptable salts may be prepared from such acids by treatment with a base, after a conventional work-up if necessary. Suitable bases include sodium hydrogen carbonate to form sodium salts.

Crystalline forms of the compounds of formula (I) where R is a salt forming cation may for example be prepared by dissolving the compound (I) in the minimum quantity of water, suitably at ambient temperature, then adding a water miscible organic solvent such as a (C₁₋₆) alcohol or ketone such as ethanol or acetone, upon which crystallisation occurs and which may be encouraged for example by cooling or trituration.

Compounds of formulae (II) and (III) are known compounds or may be prepared by procedures analogous to those described in the prior art references listed above.

R₅'/R₆' substituted compounds of formula (II) where Y is Y' and R₁₁ is H may generally be prepared from an acrylic, crotonic, β-substituted acrylic, or β,β-disubstituted acrylic acid or ester of formula (V):



in which Z is H or a hydrolysable ester forming group and the remaining variables are as previously defined, by addition of a nucleophilic sulphur reagent Y'H. Y' is R₄'S or a group convertible thereto. Thiolacetic acid is a suitable sulphur reagent. Subsequent conversion of the carboxylate group CO₂Z to a reactive acid group COW, provides the compound of structure (II).

Compounds of formula (II) where Y and R₁₁ are a bond may be obtained from compounds of formula (V) by conversion of the acid group to a leaving group COW.

Compounds of formula (V) are prepared conventionally

Novel compounds of formula (III), which are α-amino acids, may be prepared by any conventional amino acid synthesis, for example from the corresponding α-keto ester R₁'-CO-CO₂R^x via the oxime ester R₁'-C(=N-OH)-CO₂R^x by conventional routes. The α-keto ester is obtainable from the R₁'-H, R₁'-CH₂CO₂R^x or R₁'-CO₂R^x by routine methods (J. March, *vide infra*). Alternatively the compounds of formula (III) may be prepared from the aldehyde intermediate R₁'-CHO by the Strecker synthesis [cf. Advanced Organic Chemistry; Mechanism and Structure, 4th Edn, by J. March, Section 6-50, p.965; 1992, John Wiley and Sons Inc, ISBN 0-471-60180-2] or by the method of Monianari et al. (Synthesis 1979, 26). The invention also extends to novel compounds of formula (III).

A compound of formula (I) or a salt, solvate or *in vivo* hydrolysable ester thereof, may be administered in the form of a pharmaceutical composition together with a pharmaceutically acceptable carrier and the invention also relates to such compositions. The compounds of formula (I) have metallo-β-lactamase inhibitory properties, and are useful for the treatment of infections in animals, especially mammals, including humans, in particular in humans and domesticated (including farm) animals. The compounds may

be used, for example, for the treatment of infections of, *inter alia*, the respiratory tract, the urinary tract, and soft tissues and blood, especially in humans.

Accordingly, the invention further provides a method of treatment of bacterial infections in humans or animals which comprises administering, in combination with a β -lactam antibiotic, a therapeutically effective amount of a compound of formula (I) or a
5 pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof.

The compounds may be used in combination with an antibiotic partner for the treatment of infections caused by metallo- β -lactamase producing strains, in addition to those infections which are subsumed within the antibacterial spectrum of the antibiotic
10 partner. Metallo- β -lactamase producing strains include:- *Pseudomonas aeruginosa*, *Klebsiella pneumoniae*, *Xanthomonas maltophilia*, *Bacteroides fragilis*, *Serratia marcescens*, *Bacteroides distasonis*, *Pseudomonas cepacia*, *Aeromonas hydrophila*, *Aeromonas sobria*, *Aeromonas salmonicida*, *Bacillus cereus*, *Legionella gormanii* and *Flavobacterium* spp.

15 It is generally advantageous to use a compound according to the invention in admixture or conjunction with a carbapenem, penicillin, cephalosporin or other β -lactam antibiotic and that can result in a synergistic effect, because of the metallo- β -lactamase inhibitory properties of the compounds according to the invention. In such cases, the compound of formula (I) and the β -lactam antibiotic can be administered separately or in
20 the form of a single composition containing both active ingredients as discussed in more detail below. The compositions of the invention include those in a form adapted for oral, topical or parenteral use and may be used for the treatment of bacterial infection in mammals including humans. The compounds of formula (I) are particularly suitable for parenteral administration.

25 The compounds of formula (I) may be formulated for administration in any convenient way for use in human or veterinary medicine, by analogy with other antibiotics and other β -lactam antibiotic/ β -lactamase inhibitor combinations.

The composition may be formulated for administration by any route, such as oral, topical or parenteral. The compositions may be in the form of tablets, capsules, powders,
30 granules, lozenges, creams or liquid preparations, such as oral or sterile parenteral solutions or suspensions.

The topical formulations of the present invention may be presented as, for instance, ointments, creams or lotions, eye ointments and eye or ear drops, impregnated dressings and aerosols, and may contain appropriate conventional additives such as
35 preservatives, solvents to assist drug penetration and emollients in ointments and creams.

The formulations may also contain compatible conventional carriers, such as cream or ointment bases and ethanol or oleyl alcohol for lotions. Such carriers may be

present as from about 1% up to about 98% of the formulation. More usually they will form up to about 80% of the formulation.

Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example
5 syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tableting lubricants, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants, for example potato starch; or acceptable wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in normal pharmaceutical
10 practice. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives, such as suspending agents, for example sorbitol, methyl cellulose, glucose syrup, gelatin, hydroxyethyl cellulose, carboxymethyl
15 cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and, if desired, conventional flavouring or colouring agents.

20 Suppositories will contain conventional suppository bases, e.g. cocoa-butter or other glyceride.

For parenteral administration, fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, water being preferred. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In
25 preparing solutions the compound can be dissolved in water for injection and filter sterilised before filling into a suitable vial or ampoule and sealing.

Advantageously, agents such as a local anaesthetic, preservative and buffering agents can be dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. The dry
30 lyophilized powder is then sealed in the vial and an accompanying vial of water for injection may be supplied to reconstitute the liquid prior to use. Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilisation cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before
35 suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.

The compositions may contain from 0.1% by weight, preferably from 10-60% by weight, of the active material, depending on the method of administration. Where the compositions comprise dosage units, each unit will preferably contain from 50-500 mg of the active ingredient. The dosage as employed for adult human treatment will preferably range from 100 to 3000 mg per day, for instance 1500 mg per day depending on the route and frequency of administration. Such a dosage corresponds to 1.5 to 50 mg/kg per day. Suitably the dosage is from 5 to 20 mg/kg per day.

No toxicological effects are indicated when a compound of formula (I), (IA) or (IB) or a pharmaceutically acceptable salt thereof is administered in the above-mentioned dosage range.

A composition according to the invention may comprise a compound of formula (I) or a salt, solvate or *in vivo* hydrolysable ester thereof together with one or more additional active ingredients or therapeutic agents, for example a β -lactam antibiotic such as a carbapenem, penicillin or cephalosporin or pro-drug thereof. Carbapenems, penicillins, cephalosporins and other β -lactam antibiotics suitable for co-administration with the compound of formula (I) - whether by separate administration or by inclusion in the compositions according to the invention - include both those known to show instability to or to be otherwise susceptible to metallo- β -lactamases and also those known to have a degree of resistance to metallo- β -lactamases.

A serine β -lactamase inhibitor such as clavulanic acid, sulbactam or tazobactam may also be co-administered with the compound of the invention and the β -lactam antibiotic, either by separate administration, or co-formulation with one, other or both of the compounds of the invention and the β -lactam antibiotic.

Examples of carbapenems that may be co-administered with the compounds according to the invention include imipenem, meropenem, biapenem, BMS181139 ([4R-[4 α ,5 β ,6 β (R*)]]-4-[2-[(aminoiminomethyl)amino]ethyl]-3-[(2-cyanoethyl)thio]-6-(1-hydroxyethyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid), BO2727 ([4R-3[3S*,5S*(R*)],4 α ,5 β ,6 β (R*)]]-6-(1-hydroxyethyl)-3-[[5-[1-hydroxy-3-(methylamino)propyl]-3-pyrrolidinyl]thio]-4-methyl-7-oxo-1-azabicyclo[3.2.0] hept-2-ene-2-carboxylic acid monohydrochloride), ER35786 ((1R, 5S, 6S)-6-[1(R)-Hydroxymethyl]-2-[2(S)-[1(R)-hydroxy-1-[pyrrolidin-3(R)-yl] methyl]pyrrolidin-4(S)-ylsulfanyl]-1-methyl-1-carba-2-penem-3-carboxylic acid hydrochloride), S4661 ((1R,5S,6S)-2-[(3S,5S)-5-(sulfamoylaminomethyl) pyrrolidin-3-yl]thio-6-[(1R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylic acid), sanfetrinem and compounds described in WO95/11905 and WO96/34860 including sodium (5R,6S)-6-[(R)-1-hydroxyethyl]-2-(1-ethyl-5-methylpyrazol-3-yl)carbapen-2-em-3-carboxylate and *in vivo* hydrolysable esters described therein, preferably isobutyryloxymethyl (5R, 6S)-2-[1-ethyl-5-

5 methylpyrazol-3-yl]-6-[(1R)-1-hydroxyethyl]-carbapen-2-em-3-carboxylate, cyclohexyloxycarbonyloxymethyl (5R,6S)-2-(1-ethyl-5-methylpyrazol-3-yl)-6-[(R)-1-hydroxyethyl]carbapen-2-em-3-carboxylate, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl (5R, 6S)-2-[1-ethyl-5-methylpyrazol-3-yl]-6-[(1R)-1-hydroxyethyl]-carbapen-2-em-3-carboxylate or benzoyloxymethyl (5R, 6S)-2-[1-ethyl-5-methylpyrazol-3-yl]-6-[(1R)-1-hydroxyethyl]-carbapen-2-em-3-carboxylate.

10 Examples of penicillins suitable for co-administration with the compounds according to the invention include benzylpenicillin, phenoxymethylpenicillin, carbenicillin, azidocillin, propicillin, ampicillin, amoxycillin, epicillin, ticarcillin, cyclacillin, pirbenicillin, azlocillin, mezlocillin, sulbenicillin, piperacillin, and other known penicillins. The penicillins may be used in the form of pro-drugs thereof, for example as *in vivo* hydrolysable esters, for example the acetoxymethyl, pivaloyloxymethyl, α -ethoxycarbonyloxyethyl and phthalidyl esters of ampicillin, benzylpenicillin and amoxycillin; as aldehyde or ketone adducts of penicillins containing a 6- α -aminoacetamido side chain (for example hetacillin, metampicillin and analogous derivatives of amoxycillin); and as α -esters of carbenicillin and ticarcillin, for example the phenyl and indanyl α -esters.

20 Examples of cephalosporins that may be co-administered with the compounds according to the invention include, cefatrizine, cephaloridine, cephalothin, cefazolin, cephalixin, cephacetrile, cephapirin, cephmandole nafate, cephradine, 4-hydroxycephalexin, cephaloglycin, cefoperazone, cefsulodin, ceftazidime, cefuroxime, cefmetazole, cefotaxime, ceftriaxone, and other known cephalosporins, all of which may be used in the form of pro-drugs thereof.

25 Examples of β -lactam antibiotics other than penicillins and cephalosporins that may be co-administered with the compounds according to the invention include aztreonam, latamoxef (Moxalactam - Trade Mark), and other known β -lactam antibiotics, all of which may be used in the form of pro-drugs thereof.

30 Particularly suitable penicillins for co-administration with the compounds according to the invention include ampicillin, amoxycillin, carbenicillin, piperacillin, azlocillin, mezlocillin, and ticarcillin. Such penicillins may be used in the form of their pharmaceutically acceptable salts, for example their sodium salts. Alternatively, ampicillin or amoxycillin may be used in the form of fine particles of the zwitterionic form (generally as ampicillin trihydrate or amoxycillin trihydrate) for use in an injectable or infusible suspension, for example, in the manner hereinbefore described in relation to the compounds according to the invention. Amoxycillin, for example in the form of its sodium salt or the trihydrate, is particularly preferred for use in synergistic compositions according to the invention.

Particularly suitable cephalosporins for co-administration with the compounds according to the invention include cefotaxime and ceftazidime, which may be used in the form of their pharmaceutically acceptable salts, for example their sodium salts.

5 A compound of formula (I) may be administered to the patient in conjunction with a β -lactam antibiotic such as a carbapenem, penicillin or cephalosporin in a synergistically effective amount.

10 The compounds of formula (I) may suitably be administered to the patient at a daily dosage of from 0.7 to 50 mg/kg of body weight. For an adult human (of approximately 70 kg body weight), from 50 to 3000 mg, preferably from 100 to 1000 mg, of a compound according to the invention may be administered daily, suitably in from 1 to 6, preferably from 2 to 4, separate doses. Higher or lower dosages may, however, be used in accordance with clinical practice.

15 When the compositions according to the invention are presented in unit dosage form, each unit dose may suitably comprise from 25 to 1000 mg, preferably from 50 to 500 mg, of a compound according to the invention. Each unit dose may, for example, be 62.5, 100, 125, 150, 200 or 250 mg of a compound according to the invention.

20 When the compounds of formula (I) are co-administered with a penicillin, cephalosporin, carbapenem or other β -lactam antibiotic, the ratio of the amount of the compound according to the invention to the amount of the other β -lactam antibiotic may vary within a wide range. The said ratio may, for example, be from 100:1 to 1:100; more particularly, it may, for example, be from 2:1 to 1:30.

25 The amount of carbapenem, penicillin, cephalosporin or other β -lactam antibiotic in a synergistic composition according to the invention will normally be approximately similar to the amount in which it is conventionally used *per se*, for example from about 50 mg, advantageously from about 62.5 mg, to about 3000 mg per unit dose, more usually about 125, 250, 500 or 1000 mg per unit dose.

The present invention further provides a compound of formula (I) or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof for use in the treatment of bacterial infections.

30 The present invention also includes the use of a compound of formula (I) or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, in the manufacture of a medicament for the treatment of bacterial infections

35 The present invention also includes the use of a compound of formula (I) or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof as a metallo- β -lactamase inhibitor.

All the above compositions and methods may optionally include a serine β -lactamase inhibitor as above described.

The compounds of the present invention are active against metallo- β -lactamase enzymes produced by a wide range of organisms including both Gram-negative organisms and Gram-positive organisms.

The following Examples illustrate compounds useful in the present invention, and intermediates in their preparation. (All temperatures are in °C).

EXAMPLES

10 Description 1

2-(*m*-bromophenyl)-1,3-dioxolane

To a stirred solution of 3-bromobenzaldehyde (5.00g, 27.0mmol) in toluene (35 ml) was added ethylene glycol (4.52ml, 81.1mmol) and *p*-toluenesulphonic acid (0.5g). The mixture was heated to reflux for 2 hours, cooled, and washed with water and saturated sodium hydrogen carbonate solution. The organic layer was dried over MgSO₄. The solvent was removed under reduced pressure to give the desired product as a colourless oil (6.22g, 100%). δ_H (CDCl₃) 4.09 (4H, m), 5.79 (1H, s), 7.2 - 7.7 (4H) ppm.

20 Description 2

m-(1,3-dioxolan-2-yl)-benzhydrol

A stirred solution of the acetal (1.0g, 4.37 mmol) of Description 1 in dry tetrahydrofuran (50ml), under argon, was cooled to -80° and treated with a 1.6M solution of *n*-butyllithium in hexane (2.73ml, 4.37mmol). The resulting yellow solution was stirred at -80° for 0.5 hours. A solution of redistilled benzaldehyde (0.44ml, 4.37mmol) in dry tetrahydrofuran (5ml) was added over 2 minutes and the solution left to stir for 1 hour. The reaction mixture was warmed to room temperature over the next hour and then diluted with ethyl acetate and washed with water. The organic layer was dried (MgSO₄) and evaporated to afford an oil which was chromatographed on silica gel. Elution with ethyl acetate/hexane (1:2) gave the desired product as a colourless oil (0.57g, 51%). δ_H (CDCl₃) 2.23 (1H, d, J 3.5Hz), 4.1 (4H, m), 5.80 (1H, s), 5.87 (1H, d, J 3.5Hz), 7.2 - 7.6 (9H) ppm. EIMS M⁺ 256.

Description 3

35 *m*-benzyl-benzaldehyde

To a stirred, cooled (0°), solution of the alcohol (1.0g, 3.91mmol) from Description 2 in acetonitrile (10ml), under argon, was added sodium iodide (2.30g,

15.3mmol). The resulting suspension was treated with dichlorodimethylsilane (0.93ml, 7.64mmol) and allowed to remain at 0° for 5 minutes before warming to room temperature. After a further 15 minutes the mixture was diluted with ethyl acetate and washed with water and saturated sodium hydrogen carbonate solution followed by 10% sodium thiosulphate solution. The colourless organic layer was dried and evaporated to yield a brown oil which was chromatographed on silica gel. Elution with 10% ethyl acetate in hexane gave the desired product as a pale oil (0.63g, 82%). δ_H (CDCl₃) 4.07 (2H, s), 7.2 - 7.7 (9H, m), 9.99 (1H, s) ppm. EIMS M+ 196.

10 Description 4

m-benzyl-phenylglycine methyl ester

The aldehyde (0.42g, 2.14mmol) from Description 3 was converted to the crude amino acid using essentially the method of Monianari et al. (Synthesis 1979, 26), but with some changes to the final purification. The crude solid material obtained after neutralization and evaporation of the water was stirred in methanol (10ml), presaturated with hydrogen chloride gas, overnight. The methanol was removed under reduced pressure and the residue partitioned between ethyl acetate and an excess of saturated NaHCO₃ solution. The organic layer was washed with water and dried. Removal of the solvent afforded the crude product as a pale oil (56mg, 10% over 2 stages).

20 Description 5

N-(2'-acetylthiomethyl-4'-phenylbutanoyl)-*m*-benzyl-phenylglycine methyl ester.

A mixture of 2-phenylethylmalonic acid (1.8g), 40% aqueous dimethylamine (1.08ml, 1eq) and 37% aqueous formaldehyde (0.64ml, 1eq) in water (10ml) was stirred at room temperature overnight. After cooling at 0°C the solid was filtered off, washed with water and dried. The white solid was heated at 170°C for 10 minutes and cooled to room temperature. The resulting gum was dissolved in ethyl acetate (20ml), washed with 10% potassium hydrogen sulphate solution (10ml), water (2 x 10ml), saturated brine (10ml), dried (MgSO₄) and evaporated to give crude 2-methylene-4-phenylbutanoic acid. δ_H (CDCl₃) 2.55-2.90 (4H, m, 2 x CH₂), 5.65, 6.85 (2H, 2 x s, =CH_2), 7.25 (5H, m, Ph).

The solid was dissolved in thioacetic acid (1ml) and heated at 100°C for 1 hour. After evaporation the gum was dissolved in ethyl acetate (10ml) and extracted with saturated sodium hydrogen carbonate solution (2 x 10ml). The combined extracts were washed with ethyl acetate (2 x 10ml) and acidified with 10% potassium hydrogen sulphate solution (pH 3). The aqueous layer was extracted with ethyl acetate (2 x 10ml) and the combined extracts washed with water (2 x 10ml), dried (MgSO₄) and evaporated to yield 2-acetylthiomethyl-4-phenylbutanoic acid as a yellow oil (0.52g, 24%);

δ_{H} (CDCl₃) 2.00 (2H, m, CH₂), 2.71 (3H, m, CH₂, CH), 3.14 (2H, m, CH₂), 7.24 (5H, m, Ph). EIMS M^+ 252 DCIMS MNH₄⁺ 270.

To a cooled (0°), stirred solution of 2-acetylthiomethyl-4-phenylbutanoic acid (68mg, 0.27mmol) in dry tetrahydrofuran (5 ml) containing dry dimethylformamide (1 drop), was added sodium hydride (12mg of a 55% suspension in oil, 0.27mmol). The reaction mixture was allowed to reach room temperature and stirring was continued for a further 15 mins. The suspension was then recooled (0°) and treated with oxalyl chloride (28ul, 0.32mmol) and stirred at room ambient temperature for 30 mins. The resulting mixture was then evaporated *in vacuo* and the residue suspended in dry tetrahydrofuran (5 ml). The filtered solution was taken to dryness once more to afford the acid chloride as an oil.

A stirred, cooled (0°) solution of *m*-benzyl-phenylglycine methyl ester (Description 4, 56mg, 0.22mmol) in dry tetrahydrofuran (5ml) was treated with triethylamine (42ul, 0.3mmol) followed by a solution of the above acid chloride in dry tetrahydrofuran (3ml) added over 1 minute. The mixture was stirred at ambient temperature for 3 hours and then partitioned between ethyl acetate and 1M hydrochloric acid. The organic layer was washed with water and saturated brine and dried over anhydrous sodium sulphate. Evaporation of the solvent afforded crude product as an oil which was chromatographed on silica gel. Elution with 20% ethyl acetate in hexane afforded diastereoisomer A as an oil (28mg, 26%). δ_{H} (CDCl₃) 1.90 (1H, m), 2.02 (1H, m), 2.24 (3H, s), 2.27 (1H, m), 2.66 (2H, m), 3.00 (2H, m), 3.73 (3H, s), 3.99 (2H, s), 5.53 (1H, d, J 7.0 Hz), 6.41 (1H, d, J 7.0 Hz), 7.2 (14H, m) ppm. ESMS MH⁺ 490. This was followed by diastereoisomer B as an oil (26mg, 24%). δ_{H} (CDCl₃) 1.90 (2H, m), 2.33 (3H, s), 2.40 (3H, m), 3.06 (2H, m), 3.73 (3H, s), 3.98 (2H, s), 5.59 (1H, d, J 7.2 Hz), 6.57 (1H, d, J 7.2 Hz), 7.1-7.3 (14H, m) ppm. ESMS MH⁺ 490.

Description 6

m-phenoxy-phenylglycine methyl ester

m-Phenoxybenzaldehyde (3.45ml, 0.02mol) was converted to the crude amino acid using essentially the method of Monianari et al. (Synthesis 1979, 26), but with some changes to the final purification. The crude solid material obtained after neutralization and evaporation of the water was stirred in methanol (50ml), presaturated with hydrogen chloride gas, overnight. The methanol was removed under reduced pressure and the residue partitioned between ethyl acetate and an excess of saturated NaHCO₃ solution. The organic layer was washed with water and dried. Removal of the solvent afforded the crude product as a pale oil (0.48g, 9% over 2 stages). δ_{H} (CDCl₃) 1.78 (2H, br s), 3.71 (3H, s), 4.59 (1H, s), 6.9-7.4 (9H, m) ppm.

Description 7**N-(2'-acetylthiomethyl-4'-phenylbutanoyl)-*m*-phenoxy-phenylglycine methyl ester.**

To a cooled (0°), stirred solution of 2-acetylthiomethyl-4-phenylbutanoic acid, prepared as in Description 5, (252mg, 1.0mmol) in dry tetrahydrofuran (5 ml) containing
5 dry dimethylformamide (1 drop), was added sodium hydride (44mg of a 55% suspension in oil, 1.0mmol). The reaction mixture was allowed to reach room temperature and stirring was continued for a further 15 mins. The suspension was then recooled (0°) and treated with oxalyl chloride (105ul, 1.20mmol) and stirred at room ambient temperature for 30 mins. The resulting mixture was then evaporated *in vacuo* and the residue
10 suspended in dry tetrahydrofuran (5 ml). The filtered solution was taken to dryness once more to afford the acid chloride as an oil.

A stirred, cooled (0°) solution of *m*-phenoxy-phenylglycine methyl ester (Description 6, 257mg, 1.0mmol) in dry tetrahydrofuran (5ml) was treated with triethylamine (140ul, 1.0mmol) followed by a solution of the above acid chloride in dry
15 tetrahydrofuran (5ml) added over 1 minute. The mixture was stirred at ambient temperature for 3 hours and then partitioned between ethyl acetate and 1M hydrochloric acid. The organic layer was washed with water and saturated brine and dried over anhydrous sodium sulphate. Evaporation of the solvent afforded crude product as an oil which was chromatographed on silica gel. Elution with 20% ethyl acetate in hexane
20 afforded diastereoisomer A as an oil (151mg, 31%). δ_H (CDCl₃) 1.89 (1H, m), 2.02 (1H, m), 2.26 (3H, s), 2.35 (1H, m), 2.68 (2H, m), 3.01 (2H, d, J 7.0 Hz), 3.76 (3H, s), 5.54 (1H, d, J 7.0 Hz), 6.48 (1H, d, J 7.0 Hz), 7.0-7.3 (14H, m) ppm. ESMS MH⁺ 492. This was followed by diastereoisomer B as an oil (175mg, 36%). δ_H (CDCl₃) 1.90 (2H, m), 2.33 (3H, s), 2.50 (3H, m), 3.06 (2H, m), 3.75 (3H, s), 5.58 (1H, d, J 7.0 Hz), 6.60 (1H,
25 d, J 7.0 Hz), 7.0-7.3 (14H, m) ppm. ESMS MH⁺ 492.

Description 8***m*-(1,3-dioxolan-2-yl)-*p*'-methoxybenzhydrol**

A stirred solution of the acetal (3.17g, 13.8 mmol) of Description 1 in dry
30 tetrahydrofuran (60ml), under argon, was cooled to -80° and treated with a 1.6M solution of *n*-butyllithium in hexane (8.65ml, 13.8mmol). The resulting yellow solution was stirred at -80° for 0.5 hours. A solution of *p*-methoxybenzaldehyde (1.68ml, 13.8mmol) in dry tetrahydrofuran (10ml) was added over 2 minutes and the solution left to stir for 1 hour. The reaction mixture was warmed to room temperature over the next hour and then
35 diluted with ethyl acetate and washed with water. The organic layer was dried (MgSO₄) and evaporated to afford an oil which was chromatographed on silica gel. Elution with ethyl acetate/hexane (1:2) gave the desired product as a colourless oil (1.46g, 38%).

δ_H (CDCl₃) 2.17 (1H, d, J 3.5Hz), 3.79 (3H, s), 4.07 (4H, m), 5.79 (1H, s), 5.82 (1H, d, J 3.5Hz), 6.86 (2H, d, J 8.8 Hz), 7.2 - 7.5 (6H) ppm.

Description 9

5 *m*-(*p*-methoxybenzyl)-benzaldehyde

To a stirred, cooled (0°), solution of the alcohol (1.48g, 5.17mmol) from Description 8 in acetonitrile (15ml), under argon, was added sodium iodide (3.10g, 20.7mmol). The resulting suspension was treated with dichlorodimethylsilane (1.25ml, 10.34mmol) and allowed to remain at 0° for 5 minutes before warming to room
10 temperature. After a further 15 minutes the mixture was diluted with ethyl acetate and washed with water and saturated sodium hydrogen carbonate solution followed by 10% sodium thiosulphate solution. The colourless organic layer was dried and evaporated to yield a brown oil which was chromatographed on silica gel. Elution with 10% ethyl acetate in hexane gave the desired product as a pale oil (0.90g). δ_H (CDCl₃) 3.79 (3H, s),
15 4.00 (2H, s), 6.85 (2H, d, J 8.6 Hz), 7.11 (2H, d, J 8.6 Hz), 7.45 (2H, m), 7.72 (2H, m), 9.98 (1H, s) ppm. ESMS M⁺ 226.

Description 10

m-(*p*-methoxybenzyl)-phenylglycine methyl ester

The aldehyde (0.88g, 3.89mmol) from Description 9 was converted to the crude amino acid using essentially the method of Monianari et al. (Synthesis 1979, 26), but with some changes to the final purification. The crude solid material obtained after neutralization and evaporation of the water was stirred in methanol (50ml), presaturated with hydrogen chloride gas, overnight. The methanol was removed under reduced
25 pressure and the residue partitioned between ethyl acetate and an excess of saturated NaHCO₃ solution. The organic layer was washed with water and dried. Removal of the solvent afforded the crude product as a pale oil which was chromatographed on silica gel. Elution with ethyl acetate gave the desired product as an oil (122mg, 12% over 2 stages). δ_H (CDCl₃) 1.72 (2H, br s), 3.69(3H, s), 3.79 (3H, s), 3.92 (2H, s), 4.58 (1H, s), 6.83
30 (2H, d, J 8.6 Hz), 7.10 (2H, d, J 8.6 Hz), 7.25 (4H, m) ppm.

Description 11

N-(2'-acetylthiomethyl-4'-phenylbutanoyl)-*m*-(*p*-methoxybenzyl)-phenylglycine methyl ester.

35 To a cooled (0°), stirred solution of 2-acetylthiomethyl-4-phenylbutanoic acid prepared as in Description 5, (108mg, 0.43mmol) in dry tetrahydrofuran (5 ml) containing dry dimethylformamide (1 drop), was added sodium hydride (19mg of a 55%

suspension in oil, 0.43mmol). The reaction mixture was allowed to reach room temperature and stirring was continued for a further 15 mins. The suspension was then recooled (0°) and treated with oxalyl chloride (45ul, 0.52mmol) and stirred at room ambient temperature for 30 mins. The resulting mixture was then evaporated *in vacuo* and the residue suspended in dry tetrahydrofuran (5 ml). The filtered solution was taken to dryness once more to afford the acid chloride as an oil.

A stirred, cooled (0°) solution of *m*-(*p*-methoxybenzyl)-phenylglycine methyl ester (Description 10, 122mg, 0.43mmol) in dry tetrahydrofuran (5ml) was treated with triethylamine (60ul, 0.43mmol) followed by a solution of the above acid chloride in dry tetrahydrofuran (3ml) added over 1 minute. The mixture was stirred at ambient temperature for 3 hours and then partitioned between ethyl acetate and 1M hydrochloric acid. The organic layer was washed with water and saturated brine and dried over anhydrous sodium sulphate. Evaporation of the solvent afforded crude product as an oil which was chromatographed on silica gel. Elution with 20% ethyl acetate in hexane afforded diastereoisomer A as an oil (71mg, 32%). δ_H (CDCl₃) 1.90 (1H, m), 2.02 (1H, m), 2.24 (3H, s), 2.30 (1H, m), 2.72 (2H, m), 2.99 (2H, d, J 6.1 Hz), 3.74 (3H, s), 3.78 (3H, s), 3.93 (2H, s), 5.52 (1H, d, J 7.0 Hz), 6.41 (1H, d, J 7.0 Hz), 6.82 (2H, d, J 8.6 Hz), 7.09 (2H, d, J 8.6 Hz), 7.3 (9H, m) ppm. EIMS M⁺ 519. This was followed by diastereoisomer B as an oil (67mg, 30%). δ_H (CDCl₃) 1.90 (2H, m), 2.33 (3H, s), 2.50 (3H, m), 3.05 (2H, m), 3.73 (3H, s), 3.74 (3H, s), 3.98 (2H, s), 5.58 (1H, d, J 7.2 Hz), 6.55 (1H, d, J 7.2 Hz), 6.77 (2H, d, J 8.6 Hz), 7.0-7.3 (11H, m) ppm. EIMS M⁺ 519.

Description 12

m-benzyloxy-phenylglycine methyl ester

m-Benzyloxybenzaldehyde (4.24g, 0.02mol) was converted to the crude amino acid using essentially the method of Monianari et al. (Synthesis 1979, 26), but with some changes to the final purification. The crude solid material obtained after neutralization and evaporation of the water was stirred in methanol (50ml), presaturated with hydrogen chloride gas, overnight. The methanol was removed under reduced pressure and the residue partitioned between ethyl acetate and an excess of saturated NaHCO₃ solution. The organic layer was washed with water and dried. Removal of the solvent afforded the crude product as a pale oil which was purified by chromatography on silica gel. Elution with ethyl acetate gave the desired product as an oil (100mg, 2% over 2 stages). δ_H (CDCl₃) 1.70 (2H, br s), 3.70 (3H, s), 4.59 (1H, s), 5.07 (2H, s), 6.9-7.1 (3H, m), 7.2-7.4 (6H, d, J 8.6 Hz), ppm.

Description 13**N-(2'-acetylthiomethyl-4'-phenylbutanoyl)-*m*-benzyloxy-phenylglycine methyl ester.**

To a cooled (0°), stirred solution of 2-acetylthiomethyl-4-phenylbutanoic acid prepared as in Description 5, (93mg, 0.37mmol) in dry tetrahydrofuran (5 ml) containing dry dimethylformamide (1 drop), was added sodium hydride (17mg of a 55% suspension in oil, 0.37mmol). The reaction mixture was allowed to reach room temperature and stirring was continued for a further 15 mins. The suspension was then recooled (0°) and treated with oxalyl chloride (40ul, 0.44mmol) and stirred at room ambient temperature for 30 mins. The resulting mixture was then evaporated *in vacuo* and the residue suspended in dry tetrahydrofuran (5 ml). The filtered solution was taken to dryness once more to afford the acid chloride as an oil.

A stirred, cooled (0°) solution of *m*-benzyloxy-phenylglycine methyl ester (Description 12, 100mg, 0.37mmol) in dry tetrahydrofuran (5ml) was treated with triethylamine (52ul, 0.37mmol) followed by a solution of the above acid chloride in dry tetrahydrofuran (3ml) added over 1 minute. The mixture was stirred at ambient temperature for 3 hours and then partitioned between ethyl acetate and 1M hydrochloric acid. The organic layer was washed with water and saturated brine and dried over anhydrous sodium sulphate. Evaporation of the solvent afforded crude product as an oil which was chromatographed on silica gel. Elution with 20% ethyl acetate in hexane afforded a mixture of diastereoisomers as an oil (101mg, 54%). δ_H (CDCl₃) 1.90 (2H, m), 2.26 and 2.34 (3H, s), 2.4-3.1 (5H, m), 3.74 (3H, s), 5.05 and 5.08 (2H, s), 5.54 and 5.58 (1H, d, J 7.0 Hz), 6.44 and 6.59 (1H, d, J 7.0 Hz), 7.0-7.4 (14H, m) ppm.

Description 14***m*-(1,3-dioxolan-2-yl)-*p*'-benzyloxybenzhydrol**

A stirred solution of the acetal (5.00g, 21.8 mmol) of Description 1 in dry tetrahydrofuran (80ml), under argon, was cooled to -80° and treated with a 1.5M solution of *n*-butyllithium in hexane (14.6ml, 21.8mmol). The resulting yellow solution was stirred at -80° for 0.5 hours. A solution of *p*-benzyloxybenzaldehyde (4.63g, 21.8mmol) in dry tetrahydrofuran (10ml) was added over 2 minutes and the solution left to stir for 1 hour. The reaction mixture was warmed to room temperature over the next hour and then diluted with ethyl acetate and washed with water. The organic layer was dried (MgSO₄) and evaporated to afford an oil which was chromatographed on silica gel. Elution with ethyl acetate/hexane (1:2) gave the desired product as a colourless oil (3.50g, 44%). δ_H (CDCl₃) 2.19 (1H, d, J 3.5Hz), 4.07 (4H, m), 5.05 (2H, s), 5.79 (1H, s), 5.82 (1H, d, J 3.5Hz), 6.94 (2H, d, J 8.7 Hz), 7.2 - 7.5 (11H) ppm.

Description 15***m*-(*p*-benzyloxybenzyl)-benzaldehyde**

To a stirred, cooled (0°), solution of the alcohol (3.49g, 9.64mmol) from Description 14 in acetonitrile (70ml), under argon, was added sodium iodide (5.79g, 38.6mmol). The resulting suspension was treated with dichlorodimethylsilane (2.34ml, 19.3mmol) and allowed to remain at 0° for 5 minutes before warming to room temperature. After a further 15 minutes the mixture was diluted with ethyl acetate and washed with water and saturated sodium hydrogen carbonate solution followed by 10% sodium thiosulphate solution. The colourless organic layer was dried and evaporated to yield a brown oil which was chromatographed on silica gel. Elution with 10% ethyl acetate in hexane gave the desired product as a pale oil (2.19g, 75%). δ_H (CDCl₃) 4.00 (2H, s), 5.04 (2H, s), 6.94 (2H, d, J 8.6 Hz), 7.11 (2H, d, J 8.5 Hz), 7.3 - 7.5 (7H, m), 7.70 (2H, m), 9.98 (1H, s) ppm.

Description 16***m*-(*p*-hydroxybenzyl)-phenylglycine methyl ester**

The aldehyde (2.19g, 7.25mmol) from Description 15 was converted to the crude amino acid using essentially the method of Monianari et al. (Synthesis 1979, 26), but with some changes to the final purification. The crude solid material obtained after neutralization and evaporation of the water was stirred in methanol (50ml), presaturated with hydrogen chloride gas, overnight. The methanol was removed under reduced pressure and the residue partitioned between ethyl acetate and an excess of saturated NaHCO₃ solution. The organic layer was washed with water and dried. Removal of the solvent afforded the crude product as a pale oil which was chromatographed on silica gel. Elution with ethyl acetate gave the desired product as a white solid (44mg). δ_H (CD₃OD) 3.67(3H, s), 3.88 (2H, s), 4.52 (1H, s), 6.70 (2H, d, J 8.4 Hz), 7.01 (2H, d, J 8.5 Hz), 7.1-7.3 (4H, m) ppm. ESMS MH⁺ 271.

Description 17***N*-(2'-acetylthiomethyl-4'-phenylbutanoyl)-*m*-(*p*-hydroxybenzyl)-phenylglycine methyl ester.**

To a cooled (0°), stirred solution of 2-acetylthiomethyl-4-phenylbutanoic acid prepared as in Description 5, (41mg, 0.16mmol) in dry tetrahydrofuran (5 ml) containing dry dimethylformamide (1 drop), was added sodium hydride (7mg of a 55% suspension in oil, 0.16mmol). The reaction mixture was allowed to reach room temperature and stirring was continued for a further 15 mins. The suspension was then recooled (0°) and treated with oxalyl chloride (17ul, 0.19mmol) and stirred at room ambient temperature

for 30 mins. The resulting mixture was then evaporated *in vacuo* and the residue suspended in dry tetrahydrofuran (5 ml). The filtered solution was taken to dryness once more to afford the acid chloride as an oil.

A stirred, cooled (0°) solution of *m*-(*p*-hydroxybenzyl)-phenylglycine methyl ester (Description 16, 44mg, 0.16mmol) in dry tetrahydrofuran (5ml) was treated with triethylamine (22ul, 0.16mmol) followed by a solution of the above acid chloride in dry tetrahydrofuran (3ml) added over 1 minute. The mixture was stirred at ambient temperature for 3 hours and then partitioned between ethyl acetate and 1M hydrochloric acid. The organic layer was washed with water and saturated brine and dried over anhydrous sodium sulphate. Evaporation of the solvent afforded crude product as an oil which was chromatographed on silica gel. Elution with 50% ethyl acetate in hexane afforded a mixture of diastereoisomers as an oil (52mg, 64%). δ_H (CDCl₃) 1.85-2.00 (2H, m), 2.25 and 2.33 (3H, s), 2.3-2.8 (3H, m), 3.04 (2H, m), 3.74 (3H, s), 3.89 and 3.91 (2H, s), 5.01 and 5.12 (1H, s), 5.53 and 5.58 (1H, d, J 7.0 Hz), 6.61 and 6.47 (1H, d, J 7.0 Hz), 6.73 and 6.66 (2H, d, J 8.6 Hz), 7.0-7.3 (11H, m) ppm.

Description 18

1-Fluorenylmethanol

To a cooled (0°), stirred, solution of 1-fluorencarboxylic acid (2.10g, 10.0mmol) in dry tetrahydrofuran (20ml) under argon was added lithium aluminium hydride (0.19g, 5 mmol) added in portions over 10 minutes. After a further 1 hour, water was added cautiously until effervescence ceased. The reaction mixture was partitioned between ethyl acetate and water and filtered. The organic layer was washed with saturated sodium hydrogen carbonate solution followed by water and dried over MgSO₄. Evaporation of solvent gave crude product. δ_H (CDCl₃ containing CD₃OD) 3.87 (2H, s), 4.81 (2H, s), 7.2-7.75 (7H, m) ppm

Description 19

1-Fluorencarboxaldehyde

A solution of the crude alcohol from Description 18 in chloroform (130ml) was treated with activated manganese dioxide (2g) and stirred, under argon, for 10 days. The mixture was filtered through celite and the solvent removed to afford the desired product as a pale oil (0.73g, 38%). δ_H (CDCl₃) 4.29 (2H, s), 7.41 (2H, m), 7.61 (2H, m), 7.82 (2H, m), 8.06 (1H, d, J 7.3 Hz) 10.28 (1H, s) ppm.

Description 20**(1-Fluorenyl)glycine methyl ester**

The aldehyde (0.73g, 3.76mmol) from Description 19 was converted to the crude amino acid using essentially the method of Monianari et al. (Synthesis 1979, 26), but with some changes to the final purification. The crude solid material obtained after neutralization and evaporation of the water was stirred in methanol (50ml), presaturated with hydrogen chloride gas, overnight. The methanol was removed under reduced pressure and the residue partitioned between ethyl acetate and an excess of saturated NaHCO₃ solution. The organic layer was washed with water and dried. Removal of the solvent afforded the crude product as a pale oil which was chromatographed on silica gel. Elution with ethyl acetate gave the desired product as a white solid (88mg, 9% over 2 stages). δ_H (CDCl₃) 1.80 (2H, br s), 3.70(3H, s), 3.93 and 4.08 (2H, AB, J 21.7 Hz), 4.90 (1H, s), 7.3-7.8 (7H, m) ppm.

Description 21**N-(2'-acetylthiomethyl-4'-phenylbutanoyl)-(1-fluorenyl)glycine methyl ester.**

To a cooled (0°), stirred solution of 2-acetylthiomethyl-4-phenylbutanoic acid prepared as in Description 5, (88mg, 0.35mmol) in dry tetrahydrofuran (5 ml) containing dry dimethylformamide (1 drop), was added sodium hydride (15mg of a 55% suspension in oil, 0.35mmol). The reaction mixture was allowed to reach room temperature and stirring was continued for a further 15 mins. The suspension was then recooled (0°) and treated with oxalyl chloride (37ul, 0.42mmol) and stirred at room ambient temperature for 30 mins. The resulting mixture was then evaporated *in vacuo* and the residue suspended in dry tetrahydrofuran (5 ml). The filtered solution was taken to dryness once more to afford the acid chloride as an oil.

A stirred, cooled (0°) solution of (1-fluorenyl)glycine methyl ester (Description 20, 88mg, 0.35mmol) in dry tetrahydrofuran (5ml) was treated with triethylamine (49ul, 0.35mmol) followed by a solution of the above acid chloride in dry tetrahydrofuran (3ml) added over 1 minute. The mixture was stirred at ambient temperature for 3 hours and then partitioned between ethyl acetate and 1M hydrochloric acid. The organic layer was washed with water and saturated brine and dried over anhydrous sodium sulphate. Evaporation of the solvent afforded crude product as an oil which was chromatographed on silica gel. Elution with 20% ethyl acetate in hexane afforded a mixture of diastereoisomers as an oil (88mg, 52%). δ_H (CDCl₃) 1.9-2.1 (2H, m), 2.17 and 2.34 (3H, s), 2.4-2.8 (3H, m), 2.99 and 3.08 (2H, m), 3.68 and 3.75 (3H, s), 4.09 (1H, m), 5.84 and 5.87 (1H, d, J 7.0 Hz), 6.57 and 6.75 (1H, d, J 7.0 Hz), 7.0-7.8 (12H, m) ppm.

Description 22***o*-Phenoxybenzyl alcohol**

To a cooled (0°), stirred, solution of *o*-phenoxybenzoic acid (2.14g, 10.0mmol) in dry tetrahydrofuran (20ml) under argon was added lithium aluminium hydride (0.19g, 5 mmol) added in portions over 10 minutes. After a further 1 hour, water was added cautiously until effervescence ceased. The reaction mixture was partitioned between ethyl acetate and water and filtered. The organic layer was washed with saturated sodium hydrogen carbonate solution followed by water and dried over MgSO₄. Evaporation of solvent gave crude product (1.59g, 80%). δ_H (CDCl₃) 2.01 (1H, br t), 4.77 (2H, d, J 4.9 Hz), 6.9-7.5 (9H, m) ppm

Description 23***o*-Phenoxybenzaldehyde**

A solution of the crude alcohol (1.59g) from Description 22 in chloroform (25ml) was treated with activated manganese dioxide (4g) and stirred, under argon, for 10 days. The mixture was filtered through celite and the solvent removed to afford the desired product as a yellow oil (1.44g, 92%). δ_H (CDCl₃) 6.9-8.0 (9H, m), 10.54 (1H, s) ppm.

Description 24***o*-Phenoxyphenylglycine methyl ester**

The aldehyde (1.44g, 7.27mmol) from Description 23 was converted to the crude amino acid using essentially the method of Monianari et al. (Synthesis 1979, 26), but with some changes to the final purification. The crude solid material obtained after neutralization and evaporation of the water was stirred in methanol (35ml), presaturated with hydrogen chloride gas, overnight. The methanol was removed under reduced pressure and the residue partitioned between ethyl acetate and an excess of saturated NaHCO₃ solution. The organic layer was washed with water and dried. Removal of the solvent afforded the crude product as a pale oil which was chromatographed on silica gel. Elution with ethyl acetate gave the desired product as an oil (80mg, 4% over 2 stages). δ_H (CDCl₃) 1.66 (2H, br s), 3.61 (3H, s), 4.82 (1H, s), 6.89 (1H, d, J 8.0 Hz), 6.99 (2H, d, J 7.5 Hz), 7.1-7.4 (6H, m) ppm.

Description 25**N-(2'-acetylthiomethyl-4'-phenylbutanoyl)-*o*-phenoxy-phenylglycine methyl ester.**

To a cooled (0°), stirred solution of 2-acetylthiomethyl-4-phenylbutanoic acid prepared as in Description 5, (78mg, 0.31mmol) in dry tetrahydrofuran (5 ml) containing dry dimethylformamide (1 drop), was added sodium hydride (14mg of a 55% suspension

in oil, 0.31mmol). The reaction mixture was allowed to reach room temperature and stirring was continued for a further 15 mins. The suspension was then recooled (0°) and treated with oxalyl chloride (33ul, 0.37mmol) and stirred at room ambient temperature for 30 mins. The resulting mixture was then evaporated *in vacuo* and the residue
5 suspended in dry tetrahydrofuran (5 ml). The filtered solution was taken to dryness once more to afford the acid chloride as an oil.

A stirred, cooled (0°) solution of *o*-phenoxy-phenylglycine methyl ester (Description 24, 80mg, 0.31mmol) in dry tetrahydrofuran (5ml) was treated with triethylamine (44ul, 0.31mmol) followed by a solution of the above acid chloride in dry
10 tetrahydrofuran (3ml) added over 1 minute. The mixture was stirred at ambient temperature for 3 hours and then partitioned between ethyl acetate and 1M hydrochloric acid. The organic layer was washed with water and saturated brine and dried over anhydrous sodium sulphate. Evaporation of the solvent afforded crude product as an oil which was chromatographed on silica gel. Elution with 20% ethyl acetate in hexane
15 afforded diastereoisomer A as an oil (41mg, 27%). δ_H (CDCl₃) 1.86 (1H, m), 2.03 (1H, m), 2.23 (3H, s), 2.32 (1H, m), 2.73 (2H, m), 3.00 (2H, d, J 7.8 Hz), 3.61 (3H, s), 5.87 (1H, d, J 8.1 Hz), 6.65 (1H, d, J 8.1 Hz), 6.87 (1H, dd, J 8.0 and 1.0 Hz), 6.99 (2H, d, J 7.8 Hz), 7.1-7.5 (11H, m) ppm. CIMS MH⁺ 492. This was followed by diastereoisomer B as an oil (51mg, 34%). δ_H (CDCl₃) 1.90 (2H, m), 2.32 (3H, s), 2.50 (3H, m), 3.08
20 (2H, m), 3.60 (3H, s), 5.87 (1H, d, J 7.9 Hz), 6.75 (1H, d, J 7.9 Hz), 6.8-7.5 (14H, m) ppm. CIMS MH⁺ 492.

Description 26

p-Phenoxyphenylglycine methyl ester

25 *p*-Phenoxybenzaldehyde (3.96g, 0.02mol) was converted to the crude amino acid using essentially the method of Monianari et al. (Synthesis 1979, 26), but with some changes to the final purification. The crude solid material obtained after neutralization and evaporation of the water was stirred in methanol (35ml), presaturated with hydrogen chloride gas, for 3 days. The methanol was removed under reduced pressure and the
30 residue partitioned between ethyl acetate and an excess of saturated NaHCO₃ solution. The organic layer was washed with water and dried. Removal of the solvent afforded the crude product as a pale oil which was chromatographed on silica gel. Elution with ethyl acetate gave the desired product as an oil (100mg, 2% over 2 stages). δ_H (CDCl₃) 1.76 (2H, br s), 3.73(3H, s), 4.62 (1H, s), 6.9-7.4 (9H, m) ppm.

35

Description 27

N-(2'-acetylthiomethyl-4'-phenylbutanoyl)-*p*-phenoxy-phenylglycine methyl ester.

To a cooled (0°), stirred solution of 2-acetylthiomethyl-4-phenylbutanoic acid prepared as in Description 5, (98mg, 0.39mmol) in dry tetrahydrofuran (5 ml) containing
5 dry dimethylformamide (1 drop), was added sodium hydride (17mg of a 55% suspension in oil, 0.39mmol). The reaction mixture was allowed to reach room temperature and stirring was continued for a further 15 mins. The suspension was then recooled (0°) and treated with oxalyl chloride (41ul, 0.47mmol) and stirred at room ambient temperature for 30 mins. The resulting mixture was then evaporated *in vacuo* and the residue
10 suspended in dry tetrahydrofuran (5 ml). The filtered solution was taken to dryness once more to afford the acid chloride as an oil.

A stirred, cooled (0°) solution of *p*-phenoxy-phenylglycine methyl ester (Description 26, 100mg, 0.39mmol) in dry tetrahydrofuran (5ml) was treated with triethylamine (55ul, 0.39mmol) followed by a solution of the above acid chloride in dry
15 tetrahydrofuran (3ml) added over 1 minute. The mixture was stirred at ambient temperature for 3 hours and then partitioned between ethyl acetate and 1M hydrochloric acid. The organic layer was washed with water and saturated brine and dried over anhydrous sodium sulphate. Evaporation of the solvent afforded crude product as an oil which was chromatographed on silica gel. Elution with 20% ethyl acetate in hexane
20 afforded diastereoisomer A as an oil (57mg, 30%). δ_H (CDCl₃) 1.86 (1H, m), 2.03 (1H, m), 2.28 (3H, s), 2.32 (1H, m), 2.73 (2H, m), 3.04 (2H, d, J 7.9 Hz), 3.77 (3H, s), 5.55 (1H, d, J 6.9 Hz), 6.49 (1H, d, J 6.9 Hz), 7.0-7.4 (14H, m) ppm. ESMS M+NH₄⁺ 509. This was followed by diastereoisomer B as an oil (60mg, 31%). δ_H (CDCl₃) 1.90 (2H, m), 2.34 (3H, s), 2.50 (3H, m), 3.08 (2H, m), 3.77 (3H, s), 5.59 (1H, d, J 7.0 Hz), 6.65
25 (1H, d, J 7.0 Hz), 7.0-7.4 (14H, m) ppm. ESMS M+NH₄⁺ 509.

Description 28

m-(*p*-methoxyphenoxy)-phenylglycine methyl ester

m-(*p*-methoxyphenoxy)-benzaldehyde (4.56ml, 0.02mol) was converted to the
30 crude amino acid using essentially the method of Monianari et al. (Synthesis 1979, 26), but with some changes to the final purification. The crude solid material obtained after neutralization and evaporation of the water was stirred in methanol (40ml), presaturated with hydrogen chloride gas, overnight. The methanol was removed under reduced pressure and the residue partitioned between ethyl acetate and an excess of saturated
35 NaHCO₃ solution. The organic layer was washed with water and dried. Removal of the solvent afforded the crude product. Chromatography on silica gel, eluting with ethyl

acetate, gave desired product as a pale oil (0.91g, 16% over 2 stages). δ_H ($CDCl_3$) 1.26 (2H, br s), 3.71 (3H, s), 3.82 (3H, s), 4.57 (1H, s), 6.8-7.3 (8H, m) ppm.

Description 29

- 5 N-(2'-acetylthiomethyl-4'-phenylbutanoyl)-*m*-(*p*-methoxyphenoxy)-phenylglycine methyl ester.

To a cooled (0°), stirred solution of 2-acetylthiomethyl-4-phenylbutanoic acid prepared as in Description 5, (126mg, 0.50mmol) in dry tetrahydrofuran (5 ml) containing dry dimethylformamide (1 drop), was added sodium hydride (22mg of a 55%
10 suspension in oil, 0.50mmol). The reaction mixture was allowed to reach room temperature and stirring was continued for a further 15 mins. The suspension was then recooled (0°) and treated with oxalyl chloride (52ul, 0.60mmol) and stirred at room ambient temperature for 30 mins. The resulting mixture was then evaporated *in vacuo* and the residue suspended in dry tetrahydrofuran (5 ml). The filtered solution was taken
15 to dryness once more to afford the acid chloride as an oil.

A stirred, cooled (0°) solution of *m*-(*p*-methoxyphenoxy)-phenylglycine methyl ester (Description 28, 144mg, 0.50mmol) in dry tetrahydrofuran (5ml) was treated with triethylamine (70ul, 0.50mmol) followed by a solution of the above acid chloride in dry tetrahydrofuran (5ml) added over 1 minute. The mixture was stirred at ambient
20 temperature for 3 hours and then partitioned between ethyl acetate and 1M hydrochloric acid. The organic layer was washed with water and saturated brine and dried over anhydrous sodium sulphate. Evaporation of the solvent afforded crude product as an oil which was chromatographed on silica gel. Elution with 20% ethyl acetate in hexane afforded diastereoisomer A as an oil (72mg, 28%). δ_H ($CDCl_3$) 1.89 (1H, m), 2.02 (1H,
25 m), 2.28 (3H, s), 2.40 (1H, m), 2.68 (2H, m), 3.01 (2H, d, J 7.0 Hz), 3.76 (3H, s), 3.81 (3H, s), 5.53 (1H, d, J 7.0 Hz), 6.52 (1H, d, J 7.0 Hz), 6.9-7.3 (13H, m) ppm. CIMS MH^+ 522. This was followed by diastereoisomer B as an oil (95mg, 37%). δ_H ($CDCl_3$) 1.90 (2H, m), 2.34 (3H, s), 2.50 (3H, m), 3.06 (2H, m), 3.76 (3H, s), 3.79 (3H, s), 5.57 (1H, d, J 7.1 Hz), 6.61 (1H, d, J 7.1 Hz), 6.9-7.3 (13H, m) ppm. CIMS MH^+ 522.

30

Description 30

(N-Ethyl-3-carbazolyl)glycine methyl ester

N-Ethyl-3-carbazolecarboxaldehyde (4.46ml, 0.02mol) was converted to the crude amino acid using essentially the method of Monianari et al. (Synthesis 1979, 26),
35 but with some changes to the final purification. The crude solid material obtained after neutralization and evaporation of the water was stirred in methanol (35ml), presaturated with hydrogen chloride gas, overnight. The methanol was removed under reduced

pressure and the residue partitioned between ethyl acetate and an excess of saturated NaHCO₃ solution. The organic layer was washed with water and dried. Removal of the solvent afforded the crude product. Chromatography on silica gel, eluting with ethyl acetate, gave desired product as a pale oil (25 mg, 0.5% over 2 stages). δ_H (CDCl₃) 1.43 (3H, t, J 7.1 Hz), 1.95 (2H, br s), 3.72 (3H, s), 4.37 (2H, q, J 7.1 Hz), 4.83 (1H, s), 7.2-7.5 (5H, m), 8.11 (2H, m) ppm. ESMS MH⁺ 283.

Description 31

N-(2'-acetylthiomethyl-4'-phenylbutanoyl)-(N-Ethyl-3-carbazolyl)glycine methyl ester.

To a cooled (0°), stirred solution of 2-acetylthiomethyl-4-phenylbutanoic acid prepared as in Description 5, (40mg, 0.16mmol) in dry tetrahydrofuran (5 ml) containing dry dimethylformamide (1 drop), was added sodium hydride (7mg of a 55% suspension in oil, 0.16mmol). The reaction mixture was allowed to reach room temperature and stirring was continued for a further 15 mins. The suspension was then recooled (0°) and treated with oxalyl chloride (17ul, 0.19mmol) and stirred at room ambient temperature for 30 mins. The resulting mixture was then evaporated *in vacuo* and the residue suspended in dry tetrahydrofuran (5 ml). The filtered solution was taken to dryness once more to afford the acid chloride as an oil.

A stirred, cooled (0°) solution of (N-Ethyl-3-carbazolyl)glycine methyl ester (Description 30, 45mg, 0.16mmol) in dry tetrahydrofuran (5ml) was treated with triethylamine (22ul, 0.16mmol) followed by a solution of the above acid chloride in dry tetrahydrofuran (5ml) added over 1 minute. The mixture was stirred at ambient temperature for 3 hours and then partitioned between ethyl acetate and 1M hydrochloric acid. The organic layer was washed with water and saturated brine and dried over anhydrous sodium sulphate. Evaporation of the solvent afforded crude product as an oil which was chromatographed on silica gel. Elution with 20% ethyl acetate in hexane afforded diastereoisomer A as an oil (26mg, 32%). δ_H (CDCl₃) 1.43 (3H, t, J 7.2 Hz), 1.89 (1H, m), 2.02 (1H, m), 2.22 (3H, s), 2.40 (1H, m), 2.8 (2H, m), 3.04 (2H, d, J 7.7 Hz), 3.76 (3H, s), 4.38 (2H, q, J 7.2 Hz), 5.72 (1H, d, J 6.7 Hz), 6.53 (1H, d, J 6.7 Hz), 7.2-7.5 (10H, m) 8.12 (2H, m) ppm. ESMS MH⁺ 517. This was followed by diastereoisomer B as an oil (28mg, 34%). δ_H (CDCl₃) 1.43 (3H, t, J 7.2 Hz), 1.90 (2H, m), 2.35 (3H, s), 2.50 (3H, m), 3.12 (2H, m), 3.76 (3H, s), 4.37 (2H, q, J 7.2 Hz), 5.78 (1H, d, J 7.0 Hz), 6.68 (1H, d, J 7.0 Hz), 7.0-7.5 (10H, m) 8.10 (2H, m) ppm. ESMS MH⁺ 517.

Description 32

N-(2'-RS-acetylthiomethyl-4'-phenylbutanoyl)-D-p-hydroxyphenylglycine methyl ester.

To a cooled (0°), stirred solution of 2-acetylthiomethyl-4-phenylbutanoic acid prepared as in Description 5, (252mg, 1.0mmol) in dry tetrahydrofuran (5 ml) containing dry dimethylformamide (1 drop), was added sodium hydride (44mg of a 55% suspension in oil, 1.0mmol). The reaction mixture was allowed to reach room temperature and stirring was continued for a further 15 mins. The suspension was then recooled (0°) and treated with oxalyl chloride (105ul, 1.2mmol) and stirred at room ambient temperature for 30 mins. The resulting mixture was then evaporated *in vacuo* and the residue suspended in dry tetrahydrofuran (5 ml). The filtered solution was taken to dryness once more to afford the acid chloride as an oil.

A stirred, cooled (0°) solution of D-p-hydroxyphenylglycine methyl ester, prepared from D-p-hydroxyphenylglycine with hydrogen chloride in methanol as in Description 4, (181mg, 1.0mmol) in dry tetrahydrofuran (5ml) was treated with triethylamine (140ul, 1.0mmol) followed by a solution of the above acid chloride in dry tetrahydrofuran (5ml) added over 1 minute. The mixture was stirred at ambient temperature for 3 hours and then partitioned between ethyl acetate and 1M hydrochloric acid. The organic layer was washed with water and saturated brine and dried over anhydrous sodium sulphate. Evaporation of the solvent afforded crude product as an oil which was chromatographed on silica gel. Elution with 33% ethyl acetate in hexane afforded the desired mixture of diastereoisomers as a pale gum (295mg, 71%). δ_H (CDCl₃) 1.89 (1H, m), 2.02 (1H, m), 2.28 and 2.34 (3H, s), 2.4-2.7 (3H, m), 3.1 (2H, m), 3.75 (3H, s), 5.16 (1H, br s), 5.48 and 5.53 (1H, d, J 6.9 Hz), 6.44 and 6.60 (1H, d, J 6.9 Hz), 6.81 (2H, d, J 8.5 Hz), 7.0-7.3 (7H, m) ppm.

Description 33

N-(2'-R-acetylthiomethyl-4'-phenylbutanoyl)-p-benzyloxy-D-phenylglycine methyl ester and N-(2'-S-acetylthiomethyl-4'-phenylbutanoyl)-p-benzyloxy-D-phenylglycine methyl ester.

To a stirred solution of the p-hydroxyphenylglycine derivative of Description 32 (50mg, 0.12mmol) in dry tetrahydrofuran (2ml) was added triphenyl phosphine (35mg, 0.13mmol) and benzyl alcohol (12 ul, 0.12mmol) followed by diethyl azodicarboxylate (23 ul, 0.14mmol). The resulting yellow solution was stirred at room temperature for 15 minutes before dilution with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). The solvent was removed to afford a gum which was chromatographed on silica gel. Elution with 20% ethyl acetate in hexane gave diastereoisomer A as a white

solid (15mg, 25%). δ_H (CDCl₃) 1.89 (1H, m), 2.02 (1H, m), 2.27 (3H, s), 2.40 (1H, m), 2.68 (2H, m), 3.02 (2H, d, J 7.0 Hz), 3.75 (3H, s), 5.07 (2H, s), 5.50 (1H, d, J 6.8 Hz), 6.41 (1H, d, J 6.8 Hz), 6.97 (2H, d, J 8.7 Hz), 7.2-7.4 (12H, m) ppm. EIMS M⁺ 505.

This was followed by diastereoisomer B as a gum (14mg, 23%). δ_H (CDCl₃) 1.90 (2H, m), 2.34 (3H, s), 2.50 (3H, m), 3.08 (2H, m), 3.74 (3H, s), 5.06 (2H, s), 5.55 (1H, d, J 7.0 Hz), 6.57 (1H, d, J 7.0 Hz), 6.9-7.4 (14H, m) ppm, EIMS M⁺ 505.

Description 34

N-(2'-R-acetylthiomethyl-4'-phenylbutanoyl)-p-(2''-thienylmethoxy)-D-phenylglycine methyl ester and N-(2'-S-acetylthiomethyl-4'-phenylbutanoyl)-p-(2''-thienylmethoxy)-D-phenylglycine methyl ester.

To a stirred solution of the *p*-hydroxyphenylglycine derivative of Description 32 (156mg, 0.38mmol) in dry tetrahydrofuran (2ml) was added triphenyl phosphine (125mg, 0.48mmol) and 2-thiophenemethanol (53ul, 0.56mmol) followed by diethyl azodicarboxylate (78ul, 0.50mmol). The resulting yellow solution was stirred at room temperature for 15 minutes before dilution with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). The solvent was removed to afford a gum which was chromatographed on silica gel. Elution with 20% ethyl acetate in hexane gave diastereoisomer A as a colourless gum (50mg, 26%). δ_H (CDCl₃) 1.89 (1H, m), 2.02 (1H, m), 2.27 (3H, s), 2.37 (1H, m), 2.68 (2H, m), 3.02 (2H, d, J 7.6 Hz), 3.75 (3H, s), 5.22 (2H, s), 5.51 (1H, d, J 6.9 Hz), 6.44 (1H, d, J 6.9 Hz), 7.0-7.4 (12H, m) ppm. ESMS MH⁺ 512. This was followed by diastereoisomer B as a gum (60mg, 31%). δ_H (CDCl₃) 1.90 (2H, m), 2.34 (3H, s), 2.50 (3H, m), 3.08 (2H, m), 3.74 (3H, s), 5.21 (2H, s), 5.56 (1H, d, J 7.0 Hz), 6.59 (1H, d, J 7.0 Hz), 7.0-7.4 (12H, m) ppm. ESMS MH⁺ 512.

Description 35

p-Methoxycarbonylbenzaldehyde

Methanol (50ml) was cooled (0°) and saturated with hydrogen chloride gas. *p*-Carboxybenzaldehyde (5.0g) was added and the resulting solution stirred at room temperature for 3 days. The solvent was removed under reduced pressure and the residue was partitioned between ethyl acetate and 5M hydrochloric acid. The organic layer was washed twice with water and dried. The solvent was removed to afford the product as a white solid (5.40g, 100%). δ_H (CDCl₃) 3.96 (3H, s), 7.96 (2H, dd, J 6.8 and 1.7 Hz), 8.20 (2H, dd, J 6.8 and 1.7 Hz), 10.11 (1H, s) ppm.

Description 36***p*-Methoxycarbonylbenzyl alcohol.**

A stirred solution of *p*-methoxycarbonylbenzaldehyde (Description 35, 0.82g, 5.0 mmol) in methanol (10ml) at 0° under argon was treated with sodium borohydride (50mg, 1.25mmol), added in portions over 5 minutes. After stirring overnight the reaction mixture was partitioned between ethyl acetate and water. The organic layer was washed with water and dried (MgSO₄). Removal of the solvent gave the desired product as a colourless solid (0.78g, 94%). δ_H (CDCl₃) 1.83 (1H, t, J 5.9 Hz), 3.93 (3H, s), 4.78 (1H, d, J 5.9 Hz), 7.45 (2H, d, J 8.1 Hz), 8.04 (2H, d, J 8.1 Hz) ppm.

Description 37

N-(2'-*R*-acetylthiomethyl-4'-phenylbutanoyl)-*p*-(*p*-methoxycarbonyl)-benzyloxy-D-phenylglycine methyl ester and N-(2'-*S*-acetylthiomethyl-4'-phenylbutanoyl)-*p*-(*p*-methoxycarbonyl)-benzyloxy-D-phenylglycine methyl ester.

To a stirred solution of the *p*-hydroxyphenylglycine derivative from Description 32 (95mg, 0.23mmol) in dry tetrahydrofuran (2ml) was added triphenyl phosphine (75mg, 0.29mmol) and *p*-methoxycarbonylbenzyl alcohol (Description 36, 57mg, 0.34mmol) followed by diethyl azodicarboxylate (48 μ l, 0.30mmol). The resulting yellow solution was stirred at room temperature for 15 minutes before dilution with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). The solvent was removed to afford a gum which was chromatographed on silica gel. Elution with 25% ethyl acetate in hexane gave diastereoisomer A as a gum (37mg, 29%). δ_H (CDCl₃) 1.89 (1H, m), 2.02 (1H, m), 2.26 (3H, s), 2.40 (1H, m), 2.68 (2H, m), 3.01 (2H, d, J 8.0 Hz), 3.74 (3H, s), 3.92 (3H, s), 5.12 (2H, s), 5.50 (1H, d, J 6.8 Hz), 6.46 (1H, d, J 6.8 Hz), 6.95 (2H, d, J 8.7 Hz), 7.2-7.3 (7H, m), 7.49 (2H, d, J 8.3 Hz), 8.06 (2H, d, J 8.3 Hz) ppm. EIMS M⁺ 563. This was followed by diastereoisomer B as a gum (37mg, 29%). δ_H (CDCl₃) 1.90 (2H, m), 2.33 (3H, s), 2.50 (3H, m), 3.08 (2H, m), 3.73 (3H, s), 3.92 (3H, s), 5.11 (2H, s), 5.55 (1H, d, J 7.0 Hz), 6.62 (1H, d, J 7.0 Hz), 6.95 (2H, d, 8.7 Hz), 7.04 (2H, d, J 8.0 Hz), 7.2-7.3 (5H, m), 7.48 (2H, d, J 8.3 Hz), 8.05 (2H, d, J 8.3 Hz) ppm. EIMS M⁺ 563.

Description 38**Ethyl 2-(5-benzyl)thien-2-yl-2-oxoacetate**

Ethyl oxalyl chloride (1.12ml) was added to a stirred suspension of aluminium chloride (1.4g) in dichloromethane (15ml). A solution of 2-benzylthiophene (Arcoria et al., J. Het. Chem. (1972), 9, 849-852) (1.74g) in dichloromethane (10ml) was added dropwise over 15 min. When the addition was complete the mixture was stirred at room

temperature for 0.5h and then poured into dilute hydrochloric acid (25ml). The organic phase was separated, washed with water and brine, dried over magnesium sulphate and evaporated. The product (2.10g) was isolated by column chromatography of the residue (Kieselgel: 10% ethyl acetate in hexane). ν_{\max} (CHCl₃) 1731 and 1659cm⁻¹. δ (CDCl₃) 1.41 (3H, t, *J* 7.15Hz), 4.19 (2H, s), 4.40 (2H, q, *J* 7.18Hz), 6.90 (1H, d, *J* 3.93Hz), 7.23-7.37 (5H, m), 7.98 (1H, d, *J* 3.95Hz), *m/z* 274 (M⁺). [Found (HRMS): *m/z* 274.0671. Calc. for C₁₅H₁₄O₃S; 274.0664].

Description 39

10 Ethyl 2-(5-benzyl)thien-2-yl-2-hydroxyiminoacetate

Hydroxylamine hydrochloride (695mg) was added to a stirred solution of ethyl 2-(5-benzyl)thien-2-yl-2-oxoacetate (Description 38) (1.37g) in ethanol (30ml). When the solid had dissolved the mixture was allowed to stand for 48h. The solvent was evaporated and the residue partitioned between ethyl acetate and water. The organic phase was washed with water and brine, dried over magnesium sulphate and evaporated. The product (1.07g) was obtained by recrystallisation of the residue from ethyl acetate/hexane. ν_{\max} (CHCl₃) 3464, 3272, 1734cm⁻¹. δ (CDCl₃) 1.40 (3H, t, *J* 7.37), 4.12 and 4.19 (2H, two s's), 4.35-4.49 (2H, m), 6.73 and 6.85 (1H, two d's, *J* 3.79), 7.03 and 7.95 (1H, two d's, *J* 3.63), 7.21-7.36 (5H, m), 8.67 (1H, s). *m/z* 289 (M⁺). [Found (HRMS): *m/z* 289.0776. Calc. for C₁₅H₁₅NO₃S; 289.0773].

Description 40

2-[(5-Benzyl)thien-2-yl]-N-[2-(acetylthiomethyl)-4-phenylbutyryl]glycine ethyl ester

A stirred suspension of ethyl 2-(5-benzyl)thien-2-yl-2-hydroxyiminoacetate (Description 39) (289mg) in methanol (1ml) and 50% formic acid (2ml) was cooled in an ice-bath. Zinc dust (150mg) was added in portions over 20 min., then the mixture was stirred at 0°C for a further 4h. The solid was filtered off and washed with 50% formic acid. The combined filtrates were evaporated and the residue stirred with chloroform and water, potassium carbonate was added until effervescence ceased. The organic phase was separated, dried over magnesium sulphate and evaporated to ~1ml. The residue was dissolved in dichloromethane (10ml) and used as indicated below.

Oxalyl chloride (0.1ml) and dimethylformamide (1 drop) were added to a stirred solution of 2-(acetylthiomethyl)-4-phenylbutanoic acid, prepared as in Description 5, (252mg) in dichloromethane (10ml). The mixture was stirred at room temperature for 1h and then the solvent was evaporated and chloroform evaporated from the residue twice. The residue was dissolved in dichloromethane (2ml) and added to a stirred solution of the amine previously prepared. Triethylamine (0.28ml) was added and the mixture stirred

for 2h. The solution was washed successively with citric acid solution, water, sodium bicarbonate solution, water and brine, dried over magnesium sulphate and evaporated. The product (352mg) was isolated by column chromatography of the residue using gradient elution (Kieselgel:20% going to 40% ethyl acetate in hexane). ν_{\max} (CHCl_3) 3421, 1739, 1683 cm^{-1} . δ (CDCl_3) 1.27 (3H, t, J 7.01Hz), 1.74-2.11 (2H, m), 2.21-2.80 (3H, m), 2.24 and 2.32 (3H, two s's), 2.98-3.14 (2H, m), 4.08 and 4.10 (2H, two s's), 4.18-4.31 (2H, m), 5.72-5.79 (1H, two d's J 7.11Hz), 6.32 and 6.47 (1H, two d's, J 7.22Hz), 6.65-6.69 (1H, m), 6.87-6.90 (1H, m), 7.07-7.31 (1H, m). m/z 509 (M^+). [Found (HRMS): m/z 509.1685. Calc. for $\text{C}_{28}\text{H}_{31}\text{NO}_4\text{S}_2$; 509.1695].

10

Description 41**Ethyl 2-(5-benzyl)furan-2-yl-2-oxoacetate**

Ethyl oxalyl chloride (1.12) was added to a stirred suspension of aluminium chloride (1.4g) in dichloromethane (15ml). The mixture was cooled in an ice bath and a solution of 2-benzylfuran (Hall et al., (1987) 24, 1205-1213) (1.58g) in dichloromethane (10ml) was added dropwise. When the addition was complete the mixture was stirred at 0°C for 15 min. and then poured into dilute hydrochloric acid (25ml). The organic phase was separated and washed with water and brine, then dried over magnesium sulphate and evaporated. The product (877mg) was isolated by column chromatography of the residue using gradient elution (Kieselgel:10% going to 20% ethyl acetate in hexane). ν_{\max} (CHCl_3) 1733 and 1665 cm^{-1} . δ (CDCl_3) 1.14 (3H, t, J 7.09Hz), 4.09 (2H, s), 4.40 (2H, q, J 7.02Hz), 6.18 (1H, d, J 3.82Hz), 7.23-7.37 (5H, m), 7.64 (1H, d, J 3.67Hz); m/z 258 (M^+). [Found (HRMS): m/z 258.0888. Calc. for $\text{C}_{15}\text{H}_{14}\text{O}_4$; 258.0892].

25 **Description 42****Ethyl 2-(5-benzyl)furan-2-yl-2-hydroxyiminoacetate**

The title compound was prepared from ethyl 2-(5-benzyl)furan-2-yl-2-oxoacetate (Description 41) by the procedure of Description 39 except that the product was isolated by column chromatography using gradient elution (Kieselgel:20% going to 50% ethyl acetate in hexane). ν_{\max} (CHCl_3) 3563, 3282, 1736 cm^{-1} . δ (CDCl_3) 1.35 and 1.38 (3H, two t's, J 7.24Hz), 4.01 and 4.03 (2H, two s's), 4.33-4.47 (2H, m), 6.04 and 6.14 (1H, two d's, J 3.44Hz), 6.57 (½H, d, J 3.41Hz), 7.21-7.35 (5½H, m), 9.03 and 9.23 (1H, 2 broad s's). m/z 273 (M^+). [Found (HRMS): m/z 273.1006. Calc. for $\text{C}_{15}\text{H}_{15}\text{NO}_4$; 273.1001].

35

Description 43**2-[(5-Benzyl)furan-2-yl]-N-[2-(acetylthiomethyl)-4-phenylbutyryl]glycine ethyl ester**

The title compound was prepared from ethyl 2-(5-benzyl)furan-2-yl-2-hydroxyiminoacetate (Description 42) by the procedure of Description 40. ν_{\max} (CHCl₃) 3430, 1742 and 1683cm⁻¹. δ (CDCl₃) 1.21 (3H, t, *J* 7.07Hz), 1.75-2.13 (2H, m), 2.24-2.80 (2H, m), 2.26 and 2.32 (3H, two s's), 2.98-3.16 (2H, m), 3.92 and 3.95 (2H, two s's), 4.22 (2H, q, *J* 7.13Hz), 5.66 and 5.72 (1H, two d's, *J* 7.61Hz), 5.94-5.95 (1H, m), 6.27-6.29 (1H, m), 6.37 and 6.46 (1H, two d's, *J* 7.56Hz), 7.07-7.31 (10H, m). *m/z* 493 (M⁺). [Found (HRMS): *m/z* 493.1930. Calc. for C₂₈H₃₁NO₅S; 493.1923].

Description 44**2-(Tetrahydrofuran-3-ylmethyl)thiophene**

A solution of n-butyllithium (12.5ml of 1.6N in hexanes) was added to a stirred solution of thiophene (1.6ml) in tetrahydrofuran (90ml) under argon. The solution was stirred for 0.5h and then a solution of 3-bromomethyltetrahydrofuran Schweizer et al., J. Org. Chem. (1969) 34, 212-218) (3.3g) in tetrahydrofuran (10ml) was added dropwise. The mixture was stirred for 4h and then acetic acid (2ml) was added. The mixture was partitioned between ethyl acetate and water and the organic phase was washed with water, sodium bicarbonate solution, water and brine. The solution was dried over magnesium sulphate and evaporated. The product (866mg) was isolated by column chromatography (Kieselgel:20% ethyl acetate in hexane). δ (CDCl₃) 1.56-1.71 (1H, m), 2.01-2.14 (1H, m), 2.49-2.66 (1H, m), 2.90 (2H, d, *J* 7.53Hz), 3.50 (1H, dd, *J* 6.23 and 8.59Hz), 3.72-4.16 (2H, m), 6.80 (1H, dd, *J* 0.78 and 3.38Hz), 6.92 (1H, dd, *J* 3.44 and 5.05Hz), 7.13 (1H, dd, *J* 1.21 and 5.19Hz).

Description 45**Ethyl 2-[5-(tetrahydrofuran-3-ylmethyl)thien-2-yl]-2-oxoacetate**

Ethyl oxalyl chloride (0.15ml) was added to a stirred suspension of aluminium chloride (200mg) in dichloromethane (10ml). When the solid had dissolved a solution of 2-(tetrahydrofuran-3-ylmethyl)thiophene (Description 44) (240mg) in dichloromethane (2ml) was added. The mixture was stirred at room temperature for 1h and then shaken with dilute hydrochloric acid (10ml). The organic phase was separated and washed with water and brine, dried over magnesium sulphate and evaporated. The product (93mg) was isolated by column chromatography using gradient elution (Kieselgel:25% going to 50% ethyl acetate in hexane). ν_{\max} (CHCl₃) 1731 and 1659cm⁻¹. δ (CDCl₃) 1.42 (3H, t, *J* 7.24Hz), 1.57-1.71 (1H, m), 2.03-2.17 (1H, m), 2.50-2.67 (1H, m), 2.88-3.04 (1H, m), 3.50 (1H, dd, *J* 6.04 and 8.66Hz), 3.73-3.95 (2H, m), 4.42 (2H, q, *J* 7.22Hz), 6.92

(1H, d, J 3.91Hz), 7.99 (1H, d, J 3.91Hz). m/z 268 (M^+). [Found (HRMS): m/z 268.0761. Calc. for $C_{13}H_{16}O_4S$; 268.0769].

Description 46

5 Ethyl 2-[5-(tetrahydrofuran-3-ylmethyl)thien-2-yl]-2-hydroxyiminoacetate

Hydroxylamine hydrochloride (70mg) was added to a stirred solution of ethyl 2-[5-(tetrahydrofuran-3-ylmethyl)thien-2-yl]-2-oxoacetate (Description 45) (130mg) in ethanol (2ml). The mixture was stirred for 48h and the solvent evaporated. The residue was partitioned between ethyl acetate and water, the organic phase was washed with
10 brine, dried over magnesium sulphate and evaporated. The product (95mg) was obtained by column chromatography of the residue (Kieselgel:50% ethyl acetate in hexane). ν_{\max} ($CHCl_3$) 3564, 3242, 1733 cm^{-1} . δ ($CDCl_3$) 1.43 (3H, t, J 7.19Hz), 1.61-1.74 (1H, m), 2.03-2.16 (1H, m), 2.51-2.66 (1H, m), 2.87-2.96 (2H, m), 3.48-3.56 (1H, m), 3.74-3.96 (3H m), 4.38-4.51 (2H, m), 6.75 and 6.87 (1H, two d's J 3.57), 7.02 and 7.92 (1H, two
15 d's J 3.60Hz), 8.84 and 9.82 (1H, two s's). m/z 283 (M^+). [Found (HRMS): 283.0882. Calc. for $C_{13}H_{17}NO_4S$. 283.0878].

Description 47

20 2-[5-(tetrahydrofuran-3-ylmethyl)thien-2-yl]-N-[2-(acetylthiomethyl)-4-phenylbutyryl]glycine ethyl ester

The title compound was prepared from ethyl 2-[5-(tetrahydrofuran-3-ylmethyl)thien-2-yl]-2-hydroxyiminoacetate (Description 46) by the procedure of Description 40 except that the eluent used was 40% ethyl acetate in hexane. ν_{\max} ($CHCl_3$) 3422, 1739 and 1682 cm^{-1} . δ ($CDCl_3$) 1.30 (3H, t, J 7.07Hz), 1.58-1.72 (2H,
25 m), 1.80-2.18 (3H, m), 2.30 and 2.34 (3H, two s's), 2.30-2.89 (5H, m), 3.04-3.13 (2H, m), 3.44-3.52 (1H, m), 3.71-3.91 (3H, m), 4.22-4.32 (2H, m), 5.75-5.82 (1H, two d's, J 7.27Hz), 6.40 and 6.54 (1H, two d's, J 7.24Hz), 6.66 (1H, d, J 3.40Hz), 7.09-7.32 (5H, m).

30 Description 48

Ethyl 2-(5-methyl)thien-2-yl-2-oxoacetate

Ethyl oxalyl chloride (2.24mg) was added to a stirred suspension of aluminium chloride (2.8g) in dichloromethane (30ml). The mixture was stirred at room temperature for 0.5h and then a solution of 2-methylthiophene (1.96g) in dichloromethane (20ml) was
35 added dropwise. When the addition was complete the mixture was stirred for a further 0.5h and then poured into dilute hydrochloric acid (50ml). The organic phase was separated and washed with water and brine, dried over magnesium sulphate and

evaporated. The product (2.99g) was isolated by column chromatography of the residue (Kieselgel:20% ethyl acetate in hexane as eluent). ν_{\max} (CHCl_3) 1731 and 1659cm^{-1} . δ (CDCl_3) 1.42 (3H, t, J 7.18Hz), 2.58 (3H, s), 4.42 (2H, q, J 7.05Hz), 6.88 (1H, d, J 3.86Hz), 7.96 (1H, d, J 3.89Hz).

5

Description 49

Ethyl 2-(5-bromomethyl)thien-2-yl-2-oxoacetate

A mixture of ethyl 2-(5-methyl)thien-2-yl-2-oxoacetate (Description 48) (1.98g) and N-bromo-succinimide (1.78g) in carbon tetrachloride (50ml) was heated under reflux and irradiated with a tungsten filament lamp for 2h. The mixture was cooled and the solid filtered off and washed with chloroform. The combined filtrates were evaporated and the residue dissolved in ethyl acetate, and the solution was washed twice with water, then brine, dried over magnesium sulphate and evaporated. The product (1.85g) was isolated by column chromatography of the residue using gradient elution (Kieselgel:10% going to 20% ethyl acetate in hexane). ν_{\max} (film) 1731, 1665cm^{-1} . δ (CDCl_3) 1.43 (3H, t, J 7.01Hz), 4.43 (2H, q, J 7.01Hz), 4.69 (2H, s), 7.19 (1H, d, J 3.97Hz), 8.00 (1H, d, J 4.00Hz).

15

Description 50

Ethyl 2-[5-(1-tetrazolylmethyl)thien-2-yl]-2-oxoacetate and ethyl 2-[5-(2-tetrazolylmethyl)thien-2-yl]-2-oxoacetate

Triethylamine (0.42ml) was added to a stirred mixture of tetrazole (210mg) and ethyl 2-(5-bromomethyl)thien-2-yl-2-oxoacetate (Description 49) (821mg) in acetonitrile (12ml). The mixture was stirred overnight and then partitioned between ethyl acetate and water. The organic phase was washed successively with water, dilute hydrochloric acid, water and brine, dried over magnesium sulphate and evaporated. The products were separated by column chromatography using gradient elution (Kieselgel:25% going to 50% ethyl acetate in hexane). Eluted first was ethyl 2-[5-(2-tetrazolylmethyl)thien-2-yl]-2-oxoacetate (244mg). ν_{\max} (CHCl_3) 1732 and 1672cm^{-1} . δ (CDCl_3) 1.42 (3H, t, J 7.23Hz), 4.42 (2H, q, J 7.26Hz), 6.03 (2H, s), 7.23 (1H, d, J 4.14Hz), 8.04 (1H, d, J 3.94Hz), 8.56 (1H, s). m/z 266 (M^+). [Found (HRMS): m/z 266.0469. Calc. for $\text{C}_{10}\text{H}_{10}\text{N}_4\text{O}_3\text{S}$. 266.0474]. Eluted next was ethyl 2-[5-(1-tetrazolylmethyl)thien-2-yl]-2-oxoacetate (416mg). ν_{\max} (CHCl_3) 1732 and 1673cm^{-1} . δ (CDCl_3) 1.43 (3H, t, J 7.02Hz), 4.43 (2H, q, J 7.19Hz), 5.85 (2H, s), 7.20 (1H, d, J 3.93Hz), 8.07 (1H, d, J 3.96Hz), 8.69 (1H, s). m/z 266 (M^+). [Found (HRMS): m/z 266.0469. Calc. for $\text{C}_{10}\text{H}_{10}\text{N}_4\text{O}_3\text{S}$; 266.0474].

30

35

Description 51**Ethyl 2-[5-(1-tetrazolylmethyl)thien-2-yl]-2-hydroxyiminoacetate**

Hydroxylamine hydrochloride (205mg) was added to a stirred mixture of ethyl 2-[5-(1-tetrazolylmethyl)thien-2-yl]-2-oxoacetate (Description 50) (394mg) and ethanol (10ml). The mixture was left at room temperature for 3 days, then the solvent was evaporated and the residue partitioned between ethyl acetate and water. The organic phase was washed with water and brine and dried over magnesium sulphate. The solution was evaporated to give the product (376mg) as a mixture of isomers. ν_{\max} (nujol) 3131, 1746, 1724 cm^{-1} . δ (CD_3COCD_3), 1.31-1.39 (3H, m), 4.36 and 4.42 (2H, two q's, J 7.22Hz), 6.02 and 6.08 (2H, two s's), 7.10 and 7.25 (1H, two d's, J 3.73Hz), 7.31 and 7.78 (1H, two d's, J 3.98Hz), 9.26 and 9.30 (1H, two s's), 11.14 and 12.25 (1H, two broad s's). m/z 280 (M-H) $^-$. [Found: m/z 281.0584. Calc. for $\text{C}_{10}\text{H}_{11}\text{N}_5\text{O}_3\text{S}$; 281.0583].

15 Description 52**2-[5-(1-Tetrazolylmethyl)thien-2-yl]-N-[2-(acetylthiomethyl)-4-phenylbutyryl]glycine ethyl ester**

The title compound was prepared from ethyl 2-[5-(1-tetrazolylmethyl)thien-2-yl]-2-hydroxyiminoacetate (Description 51) by the procedure of Description 40. ν_{\max} (CHCl_3) 3415, 1740 and 1685 cm^{-1} . δ (CDCl_3) 1.23-1.32 (3H, m), 1.80-2.10 (2H, m), 2.30 and 2.33 (3H, two s's), 2.35-2.80 (3H, m), 2.98-3.15 (2H, m), 4.21-4.34 (2H, m), 5.71 (2H, two s's), 5.78-5.84 (1H, m), 6.62 and 6.73 (1H, two d's, J 7.27Hz), 6.99-7.32 (7H, m), 8.55 and 8.59 (1H, two s's). m/z 502 (MH^+). [Found (HRMS): m/z 502.1587. Calc. for $\text{C}_{23}\text{H}_{27}\text{N}_5\text{O}_4\text{S}_2$; 502.1583].

25

Description 53**Ethyl 2-[5-(2-tetrazolylmethyl)thien-2-yl]-2-hydroxyiminoacetate**

The title compound was prepared from ethyl 2-[5-(2-tetrazolylmethyl)thien-2-yl]-2-oxoacetate (Description 50) by the procedure of Description 51. ν_{\max} (CHCl_3) 3558, 3250, 1734 cm^{-1} . δ (CDCl_3) 1.41 and 1.42 (3H, two t's, J 7.16Hz), 4.41 and 4.47 (2H, two q's, J 7.22Hz), 5.96 and 6.03 (2H, two s's), 7.12(s) and 7.23 (d, J 3.99Hz) and 8.01 (d, J 4.08Hz) (2H), 8.55 (1H, s). m/z 299 (MNH_4^+).

Description 54

2-[5-(2-Tetrazolylmethyl)thien-2-yl]-N-[2-(acetylthiomethyl)-4-phenylbutyryl]glycine ethyl ester

- The title compound was prepared from ethyl 2-[5-(2-tetrazolylmethyl)thien-2-yl]-2-hydroxyiminoacetate (Description 53) by the procedure of Description 40. ν_{\max} (CHCl₃) 3416, 1704, 1684cm⁻¹. δ (CDCl₃) 1.23-1.31 (3H, m), 1.80-2.13 (2H, m), 2.30 and 2.33 (3H, two s's), 2.30-2.78 (3H, m), 2.97-3.15 (2H, m), 4.19-4.36 (2H, m), 5.91 and 5.92 (2H, two s's), 6.96-7.32 (7H, s), 8.44 and 8.52 (1H, two s's). m/z 519 (MNH₄⁺).

10

Description 55

Ethyl 2-[5-(1,2,3-triazol-1-ylmethyl)thien-2-yl]-2-oxoacetate and ethyl 2-[5-(1,2,3-triazol-2-ylmethyl)thien-2-yl]-2-oxoacetate

- Triethylamine (0.28ml) was added to a stirred solution of ethyl 2-(5-bromomethyl)thien-2-yl-2-oxoacetate (Description 49) (554mg) and 1,2,3-triazole (138mg) in acetonitrile. The mixture was stirred at room temperature for 20h and then partitioned between ethyl acetate and water. The organic phase was washed with water and brine, dried over magnesium sulphate and evaporated. The products were separated by column chromatography using gradient elution (Kieselgel:50% ethyl acetate in hexane going to ethyl acetate). Eluted first was ethyl 2-[5-(1,2,3-triazol-2-ylmethyl)thien-2-yl]-2-oxoacetate (31mg). ν_{\max} (CHCl₃) 1732, 1668cm⁻¹. δ (CDCl₃) 1.41 (3H, t, J 7.04Hz), 4.41 (2H, q, J 7.07Hz), 5.82 (2H, s), 7.13 (1H, d, J 4.11Hz), 7.67 (2H, s), 8.01 (1H, d, J 3.94Hz). m/z 265 (M⁺). [Found (HMRS): 265.0524. Calc. for C₁₁H₁₁N₃O₃S; 265.0521]. Eluted next was ethyl 2-[5-(1,2,3-triazol-1-ylmethyl)thien-2-yl]-2-oxoacetate (66mg). ν_{\max} (CHCl₃) 1732, 1671cm⁻¹. δ (CDCl₃) 1.42 (3H, t, J 7.16Hz), 4.42 (2H, q, J 7.14Hz), 5.80 (2H, s), 7.12 (1H, d, J 3.90Hz), 7.63 (1H, s), 7.76 (1H, s), 8.03 (1H, d, J 3.94Hz).

20

25

Description 56

- Ethyl 2-[5-(1,2,3-triazol-1-ylmethyl)thien-2-yl]-2-hydroxyiminoacetate

- Hydroxylamine hydrochloride (167mg) was added to a stirred solution of ethyl 2-[5-(1,2,3-triazol-1-ylmethyl)thien-2-yl]-2-oxoacetate (Description 55) (319mg) in ethanol (5ml). The mixture was stirred for 18h then the solvent was evaporated and the residue partitioned between ethyl acetate and water. The organic phase was washed with water and brine, dried over magnesium sulphate and evaporated to give the product (336mg). ν_{\max} (nujol) 3136, 1736cm⁻¹. δ (CD₃COCD₃) 1.33-1.39 (3H, m), 4.30-4.46

35

(2H, m), 5.89 and 5.95 (2H, two s's), 7.07 and 7.17 (1H, two d's, J 3.81Hz), 7.23 and 7.75 (1H, two d's, J 3.90Hz), 8.07 and 8.08 (1H, two s's). m/z 281 (MH^+)

Description 57

5 2-[5-(1,2,3-Triazol-1-ylmethyl)thien-2-yl]-N-[2-(acetylthiomethyl)-4-phenylbutyryl]glycine ethyl ester

The title compound was prepared from ethyl 2-[5-(1,2,3-triazol-1-ylmethyl)thien-2-yl]-2-hydroxyiminoacetate (Description 56) by the procedure of Description 40 except that the eluent was 20% going to 40% ethyl acetate in hexane. ν_{max} ($CHCl_3$) 3416,
 10 1739, 1684 cm^{-1} . δ ($CDCl_3$) 1.29 (3H, t, J 6.64Hz), 1.80-2.10 (2H, m), 2.29 and 2.33 (3H, two s's), 2.30-2.80 (3H, m), 2.98-3.15 (2H, m), 4.20-4.33 (2H, m), 5.67 and 5.68 (2H, two s's), 5.78 and 5.83 (1H, two d's, J 7.33Hz), 6.54 and 6.67 (1H, two d's, J 7.32Hz), 6.97-7.32 (7H, m), 7.49 and 7.56 (1H, two s's), 7.64 and 7.71 (1H, two s's). m/z 501 (MH^+).

15

Description 58

Ethyl 2-[5-(1,2,3-triazol-2-ylmethyl)thien-2-yl]-2-hydroxyiminoacetate

The title compound was prepared from ethyl 2-[5-(1,2,3-triazol-2-ylmethyl)thien-2-yl]-2-oxoacetate (Description 55) by the procedure of Description 56. ν_{max}
 20 (tetrahydrofuran) 3254, 1742 cm^{-1} . δ ($CDCl_3$) 1.40 (3H, t, J 7.19Hz), 4.36-4.49 (2H, m), 5.76 and 5.84 (2H, two s's), 7.05 and 7.15 (1H, two d's J 3.85Hz), 7.66 (2H, s), 7.93 and 8.01 (1H, two d's, J 3.99Hz). m/z 280 (M^+). [Found (HRMS): m/z 280.0632. Calc. for $C_{11}H_{12}N_4O_3S$; 280.0630].

25 Description 59

2-[5-(1,2,3-Triazol-2-ylmethyl)thien-2-yl]-N-[2-(acetylthiomethyl)-4-phenylbutyryl]glycine ethyl ester

The title compound was prepared from ethyl 2-[5-(1,2,3-triazol-2-ylmethyl)thien-2-yl]-2-hydroxyiminoacetate (Description 58) by the procedure of Description 40 except
 30 that the eluent was 40% ethyl acetate in hexane. ν_{max} ($CHCl_3$) 3419, 1740 and 1684 cm^{-1} . δ ($CDCl_3$) 1.27 (3H, t, J 7.17Hz), 1.79-2.11 (2H, m), 2.29 and 2.32 (3H, two s's), 2.30-2.77 (2H, m), 2.89-3.14 (2H, m), 4.17-4.83 (2H, m), 5.71 and 5.72 (2H, two s's), 5.77 and 5.81 (1H, two d's, J 7.43Hz), 6.42 and 6.56 (1H, two d's, J 7.30Hz), 7.57 and 7.63 (2H, two s's). m/z 501 (MH^+). [Found (HRMS): m/z 501.1629. Calc. for
 35 $C_{24}H_{29}N_4O_4S_2$; 501.1630].

Description 60**Ethyl 2-[5-(imidazolidin-2,4-dion-3-ylmethyl)thien-2-yl]-2-oxoacetate**

- Potassium carbonate (414mg) was added to a stirred solution of ethyl 2-(5-bromomethyl)thien-2-yl-2-oxoacetate (Description 49) (821mg) and hydantoin (400mg) in dimethylformamide (15ml). The mixture was stirred at room temperature for 24h and then partitioned between ethyl acetate and water. The organic phase was washed three times with water, then brine, dried over magnesium sulphate and evaporated. The product (340mg) was isolated by column chromatography of the residue (Kieselgel:3:1 ethyl acetate:hexane). ν_{\max} (CHCl₃) 3463, 1783, 1772, 1666cm⁻¹. δ (CDCl₃) 1.42 (3H, t, *J* 7.04Hz), 4.03 (2H, s), 4.42 (2H, q, *J* 7.11Hz), 4.88 (2H, s), 5.93 (1H, s), 7.18 (1H, d, *J* 3.93Hz), 7.99 (1H, d, *J* 3.95Hz).

Description 61**Ethyl 2-[5-(imidazolidin-2,4-dion-3-ylmethyl)thien-2-yl]-2-hydroxyiminoacetate**

- The title compound was prepared from ethyl 2-[5-(imidazolidin-2,4-dion-3-ylmethyl)thien-2-yl]-2-oxoacetate (Description 60) by the procedure of Description 36. ν_{\max} (nujol) 3290, 1603cm⁻¹. *m/z* 311 (M⁺). [Found (HRMS): *m/z* 311.0578. Calc. for C₁₂H₁₃N₃O₅S; 311.0576].

Description 62**2-[5-(Imidazolidin-2,4-dion-3-ylmethyl)thien-2-yl]-N-[2-(acetylthiomethyl)-4-phenylbutyryl]glycine ethyl ester**

- The title compound was prepared from ethyl 2-[5-(imidazolidin-2,4-dion-3-ylmethyl)thien-2-yl]-2-hydroxyiminoacetate (Description 61) by the procedure of Description 40 except that the eluent was 75% ethyl acetate in hexane. ν_{\max} (CHCl₃) 3463, 3416, 3286, 1780, 1719, 1684cm⁻¹.

Description 63**2-(4-Methoxybenzyl)thiophene**

- Butyllithium (12.5ml of 1.6N in hexanes) was added to a stirred solution of thiophene (1.68g) in dry tetrahydrofuran (80ml). The mixture was stirred at room temperature for 0.5h and then a solution of 4-methoxybenzylbromide (2.62g) in tetrahydrofuran (10ml) was added dropwise. The mixture was stirred for 1h and then acetic acid (1.2ml) was added and the solvent evaporated. The residue was partitioned between ethyl acetate and water, the organic phase was washed with water and brine dried over magnesium sulphate and evaporated. The product was isolated by column

chromatography (Kieselgel:hexane). δ (CDCl_3) 3.80 (3H, s), 4.10 (2H, s), 6.78-6.94 (4H, m), 7.13-7.20 (3H, m).

Description 64

5 Ethyl 5-(4-methoxybenzyl)thiophen-2-yl-2-oxoacetate

The title compound was prepared from 2-(4-methoxybenzyl)thiophene (Description 63) by the procedure of Description 38. ν_{max} (CHCl_3) 1731, 1658 cm^{-1} . δ (CDCl_3) 1.40 (3H, t, J 7.0 Hz), 3.80 (3H, s), 4.13 (2H, s), 4.40 (2H, q, J 7.19 Hz), 6.83-6.89 (3H, m), 7.13-7.19 (2H, m), 7.96 (1H, d, J 3.94 Hz).

10

Description 65

Ethyl 5-(4-methoxybenzyl)thiophen-2-yl-2-hydroxyiminoacetate

The title compound was prepared from ethyl 5-(4-methoxybenzyl)thiophen-2-yl-2-oxoacetate (Description 64) by the procedure of Description 39. ν_{max} (CHCl_3) 3237, 1729 cm^{-1} . δ (CDCl_3) 1.40 (3H, t, J 7.14 Hz), 3.79 (3H, s), 4.12 (2H, s), 4.39 (2H, q, J 7.18 Hz), 6.82-6.88 (3H, m), 7.17 (2H, d, J 8.52 Hz), 7.94 (1H, d, J 4.00 Hz), 10.24 (1H, br s).

15

Description 66

20 2-[5-(4-methoxybenzyl)thien-2-yl]-N-[2-(acetylthiomethyl)-4-phenylbutyryl]glycine ethyl ester

The title compound was prepared from ethyl 5-(4-methoxybenzyl)thiophen-2-yl-2-hydroxyiminoacetate (Description 65) by the procedure of Description 40. ν_{max} (CHCl_3) 3422, 1739 and 1683 cm^{-1} . m/z 539 (M^+). [Found (HRMS): m/z 539.1806].
Calc. for $\text{C}_{29}\text{H}_{33}\text{NO}_5\text{S}_2$; 539.1800].

25

Description 67

2-[(5-Benzyl)furan-2-yl]-N-[2-(acetylthiomethyl)-3-phenylpropionyl]glycine ethyl ester

The title compound was prepared from 2-(acetylthiomethyl)-3-phenylpropionic acid (US 4329495) and ethyl (5-benzyl)furan-2-yl-2-hydroxyiminoacetate (Description 42) by the procedure of Description 40. ν_{max} (CHCl_3) 3428, 1741 and 1683 cm^{-1} . m/z 479 (M^+). [Found (HRMS): m/z 479.1768. Calc. for $\text{C}_{27}\text{H}_{29}\text{NO}_5\text{S}$; 479.1766].

30

Description 68**Ethyl 2-(5-azidomethyl)thien-2-yl-2-oxoacetate**

Sodium azide (150mg) was added to a stirred solution of ethyl 2-(5-bromomethyl)thien-2-yl-2-oxoacetate (Description 49) (554mg) in dimethylformamide (5ml). The mixture was stirred at room temperature for 2h and then partitioned between ethyl acetate and water. The organic phase was washed three times with water, then brine, dried over magnesium sulphate and evaporated. The title compound (362mg) was isolated by column chromatography of the residue, using gradient elution (Kieselgel:10% going to 20% ethyl acetate in hexane). ν_{\max} (CHCl₃), 2103, 1731, 1667cm⁻¹. δ (CDCl₃) 1.44 (3H, t, *J* 7.03Hz), 4.44 (2H, q, *J* 7.15Hz), 4.58 (2H, s), 7.12 (1H, d, *J* 3.91Hz), 8.06 (1H, d, *J* 3.93Hz). *m/z* 239 (M⁺). [Found (HRMS): *m/z* 239.0368. Calc. for C₉H₉N₃O₃S 239.0365].

15 Description 69**Ethyl 2-[5-{4,5-di(methoxycarbonyl)triazol-1-ylmethyl}thien-2-yl]-2-oxoacetate**

A mixture of ethyl 2-(5-azidomethyl)thien-2-yl-2-oxoacetate (Description 68) (300mg) and dimethyl acetylenedicarboxylate (0.154ml) in toluene (10ml) was heated at reflux for 2h. A further portion of dimethyl acetylenedicarboxylate (0.1ml) was added and reflux continued for a further 2h. The solvent was evaporated and the title compound (479mg) was isolated by column chromatography of the residue using gradient elution (Kieselgel:40% ethyl acetate in hexane going to ethyl acetate). ν_{\max} (CHCl₃) 1732, 1671cm⁻¹; δ (CDCl₃) 1.42 (3H, t, *J* 7.24Hz), 3.98 (3H, s), 4.00 (3H, s), 4.42 (3H, s), 6.05 (2H, s), 7.17 (1H, d, *J* 3.93Hz), 8.00 (1H, d, *J* 3.94Hz); *m/z* 382 (MH⁺) [Found (HRMS): *m/z* 382.0714. Calc for C₁₅H₁₆N₃O₇S 382.0709].

Description 70**30 Ethyl 2-[5-{4,5-di(methoxycarbonyl)triazol-1-ylmethyl}thien-2-yl]-2-hydroxyiminoacetate**

The title compound was prepared from ethyl 2-[5-{4,5-di-methoxycarbonyl}triazol-1-ylmethyl]thien-2-yl]-2-oxoacetate (Description 69) by the procedure described in Description 56. ν_{\max} (CHCl₃) 3286 and 1732cm⁻¹; δ (CDCl₃) 1.37-1.45 (3H, m), 3.97, 3.98, 3.99 and 4.00 (3H, four s's), 4.37-4.49 (2H, m), 5.98 and 6.05 (2H, two s's), 7.04-7.19 (m) with 7.94 (d *J* 4.00Hz) and 8.01 (d *J* 3.95Hz) (total of 2H), 9.16 and 9.80 (1H, two s's); *m/z* 396 (M⁺).

Description 71

2-[5-{4,5-Di(methoxycarbonyl)triazol-1-ylmethyl}thien-2-yl]-N-[2-(acetylthiomethyl)-4-phenylbutyryl]glycine ethyl ester

The title compound was prepared from ethyl 2-[5-{4,5-di(methoxycarbonyl)-triazol-1-ylmethyl}thien-2-yl]-2-hydroxyiminoacetate (Description 70) by the procedure described in Description 40, except that the eluent used was 50% ethyl acetate in hexane. ν_{\max} (CHCl₃) 3417, 1735 and 1684cm⁻¹; δ (CDCl₃) 1.25-1.31 (3H, m), 1.80-2.11 (2H, m), 2.30 and 2.33 (3H, two s's), 2.30-2.75 (3H, m), 2.97-3.14 (2H, m), 3.93, 3.95, 3.97 and 3.98 (6H, four s's), 4.18-4.32 (2H, m), 5.76 and 5.79 (1H, two d's *J* 7.31Hz), 5.94 and 5.95 (2H, two s's), 6.47 and 6.60 (1H, two d's *J* 7.29Hz), 6.92-7.31 (7H, m); *m/e* 617 (MH⁺).

Description 72

15 Ethyl 2-[5-(4-carboxamido-1,2,3-triazol-1-ylmethyl)thien-2-yl]-2-oxoacetate

A mixture of ethyl 2-(5-azidomethyl)thien-2-yl-2-oxoacetate (Description 68) (355mg) and propiolamide (113mg) in toluene (20ml) was heated at reflux for 7h. The mixture was cooled and the solvent evaporated. The residue was dissolved in ethyl acetate and the solid filtered off and washed with ethyl acetate. The combined filtrates were evaporated and the title compound (199mg) was obtained by column chromatography of the residue (Kieselgel; ethyl acetate as eluent). ν_{\max} (CHCl₃) 3522, 3487, 3406, 3300, 3189, 1732, 1691, 1671cm⁻¹; δ (CDCl₃) 1.40 (3H, t, *J* 7.15Hz), 4.40 (2H, q, *J* 7.23Hz), 5.8-6.6 (2H, br), 6.18 (1H, s), 7.22 (1H, d, *J* 3.93Hz), 7.97 (1H, d, *J* 3.94Hz), 8.04 (1H, s); *m/z* 308 (M⁺) [Found (HRMS), *m/z* 308.0582. Calc. for C₁₂H₁₂N₄O₄S; 308.0579].

Description 73

30 Ethyl 2-[5-(4-carboxamido-1,2,3-triazol-1-ylmethyl)thien-2-yl]-2-hydroximinoacetate

The title compound was prepared from ethyl 2-[5-(4-carboxamido-1,2,3-triazol-1-ylmethyl)thien-2-yl]-2-oxoacetate (Description 72) by the procedure described in Description 56. ν_{\max} (nujol) 3172, 1722, 1674, 1613cm⁻¹. δ (CD₃COCD₃) 1.33 and 1.34 (3H, two t's, *J* 7.08Hz), 4.34 and 4.40 (2H, two q's, *J* 7.16Hz), 6.17 and 6.25 (2H, two s's), 7.03 and 7.22 (1H, two d's, *J* 3.63Hz), 7.16 and 7.69 (1H, two d's *J* 3.94Hz), 7.33 (1H, br, s), 7.79 (1H, br, s), 8.21

(1H, s). m/z 323 (M^+) [Found (HRMS): m/z 323.0686. Calc. for $C_{12}H_{13}N_5O_4S$: 323.0688].

Description 74

- 5 2-[5-(4-Carboxamido-1,2,3-triazol-1-ylmethyl)thien-2-yl]-N-[2-(acetylthiomethyl)-4-phenylbutyryl]glycine ethyl ester

The title compound was prepared from ethyl 2-[5-(4-carboxamido-1,2,3-triazol-1-ylmethyl)thien-2-yl]-2-hydroximinooacetate (Description 73) by the procedure described in Description 40. ν_{\max} ($CHCl_3$) 3408, 3320, 3190, 1739, 1688 cm^{-1} . δ ($CDCl_3$) 1.26 and 1.27 (3H, two t's, J 7.16Hz), 1.76-2.05 (2H, m), 2.27 and 2.31 (3H, two s's), 2.35-2.75 (3H, m), 2.98-3.12 (2H, m), 4.17-4.29 (2H, m), 5.72 and 5.77 (1H, two d's, J 7.32Hz), 6.06 and 6.08 (2H, two s's), 6.65 and 6.74 (1H, two d's, J 7.28Hz), 6.87-6.88 (1H, m), 7.08-7.30 (6H, m), 7.93 and 8.02 (1H, two s's). m/z 544 (MH^+).

15

Description 75

Ethyl 2-[5-(4-methoxycarbonyl)triazol-1-ylmethylthien-2-yl]-2-oxoacetate and Ethyl 2-[5-(5-methoxycarbonyl)triazol-1-ylmethylthien-2-yl]-2-oxoacetate

A mixture of ethyl 2-(5-azidomethyl)thien-2-yl-2-oxoacetate (Description 68) (645mg) and methyl propiolate (0.27ml) in toluene (20ml) was heated at reflux for 1.5h. A further portion of methyl propiolate (0.27ml) was added and refluxing continued for a further 2h. The solvent was evaporated and the products isolated by column chromatography of the residue using gradient elution (Kieselgel:1:1 ethyl acetate:hexane going to ethyl acetate). Ethyl 2-[5-(5-methoxycarbonyl)triazol-1-ylmethylthien-2-yl]-2-oxoacetate was eluted first; ν_{\max} ($CHCl_3$) 1731 and 1669 cm^{-1} . δ ($CDCl_3$) 1.41 (3H, t, J 7.25Hz), 3.95 (3H, s), 4.41 (2H, q, J 7.02Hz), 6.13 (2H, s), 7.19 (1H, d, J 4.04Hz), 7.99 (1H, d, J 3.98Hz), 8.15 (1H, s), followed by ethyl 2-[5-(4-methoxycarbonyl)triazol-1-ylmethylthien-2-yl]-2-oxoacetate; ν_{\max} ($CHCl_3$) 1731 and 1672 cm^{-1} . δ ($CDCl_3$) 1.42 (3H, t, J 7.24Hz), 3.94 (3H, s), 4.42 (2H, q, J 7.02Hz), 5.82 (2H, s), 7.17 (1H, d, J 3.94Hz), 8.05 (1H, d, J 3.93Hz), 8.14 (1H, s).

30

Description 76

Ethyl 2-[5-(4-methoxycarbonyl)triazol-1-ylmethylthien-2-yl]-2-hydroxyiminoacetate

35 The title compound was prepared from ethyl 2-[5-(4-methoxycarbonyl)triazol-1-ylmethylthien-2-yl]-2-oxoacetate (Description 75) by the procedure described in Description 56; ν_{\max} ($CHCl_3$) 3555, 3282, 1731 and

1672cm⁻¹. δ (CDCl₃) 1.41 and 1.42 (3H, two t's, *J* 7.02Hz), 4.38-4.50 (2H, m), 5.73 and 5.82 (2H, two s's), 7.05-7.17 (1H, m), 7.98 and 8.05 (1H, two d's, *J* 3.94Hz), 8.10 and 8.15 (1H, two s's). *m/z* 338 (M⁺) [Found (HRMS): *m/z* 338.0682. Calc. for C₁₃H₄N₄O₅S 338.0685].

5

Description 77

2-[5-(4-Methoxycarbonyl)triazol-1-ylmethylthien-2-yl]-N-[2-(acetylthiomethyl)-4-phenylbutyryl]glycine ethyl ester

The title compound was prepared from ethyl 2-[5-(4-methoxycarbonyl)triazol-1-ylmethylthien-2-yl]-2-hydroxyiminoacetate (Description 76) by the procedure described in Description 40, except that the eluent was 1:1 ethyl acetate:hexane; ν_{\max} (CHCl₃) 3416, 1738, 1684cm⁻¹. δ (CDCl₃) 1.26-1.33 (3H, m), 1.77-2.13 (2H, m), 2.32 and 2.36 (3H, two s's), 2.30-2.75 (3H, m), 2.97-3.15 (2H, m), 3.92 and 3.93 (3H, two s's), 4.20-4.36 (2H, m), 5.68 and 5.70 (2H, two s's), 5.78 and 5.84 (1H, two d's, *J* 7.31Hz), 6.56 and 6.67 (1H, two d's, *J* 7.29Hz), 6.97-7.31 (7H, m), 8.40-8.07 (1H, m).

15

Description 78

Ethyl 2-[5-(5-methoxycarbonyl)triazol-1-ylmethylthien-2-yl]-2-hydroxyiminoacetate

The title compound was prepared from ethyl 2-[5-(5-methoxycarbonyl)triazol-1-ylmethylthien-2-yl]-2-oxoacetate (Description 75) by the procedure described in Description 56; ν_{\max} (tetrahydrofuran) 3221 and 1738cm⁻¹; *m/z* 338 (M⁺). [Found (HRMS); *m/z* 338.0689. Calc. for C₁₃H₁₄N₄O₅S 338.0685].

25

Description 79

2-[5-(5-Methoxycarbonyl)triazol-1-ylmethylthien-2-yl]-N-[2-(acetylthiomethyl)-4-phenylbutyryl]glycine ethyl ester

The title compound was prepared from ethyl 2-[5-(5-methoxycarbonyl)triazol-1-ylmethylthien-2-yl]-2-hydroxyiminoacetate (Description 78) by the procedure described in Description 40, except that the eluent was 1:1 ethyl acetate:hexane. ν_{\max} (CHCl₃) 3418, 1735, 1684cm⁻¹. δ (CDCl₃) 1.27 and 1.28 (3H, two t's, *J* 7.00Hz), 1.70-2.10 (2H, m), 2.30 and 2.32 (3H, s), 2.30-2.75 (3H, m), 2.96-3.12 (2H, m), 3.89 and 3.95 (3H, two s's), 4.17-4.31 (2H, m), 5.75 and 5.79 (1H, two d's, *J* 6.31Hz), 6.02 and 6.04 (2H, two s's), 6.43 and 6.56 (1H, two d's, *J* 7.31Hz), 6.90-7.31 (7H, m), 8.08 and 8.11 (1H, two s's).

35

Description 80

N-(2'-R-acetylthiomethyl-4'-phenylbutanoyl)-p-(p-methoxy)-benzyloxy-D-phenylglycine methyl ester and N-(2'-S-acetylthiomethyl-4'-phenylbutanoyl)-p-(p-methoxy)-benzyloxy-D-phenylglycine methyl ester.

- 5 To a stirred solution of the *p*-hydroxyphenylglycine derivative (90mg, 0.22mmol), from Description 32, in dry tetrahydrofuran (2ml) was added triphenyl phosphine (71mg, 0.27mmol) and *p*-methoxybenzyl alcohol (45mg, 0.33mmol) followed by diethyl azodicarboxylate (43 ul, 0.28mmol). The resulting yellow solution was stirred at room temperature for 15 minutes before dilution with ethyl acetate. The organic layer
- 10 was washed with water and dried (MgSO₄). The solvent was removed to afford a gum which was chromatographed on silica gel. Elution with 20% ethyl acetate in hexane gave diastereoisomer A as a gum (21mg, 18%). δ_H (CDCl₃) 1.89 (1H, m), 2.02 (1H, m), 2.27 (3H, s), 2.40 (1H, m), 2.68 (2H, m), 3.01 (2H, d, J 8.0 Hz), 3.75 (3H, s), 3.82 (3H, s), 4.98 (2H, s), 5.49 (1H, d, J 6.8 Hz), 6.40 (1H, d, J 6.8 Hz), 6.96 (4H, overlapping d), 7.2-
- 15 7.3 (9H, m) ppm. EIMS M⁺ 535. This was followed by diastereoisomer B as a gum (24mg, 21%). δ_H (CDCl₃) 1.90 (2H, m), 2.34 (3H, s), 2.50 (3H, m), 3.06 (2H, m), 3.74 (3H, s), 3.81 (3H, s), 4.97 (2H, s), 5.54 (1H, d, J 7.1 Hz), 6.56 (1H, d, J 7.1 Hz), 6.95 (4H, overlapping d), 7.0-7.3 (9H, m), ppm. EIMS M⁺ 535.

20 **Description 81**

3'-dibenzofuranylglycine methyl ester

- Dibenzofuranyl-3-carboxaldehyde (1.0g, 5.1mmol) was converted to the crude amino acid using essentially the method of Monianari et al. (Synthesis 1979, 26), but with some changes to the final purification. The crude solid material obtained after
- 25 neutralization and evaporation of the water was stirred in methanol (35ml), presaturated with hydrogen chloride gas, overnight. The methanol was removed under reduced pressure and the residue partitioned between ethyl acetate and an excess of saturated NaHCO₃ solution. The organic layer was washed with water and dried. Removal of the solvent afforded the crude product. Chromatography on silica gel, eluting with ethyl
- 30 acetate, gave desired product as a pale oil (41 mg, 3% over 2 stages). δ_H (CDCl₃) 1.68 (2H, br s), 3.73 (3H, s), 4.81 (1H, s), 7.3-7.5 (5H, m), 7.95 (2H, m) ppm.

Description 82

- N-(2'-SR-acetylthiomethyl-4'-phenylbutanoyl)-(3''-dibenzofuranyl) glycine methyl ester**
- 35

To a cooled (0°), stirred solution of 2-acetylthiomethyl-4-phenylbutanoic acid prepared as in Description 5 (41mg, 0.16mmol) in dry tetrahydrofuran (5 ml) containing

dry dimethylformamide (1 drop), was added sodium hydride (7mg of a 55% suspension in oil, 0.16mmol). The reaction mixture was allowed to reach room temperature and stirring was continued for a further 15 mins. The suspension was then recooled (0°) and treated with oxalyl chloride (17ul, 0.19mmol) and stirred at room ambient temperature for 30 mins. The resulting mixture was then evaporated *in vacuo* and the residue suspended in dry tetrahydrofuran (5 ml). The filtered solution was taken to dryness once more to afford the acid chloride as an oil.

A stirred, cooled (0°) solution of (3'-dibenzofuranyl)glycine methyl ester from Description 81 (41mg, 0.16mmol) in dry tetrahydrofuran (5ml) was treated with triethylamine (22ul, 0.16mmol) followed by a solution of the above acid chloride in dry tetrahydrofuran (5ml) added over 1 minute. The mixture was stirred at ambient temperature for 3 hours and then partitioned between ethyl acetate and 1M hydrochloric acid. The organic layer was washed with water and saturated brine and dried over anhydrous sodium sulphate. Evaporation of the solvent afforded crude product as an oil which was chromatographed on silica gel. Elution with 20% ethyl acetate in hexane afforded diastereoisomer A as a gum (15mg, 19%). δ_H (CDCl₃) 1.93 (1H, m), 2.05 (1H, m), 2.24 (3H, s), 2.41 (1H, m), 2.7 (2H, m), 3.77 (3H, s), 4.38 (2H, q, J 7.2 Hz), 5.71 (1H, d, J 6.8 Hz), 6.63 (1H, d, J 6.8 Hz), 7.2-7.5 (10H, m) 7.95 (2H, m) ppm. This was followed by diastereoisomer B as a gum (16mg, 21%). δ_H (CDCl₃) 1.87 (1H, m), 1.95 (1H, m), 2.35 (3H, s), 2.50 (3H, m), 3.09 (2H, m), 3.76 (3H, s), 5.76 (1H, d, J 6.9 Hz), 6.76 (1H, d, J 6.9 Hz), 7.0-7.5 (10H, m) 8.00 (2H, m) ppm. EIMS M⁺ 489.

Description 83

N-(2'-R-acetylthiomethyl-4'-phenylbutanoyl)-p-(2''-furanylmethoxy)-D-phenylglycine methyl ester and N-(2'-S-acetylthiomethyl-4'-phenylbutanoyl)-p-(2''-furanylmethoxy)-D-phenylglycine methyl ester.

To a stirred solution of the p-hydroxyphenylglycine derivative (85mg, 0.21mmol), from Description 32, in dry tetrahydrofuran (2ml) was added triphenyl phosphine (67mg, 0.26mmol) and furfuryl alcohol (26ul, 0.30mmol) followed by diethyl azodicarboxylate (42 ul, 0.27mmol). The resulting yellow solution was stirred at room temperature for 15 minutes before dilution with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). The solvent was removed to afford a gum which was chromatographed on silica gel. Elution with 20% ethyl acetate in hexane gave diastereoisomer A as a gum (27mg, 26%). δ_H (CDCl₃) 1.89 (1H, m), 2.02 (1H, m), 2.27 (3H, s), 2.40 (1H, m), 2.68 (2H, m), 3.02 (2H, d, J 6.5 Hz), 3.75 (3H, s), 5.00 (2H, s), 5.49 (1H, d, J 6.8 Hz), 6.40 (3H, m), 6.98 (2H, d, J 8.7 Hz), 7.1-7.5 (8H, m) ppm. EIMS M⁺ 495. This was followed by diastereoisomer B as a gum (30mg, 30%). δ_H (CDCl₃)

1.90 (2H, m), 2.33 (3H, s), 2.50 (3H, m), 3.06 (2H, m), 3.74 (3H, s), 4.99 (2H, s), 5.55 (1H, d, J 7.0 Hz), 6.4-6.6 (3H, overlapping m), 7.0-7.5 (10H, m), ppm. EIMS M⁺ 495.

Description 84

- 5 N-(2'-*R*-acetylthiomethyl-4'-phenylbutanoyl)-*p*-(*p*-acetoxy)-benzyloxy-D-phenylglycine methyl ester and N-(2'-*S*-acetylthiomethyl-4'-phenylbutanoyl)-*p*-(*p*-acetoxy)-benzyloxy-D-phenylglycine methyl ester.

To a stirred solution of the *p*-hydroxyphenylglycine derivative (138mg, 0.33mmol), from Description 32, in dry tetrahydrofuran (2ml) was added triphenyl
 10 phosphine (108mg, 0.41mmol) and *p*-acetoxybenzyl alcohol (55mg, 0.33mmol) followed by diethyl azodicarboxylate (67 ul, 0.43mmol). The resulting yellow solution was stirred at room temperature for 15 minutes before dilution with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). The solvent was removed to afford a gum which was chromatographed on silica gel. Elution with 25% ethyl acetate in hexane gave
 15 diastereoisomer A as a gum (65mg, 35%). δ_H (CDCl₃) 1.89 (1H, m), 2.02 (1H, m), 2.26 (3H, s), 2.30 (3H, s), 2.40 (1H, m), 2.68 (2H, m), 3.01 (2H, d, J 7.7 Hz), 3.75 (3H, s), 5.04 (2H, s), 5.49 (1H, d, J 6.8 Hz), 6.48 (1H, d, J 6.8 Hz), 6.9-7.5 (13H, m) ppm. ESMS MH⁺ 564. This was followed by diastereoisomer B as a gum (65mg, 35%). δ_H (CDCl₃)
 20 1.90 (2H, m), 2.28 (3H, s), 2.31 (3H, s), 2.50 (3H, m), 3.06 (2H, m), 3.74 (3H, s), 5.03 (2H, s), 5.54 (1H, d, J 7.0 Hz), 6.59 (1H, d, J 7.0 Hz), 6.9-7.5 (13H, m), ppm. ESMS MH⁺ 564.

Description 85

- 25 N-(2'-*R*-acetylthiomethyl-4'-phenylbutanoyl)-*p*-(*p*-dimethylamino)-benzyloxy-D-phenylglycine methyl ester and N-(2'-*S*-acetylthiomethyl-4'-phenylbutanoyl)-*p*-(*p*-dimethylamino)-benzyloxy-D-phenylglycine methyl ester.

To a stirred solution of the *p*-hydroxyphenylglycine derivative (138mg, 0.33mmol), from Description 32, in dry tetrahydrofuran (2ml) was added triphenyl
 30 phosphine (108mg, 0.41mmol) and *p*-dimethylaminobenzyl alcohol (50mg, 0.33mmol) followed by diethyl azodicarboxylate (67 ul, 0.43mmol). The resulting yellow solution was stirred at room temperature for 15 minutes before dilution with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). The solvent was removed to afford a gum which was chromatographed on silica gel. Elution with 25% ethyl acetate in hexane gave diastereoisomer A as a gum (33mg). δ_H (CDCl₃) 1.89 (1H, m), 2.02 (1H,
 35 m), 2.26 (3H, s), 2.35 (1H, s), 2.68 (2H, m), 2.95 (6H, s), 3.01 (2H, d, J 7.7 Hz), 3.74 (3H, s), 4.94 (2H, s), 5.49 (1H, d, J 6.8 Hz), 6.38 (1H, d, J 6.8 Hz), 6.74 (2H, d, J 8.7 Hz), 6.97 (2H, d, J 8.7 Hz), 7.3 (9H, m) ppm. ESMS MH⁺ 549. This was followed by

diastereoisomer B as a gum (55mg). δ_H (CDCl₃) 1.90 (2H, m), 2.33 (3H, s), 2.50 (3H, m), 2.95 (6H, s), 3.06 (2H, m), 3.73 (3H, s), 4.93 (2H, s), 5.54 (1H, d, J 7.0 Hz), 6.61 (1H, d, J 7.0 Hz), 6.73 (2H, d, J 8.8 Hz), 6.97 (2H, d, J 8.7 Hz), 7.0-7.3 (9H, m), ppm. ESMS MH⁺ 549.

5

Description 86

N-(2'-R-acetylthiomethyl-4'-phenylbutanoyl)-p-(m-methoxycarbonyl)-benzyloxy-D-phenylglycine methyl ester and N-(2'-S-acetylthiomethyl-4'-phenylbutanoyl)-p-(m-methoxycarbonyl)-benzyloxy-D-phenylglycine methyl ester.

- 10 To a stirred solution of the *p*-hydroxyphenylglycine derivative (121mg, 0.29mmol), from Description 32, in dry tetrahydrofuran (2ml) was added triphenylphosphine (95mg, 0.36mmol) and *m*-methoxycarbonylbenzyl alcohol (48mg, 0.29mmol) followed by diethyl azodicarboxylate (60 ul, 0.38mmol). The resulting yellow solution was stirred at room temperature for 15 minutes before dilution with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). The solvent was removed to afford a gum which was chromatographed on silica gel. Elution with 25% ethyl acetate in hexane gave diastereoisomer A as a gum (47mg). δ_H (CDCl₃) 1.89 (1H, m), 2.05 (1H, m), 2.29 (3H, s), 2.40 (1H, m), 2.68 (2H, m), 3.05 (2H, m), 3.77 (3H, s), 3.96 (3H, s), 5.12 (2H, s), 5.52 (1H, d, J 6.9 Hz), 6.43 (1H, d, J 6.9 Hz), 6.98 (2H, d, J 8.8 Hz), 7.2-7.3 (7H, m), 7.50 (1H, dd, J 8 Hz), 7.64 (1H, d, 8 Hz), 8.03 (1H, d, J 7.8 Hz), 8.13 (1H, s) ppm. ESMS MNa⁺ 587. This was followed by diastereoisomer B as a gum (64mg). δ_H (CDCl₃) 1.89 (1H, m), 2.05 (1H, m), 2.29 (3H, s), 2.40 (1H, m), 2.68 (2H, m), 3.05 (2H, m), 3.77 (3H, s), 3.96 (3H, s), 5.12 (2H, s), 5.52 (1H, d, J 6.9 Hz), 6.43 (1H, d, J 6.9 Hz), 6.98 (2H, d, J 8.8 Hz), 7.2-7.3 (7H, m), 7.50 (1H, dd, J 8 Hz), 7.64 (1H, d, 8 Hz), 8.03 (1H, d, J 7.8 Hz), 8.13 (1H, s) ppm. ESMS MNa⁺ 587
- 25

Description 87

N-(2'-R-acetylthiomethyl-4'-phenylbutanoyl)-p-(3,4-diacetoxy)-benzyloxy-D-phenylglycine methyl ester and N-(2'-S-acetylthiomethyl-4'-phenylbutanoyl)-p-(3,4-diacetoxy)-benzyloxy-D-phenylglycine methyl ester.

- 30 To a stirred solution of the *p*-hydroxyphenylglycine derivative (145mg, 0.35mmol), from Description 32, in dry tetrahydrofuran (2ml) was added triphenylphosphine (114mg, 0.44mmol) and 3,4-diacetoxybenzyl alcohol (78mg, 0.35mmol) followed by diethyl azodicarboxylate (72 ul, 0.46mmol). The resulting yellow solution was stirred at room temperature for 15 minutes before dilution with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). The solvent was removed to afford a gum which was chromatographed on silica gel. Elution with 33%
- 35

ethyl acetate in hexane gave diastereoisomer A as a gum (81mg). δ_H ($CDCl_3$) 1.89 (1H, m), 2.05 (1H, m), 2.29 (3H, s), 2.32 (6H, s), 2.40 (1H, m), 2.68 (2H, m), 3.05 (2H, d, J 7.1 Hz), 3.78 (3H, s), 5.12 (2H, s), 5.52 (1H, d, J 6.7 Hz), 6.46 (1H, d, J 6.7 Hz), 6.98 (2H, d, J 8.8 Hz), 7.2-7.4 (10H, m) ppm. ESMS MNa^+ 644. This was followed by
5 diastereoisomer B as a gum (70mg). δ_H ($CDCl_3$) 1.89 (1H, m), 2.05 (1H, m), 2.35 (6H, s), 2.38 (3H, s), 2.4-2.7 (3H, m), 3.05 (2H, m), 3.78 (3H, s), 5.10 (2H, s), 5.58 (1H, d, J 6.7 Hz), 6.62 (1H, d, J 6.7 Hz), 6.98 (2H, d, J 8.8 Hz), 7.2-7.4 (10H, m) ppm. ESMS MNa^+ 644.

10 **Description 88**

N-(2'-R-acetylthiomethyl-4'-phenylbutanoyl)-p-(p-nitro)-benzyloxy-D-phenylglycine methyl ester and N-(2'-S-acetylthiomethyl-4'-phenylbutanoyl)-p-(p-nitro)-benzyloxy-D-phenylglycine methyl ester.

To a stirred solution of the *p*-hydroxyphenylglycine derivative (106mg, 0.26mmol), from Description 32, in dry tetrahydrofuran (2ml) was added
15 triphenylphosphine (85mg, 0.32mmol) and *p*-nitrobenzyl alcohol (39mg, 0.26mmol) followed by diethyl azodicarboxylate (53 μ l, 0.34mmol). The resulting yellow solution was stirred at room temperature for 15 minutes before dilution with ethyl acetate. The organic layer was washed with water and dried ($MgSO_4$). The solvent was removed to
20 afford a gum which was chromatographed on silica gel. Elution with 25%-33% ethyl acetate in hexane gave diastereoisomer A as a gum (68mg). δ_H ($CDCl_3$) 1.89 (1H, m), 2.05 (1H, m), 2.27 (3H, s), 2.40 (1H, m), 2.68 (2H, m), 3.03 (2H, m), 3.74 (3H, s), 5.17 (2H, s), 5.52 (1H, d, J 6.9 Hz), 6.52 (1H, d, J 6.9 Hz), 6.95 (2H, d, J 8.7 Hz), 7.2-7.4 (7H, m) 7.60 (2H, d, J 8.7 Hz), 8.25 (2H, d, J 8.7 Hz) ppm. APCI MH^+ 551. This was
25 followed by diastereoisomer B as a gum (43mg). δ_H ($CDCl_3$) 1.90 (2H, m), 2.33 (3H, s), 2.4-2.6 (3H, m), 3.05 (2H, m), 3.74 (3H, s), 5.16 (2H, s), 5.55 (1H, d, J 6.7 Hz), 6.64 (1H, d, J 6.7 Hz), 6.98 (2H, d, J 8.8 Hz), 7.0-7.4 (7H, m)) 7.59 (2H, d, J 8.7 Hz), 8.25 (2H, d, J 8.7 Hz) ppm. APCI MH^+ 551.

30 **Description 89**

N-(2'-RS-acetylthiomethyl-4'-phenylbutanoyl)-p-(4-pyridylmethoxy)-D-phenylglycine methyl ester

To a stirred solution of the *p*-hydroxyphenylglycine derivative (118mg, 0.28mmol), from Description 32, in dry tetrahydrofuran (2ml) was added
35 triphenylphosphine (93mg, 0.35mmol) and 4-pyridylcarbinol (31mg, 0.28mmol) followed by diethyl azodicarboxylate (57 μ l, 0.36mmol). The resulting yellow solution was stirred at room temperature for 15 minutes before dilution with ethyl acetate. The

organic layer was washed with water and dried (MgSO₄). The solvent was removed to afford a gum which was chromatographed on silica gel. Elution with ethyl acetate gave a mixture of diastereoisomers A and B as a gum (92mg). δ_H (CDCl₃) 1.85 (1H, m), 2.0 (1H, m), 2.22 and 2.28 (3H, s), 2.4-2.7 (3H, m), 3.0 (2H, m), 3.69 (3H, s), 5.02 and 5.03 (2H, s), 5.44 and 5.49 (1H, d, J 6.9 Hz), 6.37 and 6.52 (1H, d, J 6.9 Hz), 6.89 (2H, d, J 8.7 Hz), 7.0-7.3 (9H, m) 8.25 (2H, m) ppm. ESMS MH⁺ 507.

Description 90

10 N-(2'-RS-acetylthiomethyl-4'-phenylbutanoyl)-p-(2-pyridylmethoxy)-D-phenylglycine methyl ester

To a stirred solution of the *p*-hydroxyphenylglycine derivative (123mg, 0.30mmol), from Description 32, in dry tetrahydrofuran (2ml) was added triphenylphosphine (97mg, 0.37mmol) and 2-pyridylcarbinol (32mg, 0.30mmol) followed by diethyl azodicarboxylate (60 μ l, 0.39mmol). The resulting yellow solution was stirred at room temperature for 15 minutes before dilution with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). The solvent was removed to afford a gum which was chromatographed on silica gel. Elution with ethyl acetate/hexane (1:1) gave a mixture of diastereoisomers A and B as a gum (83mg). δ_H (CDCl₃) 1.85 (1H, m), 2.0 (1H, m), 2.27 and 2.33 (3H, s), 2.4-2.7 (3H, m), 3.0 (2H, m), 3.74 (3H, s), 5.20 (2H, s), 5.48 and 5.54 (1H, d, J 6.7 Hz), 6.39 and 6.55 (1H, d, J 6.7 Hz), 6.98 (2H, d, J 8.7 Hz), 7.0-7.3 (8H, m) 7.50 (1H, m), 7.72 (1H, m), 8.60 (1H, m) ppm. ESMS MNa⁺ 529.

Description 91

25 N-(2'-RS-acetylthiomethyl-4'-phenylbutanoyl)-p-(3-pyridylmethoxy)-D-phenylglycine methyl ester

To a stirred solution of the *p*-hydroxyphenylglycine derivative (114mg, 0.28mmol), from Description 32, in dry tetrahydrofuran (2ml) was added triphenylphosphine (90mg, 0.34mmol) and 3-pyridylcarbinol (30mg, 0.28mmol) followed by diethyl azodicarboxylate (56 μ l, 0.36mmol). The resulting yellow solution was stirred at room temperature for 15 minutes before dilution with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). The solvent was removed to afford a gum which was chromatographed on silica gel. Elution with ethyl acetate/hexane (1:1) gave a mixture of diastereoisomers A and B as a gum (104mg). δ_H (CDCl₃) 1.85 (1H, m), 2.0 (1H, m), 2.28 and 2.34 (3H, s), 2.4-2.7 (3H, m), 3.0 (2H, m), 3.74 (3H, s), 5.07 (2H, s), 5.50 and 5.55 (1H, d, J 6.7 Hz), 6.45 and 6.60 (1H, d, J 6.7 Hz), 6.97 (2H, d, J 8.7 Hz), 7.0-7.8 (9H, m) 8.58 (1H, m), 8.67 (1H, s) ppm. ESMS MH⁺ 507.

Description 92

N-(2'-RS-acetylthiomethyl-4'-phenylbutanoyl)-p-(p-acetamido)-benzyloxy-D-phenylglycine methyl ester

To a stirred solution of the *p*-hydroxyphenylglycine derivative (151mg, 0.36mmol), from Description 32, in dry tetrahydrofuran (2ml) was added triphenylphosphine (119mg, 0.45mmol) and 4-acetamidobenzyl alcohol (60mg, 0.36mmol) followed by diethyl azodicarboxylate (74 μ l, 0.47mmol). The resulting yellow solution was stirred at room temperature for 15 minutes before dilution with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). The solvent was removed to afford a gum which was chromatographed on silica gel. Elution with ethyl acetate gave a mixture of diastereoisomers A and B as a gum (101mg). δ_H (CDCl₃) 1.85 (1H, m), 2.0 (1H, m), 2.18 (3H, s), 2.26 and 2.33 (3H, s), 2.4-2.7 (3H, m), 3.0 (2H, m), 3.74 (3H, s), 5.00 (2H, s), 5.48 and 5.53 (1H, d, J 6.7 Hz), 6.43 and 6.59 (1H, d, J 6.7 Hz), 6.94 (2H, d, J 8.7 Hz), 7.0-7.5 (11H, m) ppm. ESMS MH⁺ 563.

Description 93

N-(2'-RS-acetylthiomethyl-4'-phenylbutanoyl)-D-m-hydroxyphenylglycine methyl ester.

To a cooled (0°), stirred solution of 2-acetylthiomethyl-4-phenylbutanoic acid prepared as in Description 5, (0.50g, 2.0mmol) in dry tetrahydrofuran (10ml) containing dry dimethylformamide (1 drop), was added sodium hydride (88mg of a 55% suspension in oil, 2.0mmol). The reaction mixture was allowed to reach room temperature and stirring was continued for a further 15 mins. The suspension was then re-cooled (0°) and treated with oxalyl chloride (210 μ l, 2.4mmol) and stirred at room ambient temperature for 30 mins. The resulting mixture was then evaporated *in vacuo* and the residue suspended in dry tetrahydrofuran (5 ml). The filtered solution was taken to dryness once more to afford the acid chloride as an oil.

A stirred, cooled (0°) solution of D-m-hydroxyphenylglycine methyl ester (435mg, 2.0mmol), prepared from D-m-hydroxyphenylglycine with hydrogen chloride in methanol as in Description 4, in dry tetrahydrofuran (10ml) was treated with triethylamine (560 μ l, 4.0mmol) followed by a solution of the above acid chloride in dry tetrahydrofuran (5ml) added over 1 minute. The mixture was stirred at ambient temperature for 3 hours and then partitioned between ethyl acetate and 1M hydrochloric acid. The organic layer was washed with water and saturated brine and dried over anhydrous sodium sulphate. Evaporation of the solvent afforded crude product as an oil which was chromatographed on silica gel. Elution with 33% ethyl acetate in hexane afforded the desired mixture of diastereoisomers as a pale gum (300mg). δ_H (CDCl₃)

1.89 (1H, m), 2.02 (1H, m), 2.28 and 2.34 (3H, s), 2.4-2.7 (3H, m), 3.1 (2H, m), 3.74 and 3.75 (3H, s), 5.51 and 5.55 (1H, d, J 6.9 Hz), 6.54 and 6.67 (1H, d, J 6.9 Hz), 6.8-7.3 (9H, m) ppm.

5 **Description 94**

N-(2'-R-acetylthiomethyl-4'-phenylbutanoyl)-m-(m-methoxycarbonyl)-benzyloxy-D-phenylglycine methyl ester and N-(2'-S-acetylthiomethyl-4'-phenylbutanoyl)-m-(m-methoxycarbonyl)-benzyloxy-D-phenylglycine methyl ester.

To a stirred solution of the *m*-hydroxyphenylglycine derivative (93mg, 0.22mmol), from Description 93, in dry tetrahydrofuran (2ml) was added triphenylphosphine (72mg, 0.28mmol) and *m*-methoxycarbonylbenzyl alcohol (37mg, 0.22mmol) followed by diethyl azodicarboxylate (45 ul, 0.29mmol). The resulting yellow solution was stirred at room temperature for 15 minutes before dilution with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). The solvent was removed to afford a gum which was chromatographed on silica gel. Elution with 25% ethyl acetate in hexane gave diastereoisomer A as a gum (31mg). δ_H (CDCl₃) 1.89 (1H, m), 2.05 (1H, m), 2.25 (3H, s), 2.40 (1H, m), 2.68 (2H, m), 3.03 (2H, m), 3.74 (3H, s), 3.93 (3H, s), 5.10 (2H, s), 5.54 (1H, d, J 6.9 Hz), 6.48 (1H, d, J 6.9 Hz), 6.9-7.3 (9H, m), 7.50 (1H, dd, J 8 Hz), 7.64 (1H, d, 8 Hz), 8.00 (1H, dd, J 7.8 Hz), 8.11 (1H, s) ppm.

ESMS MH⁺ 564. This was followed by diastereoisomer B as a gum (33mg). δ_H (CDCl₃) 1.89 (1H, m), 2.00 (1H, m), 2.33 (3H, s), 2.4 - 2.6 (3H, m), 3.08 (2H, m), 3.73 (3H, s), 3.92 (3H, s), 5.08 (2H, s), 5.58 (1H, d, J 6.9 Hz), 6.64 (1H, d, J 6.9 Hz), 6.9 - 7.3 (9H, m), 7.44 (1H, dd, J 8 Hz), 7.60 (1H, d, 8 Hz), 8.00 (1H, d, J 7.8 Hz), 8.10 (1H, s) ppm. ESMS MH⁺ 564.

25

Description 95

N-(2'-R-acetylthiomethyl-4'-phenylbutanoyl)-m-(p-methoxycarbonyl)-benzyloxy-D-phenylglycine methyl ester and N-(2'-S-acetylthiomethyl-4'-phenylbutanoyl)-m-(p-methoxycarbonyl)-benzyloxy-D-phenylglycine methyl ester.

To a stirred solution of the *m*-hydroxyphenylglycine derivative (92mg, 0.22mmol), from Description 93, in dry tetrahydrofuran (2ml) was added triphenylphosphine (72mg, 0.28mmol) and *p*-methoxycarbonylbenzyl alcohol (37mg, 0.22mmol) followed by diethyl azodicarboxylate (45 ul, 0.29mmol). The resulting yellow solution was stirred at room temperature for 15 minutes before dilution with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). The solvent was removed to afford a gum which was chromatographed on silica gel. Elution with 25% ethyl acetate in hexane gave diastereoisomer A as a gum (30mg). δ_H (CDCl₃) 1.89 (1H,

m), 2.05 (1H, m), 2.25 (3H, s), 2.40 (1H, m), 2.68 (2H, m), 3.03 (2H, m), 3.74 (3H, s), 3.93 (3H, s), 5.13 (2H, s), 5.53 (1H, d, J 6.9 Hz), 6.48 (1H, d, J 6.9 Hz), 6.9-7.3 (9H, m), 7.50 (2H, d, J 8 Hz), 8.06 (2H, d, J 8 Hz) ppm. ESMS MH⁺ 564. This was followed by diastereoisomer B as a gum (30mg). δ_H (CDCl₃) 1.89 (1H, m), 2.00 (1H, m), 2.34 (3H, s), 2.4 - 2.6 (3H, m), 3.08 (2H, m), 3.73 (3H, s), 3.92 (3H, s), 5.10 (2H, s), 5.58 (1H, d, J 6.9 Hz), 6.65 (1H, d, J 6.9 Hz), 6.9 - 7.3 (9H, m), 7.47 (2H, d, J 8 Hz), 8.10 (2H, d, J 8 Hz) ppm. ESMS MH⁺ 564.

Description 96

10 N-(2'-*R*-acetylthiomethyl-4'-phenylbutanoyl)-*p*-(*m*-amino)-benzyloxy-D-phenylglycine methyl ester and N-(2'-*S*-acetylthiomethyl-4'-phenylbutanoyl)-*p*-(*m*-amino)-benzyloxy-D-phenylglycine methyl ester.

To a stirred solution of the *p*-hydroxyphenylglycine derivative (133mg, 0.32mmol), from Description 32, in dry tetrahydrofuran (2ml) was added triphenyl
15 phosphine (104mg, 0.40mmol) and *m*-aminobenzyl alcohol (40mg, 0.32mmol) followed by diethyl azodicarboxylate (65 μ l, 0.42mmol). The resulting yellow solution was stirred at room temperature for 15 minutes before dilution with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). The solvent was removed to afford a gum
20 which was chromatographed on silica gel. Elution with 50% ethyl acetate in hexane gave diastereoisomer A as a gum (36mg). δ_H (CDCl₃) 1.89 (1H, m), 2.02 (1H, m), 2.26 (3H, s), 2.35 (1H, s), 2.68 (2H, m), 3.02 (2H, d, J 7.7 Hz), 3.70 (2H, br s), 3.74 (3H, s), 4.97 (2H, s), 5.48 (1H, d, J 6.8 Hz), 6.39 (1H, d, J 6.8 Hz), 6.64 (1H, dd, J 7.7 and 2 Hz), 6.74 (1H, s), 6.79 (1H, d, J 7.6 Hz), 6.95 (2H, d, J 8.7 Hz), 7.2-7.3 (8H, m) ppm. ESMS MH⁺ 521. This was followed by diastereoisomer B as a gum (27mg). δ_H (CDCl₃) 1.90 (2H, m), 2.33 (3H, s), 2.50 (3H, m), 3.06 (2H, m), 3.69 (2H, br s), 3.73 (3H, s), 4.97 (2H, s),
25 5.54 (1H, d, J 7.0 Hz), 6.55 (1H, d, J 7.0 Hz), 6.64 (1H, dd, J 7.5 and 2Hz), 6.74 (1H, s), 6.78 (1H, d, J 7.6 Hz), 6.95 (2H, d, J 8.7 Hz), 7.0-7.3 (8H, m), ppm. ESMS MH⁺ 521.

Description 97

30 N-(2'-*R*-acetylthiomethyl-4'-phenylbutanoyl)-*p*-(*p*-dimethylamino)-phenethyloxy-D-phenylglycine methyl ester and N-(2'-*S*-acetylthiomethyl-4'-phenylbutanoyl)-*p*-(*p*-dimethylamino)-phenethyloxy-D-phenylglycine methyl ester.

To a stirred solution of the *p*-hydroxyphenylglycine derivative (116mg, 0.28mmol), from Description 32, in dry tetrahydrofuran (2ml) was added triphenyl
35 phosphine (92mg, 0.35mmol) and *p*-dimethylaminophenethyl alcohol (46mg, 0.28mmol) followed by diethyl azodicarboxylate (58 μ l, 0.36mmol). The resulting yellow solution was stirred at room temperature for 15 minutes before dilution with ethyl acetate. The

organic layer was washed with water and dried (MgSO₄). The solvent was removed to afford a gum which was chromatographed on silica gel. Elution with 25% ethyl acetate in hexane gave diastereoisomer A as a gum (26mg). δ_H (CDCl₃) 1.89 (1H, m), 2.02 (1H, m), 2.26 (3H, s), 2.35 (1H, s), 2.68 (2H, m), 2.92 (6H, s), 3.00 (4H, m), 3.73 (3H, s), 4.10 (2H, t, J 7.3 Hz), 5.47 (1H, d, J 6.8 Hz), 6.36 (1H, d, J 6.8 Hz), 6.71 (2H, d, J 8.7 Hz), 6.88 (2H, d, J 8.7 Hz), 7.3 (9H, m) ppm. This was followed by diastereoisomer B as a gum (48mg). δ_H (CDCl₃) 1.90 (2H, m), 2.33 (3H, s), 2.50 (3H, m), 2.95 (6H, s), 3.06 (4H, m), 3.73 (3H, s), 4.20 (2H, m), 5.53 (1H, d, J 7.0 Hz), 6.53 (1H, d, J 7.0 Hz), 6.7-7.3 (13H, m), ppm.

10

Description 98

N-(2'-*RS*-acetylthiomethyl-4'-phenylbutanoyl)-*p*-(*N*-methyl-3-pyridiniummethoxy)-*D*-phenylglycine methyl ester iodide

A solution of the 3-pyridyl compound (87mg, 0.17mmol) from Description 91 was dissolved in methanol (1ml) and treated with methyl iodide (54 μ l, 0.86mmol). The reaction mixture was stoppered and warmed at 50° for 2 hours and then left overnight at room temperature. Evaporation of the solvent afforded the desired product as an oil (95mg). δ_H (CDCl₃) 1.86 (1H, m), 2.0 (1H, m), 2.32 and 2.34 (3H, s), 2.4-2.7 (3H, m), 3.0 (2H, m), 3.74 (3H, s), 4.58 (3H, s), 5.38 (2H, s), 5.46 and 5.51 (1H, d, J 6.7 Hz), 6.75 and 6.82 (1H, d, J 6.7 Hz), 7.0-7.3 (9H, m) 7.95 (1H, dd, J 6.0 and 6.0 Hz), 8.56 and 8.60 (1H, d, 6.0 and 6.0 Hz), 8.90 and 8.95 (1H, d, J 6.0 Hz), 9.46 and 9.50 (1H, s) ppm. ESMS M⁺ 521.

Description 99

N-(2'-*R*-acetylthiomethyl-4'-phenylbutanoyl)-*p*-(*p*-benzyloxy)-benzyloxy-*D*-phenylglycine methyl ester and N-(2'-*S*-acetylthiomethyl-4'-phenylbutanoyl)-*p*-(*p*-benzyloxy)-benzyloxy-*D*-phenylglycine methyl ester.

To a stirred solution of the *p*-hydroxyphenylglycine derivative (117mg, 0.28mmol), from Description 32, in dry tetrahydrofuran (2ml) was added triphenyl phosphine (92mg, 0.35mmol) and *p*-benzyloxybenzyl alcohol (60mg, 0.28mmol) followed by diethyl azodicarboxylate (57 μ l, 0.36mmol). The resulting yellow solution was stirred at room temperature for 15 minutes before dilution with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). The solvent was removed to afford a gum which was chromatographed on silica gel. Elution with 33% ethyl acetate in hexane gave diastereoisomer A as a gum (48mg). δ_H (CDCl₃) 1.89 (1H, m), 2.02 (1H, m), 2.26 (3H, s), 2.36 (1H, m), 2.68 (2H, m), 3.02 (2H, d, J 8.0 Hz), 3.74 (3H, s), 4.97 (2H, s), 5.07 (2H, s), 5.49 (1H, d, J 6.8 Hz), 6.40 (1H, d, J 6.8 Hz), 6.96 (4H,

overlapping d), 7.2-7.3 (14H, m) ppm. ESMS MH^+ 612. This was followed by diastereoisomer B as a gum (48mg). δ_H ($CDCl_3$) 1.90 (2H, m), 2.33 (3H, s), 2.50 (3H, m), 3.06 (2H, m), 3.73 (3H, s), 4.97 (2H, s), 5.06 (2H, s), 5.54 (1H, d, J 7.1 Hz), 6.56 (1H, d, J 7.1 Hz), 6.95 (4H, overlapping d), 7.0-7.3 (14H, m), ppm. ESMS MH^+ 612.

5

Description 100

N-(2'-*R*-acetylthiomethyl-4'-phenylbutanoyl)-*p*-(*p*-trifluoromethoxy)-benzyloxy-D-phenylglycine methyl ester and N-(2'-*S*-acetylthiomethyl-4'-phenylbutanoyl)-*p*-(*p*-trifluoromethoxy)-benzyloxy-D-phenylglycine methyl ester.

10 To a stirred solution of the *p*-hydroxyphenylglycine derivative (116mg, 0.28mmol), from Description 32, in dry tetrahydrofuran (2ml) was added triphenyl phosphine (92mg, 0.35mmol) and *p*-(trifluoromethoxy)benzyl alcohol (54mg, 0.28mmol) followed by diethyl azodicarboxylate (57 μ l, 0.36mmol). The resulting yellow solution was stirred at room temperature for 15 minutes before dilution with ethyl acetate. The organic layer was washed with water and dried ($MgSO_4$). The solvent was removed to afford a gum which was chromatographed on silica gel. Elution with 25% ethyl acetate in hexane gave diastereoisomer A as a gum (60mg). δ_H ($CDCl_3$) 1.89 (1H, m), 2.02 (1H, m), 2.27 (3H, s), 2.36 (1H, m), 2.68 (2H, m), 3.02 (2H, d, J 8.0 Hz), 3.75 (3H, s), 5.05 (2H, s), 5.49 (1H, d, J 6.8 Hz), 6.44 (1H, d, J 6.8 Hz), 6.96 (2H, d, J 8.6 Hz), 7.2-7.3 (9H, m), 7.46 (2H, d, J 8.6 Hz) ppm. ESMS MH^+ 590. This was followed by diastereoisomer B as a gum (63mg). δ_H ($CDCl_3$) 1.90 (2H, m), 2.33 (3H, s), 2.50 (3H, m), 3.06 (2H, m), 3.73 (3H, s), 5.04 (2H, s), 5.55 (1H, d, J 7.0 Hz), 6.61 (1H, d, J 7.0 Hz), 6.95 (2H, d, J 8.6 Hz), 7.04 (2H, d), 7.2-7.3 (7H, m), 7.45 (2H, d, J 8.6 Hz) ppm. ESMS MH^+ 590.

25

Example 1

N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*m*-benzyl-phenylglycine (Diastereoisomer A)

30 The diastereoisomer A methyl ester (28mg, 57.3 μ mol) from Description 5 was suspended in methanol (0.5 ml) and treated with a solution of sodium sulphide nonahydrate (41mg, 172 μ mol) in water (0.5ml). The suspension was stirred under argon for 30 minutes. The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (5 drops) and diluted with ethyl acetate. The organic layer was washed with water and dried ($MgSO_4$). Removal of the solvent afforded the desired product as a crisp foam (24mg). δ_H ($CDCl_3$) 1.30 (1H, t, J 9.3 Hz), 1.85 (1H, m), 2.02 (1H, m), 2.30 (1H, m), 2.5-3.1 (4H, m), 3.97 (2H, s), 5.58 (1H, d, J 6.6 Hz), 6.48 (1H, d, J 6.6 Hz), 7.2 (14H, m) ppm. ESMS MH^+ 434.

35

Example 2**N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*m*-benzyl-phenylglycine (Diastereoisomer B)**

The diastereoisomer B methyl ester (26mg, 53.2 μ mol) from Description 5 was suspended in methanol (0.5 ml) and treated with a solution of sodium sulphide nonahydrate (41mg, 172 μ mol) in water (0.5ml). The suspension was stirred under argon for 30 minutes. The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (5 drops) and diluted with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (22mg). δ_H (CDCl₃) 1.70 (1H, dd, J 10.0 & 7.6 Hz), 1.85 (1H, m), 1.95 (1H, m), 2.45 (3H, m), 2.83 (1H, m), 3.05 (1H, m), 3.98 (2H, s), 5.58 (1H, d, J 6.7 Hz), 6.50 (1H, d, J 6.7 Hz), 7.2 (14H, m) ppm. ESMS MH⁺ 434.

Example 3**N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*m*-phenoxy-phenylglycine (Diastereoisomer A)**

The diastereoisomer A methyl ester (141mg, 0.29mmol) from Description 7 was suspended in methanol (2ml) and treated with a solution of sodium sulphide nonahydrate (207mg, 0.86mmol) in water (2ml). The suspension was stirred under argon for 60 minutes. The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (5 drops) and diluted with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (120mg). EIMS M⁺ 435.1499. Calculated C₂₅H₂₅NO₄S, 435.1504.

Example 4**N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*m*-phenoxy-phenylglycine (Diastereoisomer B)**

The diastereoisomer B methyl ester (166mg, 0.34mmol) from Description 7 was suspended in methanol (2ml) and treated with a solution of sodium sulphide nonahydrate (243mg, 1.0mmol) in water (2ml). The suspension was stirred under argon for 30 minutes. The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (5 drops) and diluted with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (130mg). δ_H (CDCl₃) 1.67 (1H, dd, J 9.7 & 7.8 Hz), 1.85 (1H, m), 1.95 (1H, m), 2.55 (3H, m), 2.83 (1H, m), 3.05 (1H, m), 5.59 (1H, d, J 6.8 Hz), 6.54 (1H, d, J 6.8 Hz), 7.0-7.4 (14H, m) ppm. EIMS M⁺ 435.1508. Calculated C₂₅H₂₅NO₄S, 435.1504.

Example 5**N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*m*-(*p*-methoxybenzyl)-phenylglycine
(Diastereoisomer A)**

The diastereoisomer A methyl ester (67mg, 0.129mmol) from Description 11 was
5 suspended in methanol (2ml) and treated with a solution of sodium sulphide nonahydrate
(93mg, 0.39mmol) in water (2ml). The suspension was stirred under argon for 2 hours.
The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (5
drops) and diluted with ethyl acetate. The organic layer was washed with water and dried
(MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (22mg).
10 δ_H (CDCl₃) 1.31 (1H, dd, J 9.3 and 8.3 Hz), 1.85 (1H, m), 2.02 (1H, m), 2.30 (1H, m),
2.5-3.1 (4H, m), 3.77 (3H, s), 3.91 (2H, s), 5.57 (1H, d, J 6.6 Hz), 6.44 (1H, d, J 6.6 Hz),
6.81 (2H, d, J 8.6 Hz), 7.1-7.3 (11H, m) ppm.

Example 6**N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*m*-(*p*-methoxybenzyl)-phenylglycine
(Diastereoisomer B)**

The diastereoisomer B methyl ester (62mg, 0.12mmol) from Description 11 was
suspended in methanol (2ml) and treated with a solution of sodium sulphide nonahydrate
(86mg, 0.36mmol) in water (2ml). The suspension was stirred under argon for 2 hours.
20 The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (5
drops) and diluted with ethyl acetate. The organic layer was washed with water and dried
(MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (36mg).
 δ_H (CDCl₃) 1.70 (1H, dd, J 9.8 & 7.7 Hz), 1.85 (1H, m), 1.95 (1H, m), 2.45 (3H, m),
2.83 (1H, m), 3.05 (1H, m), 3.75 (3H, s), 3.93 (2H, s), 5.58 (1H, d, J 6.9 Hz), 6.44 (1H,
25 d, J 6.9 Hz), 6.78 (2H, d, J 8.6 Hz), 7.0-7.3 (11H, m) ppm.

Example 7**N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*m*-benzyloxy-phenylglycine**

The diastereoisomeric mixture (100mg, 0.20mmol) from Description 13 was
30 suspended in methanol (2ml) and treated with a solution of sodium sulphide nonahydrate
(172mg, 0.72mmol) in water (2ml). The suspension was stirred under argon for 2 hours.
The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (5
drops) and diluted with ethyl acetate. The organic layer was washed with water and dried
(MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (88mg).
35 δ_H (CDCl₃) 1.38 (0.5H, t, J 8.5 Hz), 1.72 (0.5H, dd, J 9.9 and 7.3 Hz), 1.8-2.0 (2H, m),
2.30-3.0 (5H, m), 5.05 (2H, s), 5.58 (1H, d, J 6.8 Hz), 6.48 and 6.51 (1H, d, J 6.8 Hz),
7.0-7.4 (14H, m) ppm. ESMS MH⁺ 450.

Example 8**N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*m*-(*p*-hydroxybenzyl)-phenylglycine**

The mixture of diastereoisomeric methyl esters (50mg, 0.10mmol) from Description 17 was suspended in methanol (1ml) and treated with a solution of sodium sulphide nonahydrate (96mg, 0.40mmol) in water (1ml). The suspension was stirred under argon for 1 hour. The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (5 drops) and diluted with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (46mg). δ_H (CD₃OD) 1.85 (2H, m), 2.5-2.8 (5H, m), 3.88 (2H, s), 5.49 (1H, s), 6.68 (2H, m), 7.0-7.3 (11H, m) ppm. EIMS M⁺ 449.1657. Calculated for C₂₆H₂₇NO₄S; 449.1661.

Example 9**N-(2'-mercaptomethyl-4'-phenylbutanoyl)-(1-fluorenyl)glycine**

The mixture of diastereoisomeric methyl esters (88mg, 0.18mmol) from Description 21 was suspended in methanol (2ml) and treated with a solution of sodium sulphide nonahydrate (173mg, 0.72mmol) in water (2ml). The suspension was stirred under argon for 1 hour. The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (10 drops) and diluted with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (80mg). δ_H (CDCl₃) 1.32 and 1.74 (1H, dd, J 9.8 and 7.8 Hz), 1.8-2.0 (2H, m), 2.3-3.1 (5H, m), 4.10 (2H, s), 5.88 and 5.91 (1H, d, J 6.8 Hz), 6.58 and 6.63 (1H, d, J 6.8 Hz), 7.0-7.8 (12H, m) ppm. EIMS M⁺ 449.1657. Calculated for C₂₆H₂₇NO₄S; 449.1661.

Example 10**N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*o*-phenoxy-phenylglycine (Diastereoisomer A)**

The diastereoisomer A methyl ester (41mg, 0.083mmol) from Description 25 was suspended in methanol (2ml) and treated with a solution of sodium sulphide nonahydrate (80mg, 0.33mmol) in water (2ml). The suspension was stirred under argon for 2 hours. The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (5 drops) and diluted with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (37mg). δ_H (CDCl₃) 1.28 (1H, dd, J 9.5 and 7.9 Hz), 1.82 (1H, m), 2.02 (1H, m), 2.25 (1H, m), 2.5-2.8 (4H, m), 5.94 (1H, d, J 8.0 Hz), 6.70 (1H, d, J 8.0 Hz), 6.84 (1H, d, J 8.3 Hz), 7.1-7.3 (13H, m) ppm. EIMS M⁺ 435.1512. Calculated for C₂₅H₂₅NO₄S, 435.1504.

Example 11**N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*o*-phenoxy-phenylglycine
(Diastereoisomer B)**

- The diastereoisomer B methyl ester (50mg, 0.10mmol) from Description 25 was suspended in methanol (2ml) and treated with a solution of sodium sulphide nonahydrate (98mg, 0.41mmol) in water (2ml). The suspension was stirred under argon for 2 hours. The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (5 drops) and diluted with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (44mg).
- 10 δ_H (CDCl₃) 1.66 (1H, dd, J 9.8 & 7.7 Hz), 1.8-2.8 (7H, m), 5.96 (1H, d, J 7.8 Hz), 6.69 (1H, d, J 7.8 Hz), 6.89 (1H, d, J 8.2 Hz), 6.9-7.5 (13H, m) ppm. EIMS M⁺ 435.1512. Calculated for C₂₅H₂₅NO₄S, 435.1504.

Example 12

- 15 **N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*p*-phenoxy-phenylglycine
(Diastereoisomer A)**

- The diastereoisomer A methyl ester (57mg, 0.116mmol) from Description 27 was suspended in methanol (2ml) and treated with a solution of sodium sulphide nonahydrate (111mg, 0.46mmol) in water (2ml). The suspension was stirred under argon for 3 hours.
- 20 The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (10 drops) and diluted with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (52mg).
- δ_H (CDCl₃) 1.37 (1H, dd, J 9.2 and 8.3 Hz), 1.82 (1H, m), 2.02 (1H, m), 2.30 (1H, m), 2.6-2.9 (4H, m), 5.58 (1H, d, J 6.5 Hz), 6.47 (1H, d, J 6.5 Hz), 7.0-7.4 (14H, m) ppm.
- 25 FABMS MH⁺ 436.1583. Calculated for C₂₅H₂₅NO₄S, 435.1504.

Example 13**N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*p*-phenoxy-phenylglycine
(Diastereoisomer B)**

- 30 The diastereoisomer B methyl ester (60mg, 0.122mmol) from Description 27 was suspended in methanol (2ml) and treated with a solution of sodium sulphide nonahydrate (117mg, 0.49mmol) in water (2ml). The suspension was stirred under argon for 3 hours. The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (10 drops) and diluted with ethyl acetate. The organic layer was washed with water and dried
- 35 (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (56mg).
- δ_H (CDCl₃) 1.71 (1H, dd, J 9.7 & 7.8 Hz), 1.85 (1H, m), 1.95 (1H, m), 2.35 (1H, m),

2.55 (3H, m), 2.83 (1H, m), 5.60 (1H, d, J 6.6 Hz), 6.62 (1H, d, J 6.6 Hz), 7.0-7.4 (14H, m) ppm.

Example 14

5 N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*m*-(*p*-methoxyphenoxy)-phenylglycine (Diastereoisomer A)

The diastereoisomer A methyl ester (72mg, 0.138mmol) from Description 29 was suspended in methanol (2ml) and treated with a solution of sodium sulphide nonahydrate (133mg, 0.55mmol) in water (2ml). The suspension was stirred under argon for 3 hours.

10 The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (10 drops) and diluted with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (65mg). δ_H (CDCl₃) 1.35 (1H, dd, J 9.2 and 8.3 Hz), 1.82 (1H, m), 2.02 (1H, m), 2.30 (1H, m), 2.6-2.9 (4H, m), 3.81 (3H, s), 5.56 (1H, d, J 6.6 Hz), 6.48 (1H, d, J 6.6 Hz), 6.9-7.3 (13H, m) ppm. EIMS M⁺ 465.1621. Calculated C₂₆H₂₇NO₅S, 465.1610.

Example 15

20 N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*m*-(*p*-methoxyphenoxy)-phenylglycine (Diastereoisomer B)

The diastereoisomer B methyl ester (166mg, 0.34mmol) from Description 29 was suspended in methanol (2ml) and treated with a solution of sodium sulphide nonahydrate (243mg, 1.0mmol) in water (2ml). The suspension was stirred under argon for 30 minutes. The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (5 drops) and diluted with ethyl acetate. The organic layer was washed with

25 water and dried (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (130mg). δ_H (CDCl₃) 1.67 (1H, dd, J 9.8 & 7.8 Hz), 1.85 (1H, m), 1.95 (1H, m), 2.35 (1H, m), 2.55 (3H, m), 2.83 (1H, m), 3.78 (3H, s), 5.57 (1H, d, J 6.7 Hz), 6.65 (1H, d, J 6.7 Hz), 6.9-7.3 (13H, m) ppm. EIMS M⁺ 465.1597. Calculated C₂₆H₂₇NO₅S, 465.1610.

30

Example 16

N-(2'-mercaptomethyl-4'-phenylbutanoyl)-(N-Ethyl-3-carbazolyl)glycine (Diastereoisomer A)

The diastereoisomer A methyl ester (26mg, 0.05mmol) from Description 31 was

35 suspended in methanol (2ml) and treated with a solution of sodium sulphide nonahydrate (48mg, 0.20mmol) in water (2ml). The suspension was stirred under argon for 3 hours. The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (10

drops) and diluted with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (23mg).

δ_H (CDCl₃) 1.40 (3H, t, J 7.1 Hz), 1.82 (1H, m), 2.02 (1H, m), 2.30 (1H, m), 2.6-2.8 (4H, m), 4.32 (2H, q, J 7.1 Hz), 5.78 (1H, d, J 7.0 Hz), 6.61 (1H, d, J 7.0 Hz), 7.0-7.5

5 (10H, m) 8.18 (2H, m) ppm. EIMS M⁺ 460.1823. Calculated C₂₇H₂₈N₂O₃S, 460.1821.

Example 17

N-(2'-mercaptomethyl-4'-phenylbutanoyl)-(N-Ethyl-3-carbazolyl)glycine
(Diastereoisomer B)

10 The diastereoisomer B methyl ester (28mg, 0.054mmol) from Description 31 was suspended in methanol (2ml) and treated with a solution of sodium sulphide nonahydrate (52mg, 0.20mmol) in water (2ml). The suspension was stirred under argon for 3 hours. The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (10 drops) and diluted with ethyl acetate. The organic layer was washed with water and dried
15 (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (24mg). δ_H (CDCl₃) 1.42 (3H, t, J 7.2 Hz), 1.79 (1H, dd, J 10.0 & 7.5 Hz), 1.85 (1H, m), 1.95 (1H, m), 2.3-2.8 (5H, m), 4.36 (2H, q, J 7.2 Hz), 5.80 (1H, d, J 6.6 Hz), 6.64 (1H, d, J 6.6 Hz), 7.0-7.5 (10H, m) 8.10 (2H, m) ppm.

20 Example 18

N-(2'-mercaptomethyl-4'-phenylbutanoyl)-p-benzyloxy-D-phenylglycine.
(Diastereoisomer A)

The diastereoisomer A methyl ester (32mg, 0.063mmol) from Description 33 was suspended in methanol (2ml) and treated with a solution of sodium sulphide nonahydrate
25 (61mg, 0.25mmol) in water (2ml). The suspension was stirred under argon for 3 hours. The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (10 drops) and diluted with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (28mg). δ_H (CDCl₃) 1.36 (1H, dd, J 9.1 and 8.3 Hz), 1.82 (1H, m), 2.02 (1H, m), 2.29 (1H, m),
30 2.5-2.8 (4H, m), 5.05 (2H, s), 5.54 (1H, d, J 6.4 Hz), 6.49 (1H, d, J 6.4 Hz), 6.9-7.4 (14H, m) ppm. ESMS MH⁺ 450.

Example 19

N-(2'-mercaptomethyl-4'-phenylbutanoyl)-p-benzyloxy-D-phenylglycine.
35 (Diastereoisomer B)

The diastereoisomer B methyl ester (31mg, 0.061mmol) from Description 33 was suspended in methanol (2ml) and treated with a solution of sodium sulphide nonahydrate

- (59mg, 0.24mmol) in water (2ml). The suspension was stirred under argon for 3 hours. The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (10 drops) and diluted with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (27mg).
- 5 δ_H (CDCl₃) 1.74 (1H, dd, J 10.0 & 7.5 Hz), 1.85 (1H, m), 1.95 (1H, m), 2.3-2.8 (5H, m), 5.06 (2H, s), 5.55 (1H, d, J 6.6 Hz), 6.51 (1H, d, J 6.6 Hz), 7.0-7.5 (14H, m) ppm. ESMS MH⁺ 450.

Example 20

- 10 N-(2'-mercaptomethyl-4'-phenylbutanoyl)-p-(2''-thienylmethoxy)-D-phenylglycine. (Diastereoisomer A)

- The diastereoisomer A methyl ester (50mg, 0.10mmol) from Description 34 was suspended in methanol (2ml) and treated with a solution of sodium sulphide nonahydrate (94mg, 0.40mmol) in water (2ml). The suspension was stirred under argon for 2 hours.
- 15 The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (10 drops) and diluted with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (45mg). δ_H (CDCl₃) 1.36 (1H, dd, J 9.1 and 8.3 Hz), 1.82 (1H, m), 2.02 (1H, m), 2.29 (1H, m), 2.5-2.8 (4H, m), 5.19 (2H, s), 5.55 (1H, d, J 6.6 Hz), 6.54 (1H, d, J 6.6 Hz), 6.9-7.4
- 20 (12H, m) ppm. ESMS MH⁺ 456.

Example 21

- N-(2'-mercaptomethyl-4'-phenylbutanoyl)-p-(2''-thienylmethoxy)-D-phenylglycine. (Diastereoisomer B)

- 25 The diastereoisomer B methyl ester (60mg, 0.117mmol) from Description 34 was suspended in methanol (2ml) and treated with a solution of sodium sulphide nonahydrate (113mg, 0.47mmol) in water (2ml). The suspension was stirred under argon for 2 hours. The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (10 drops) and diluted with ethyl acetate. The organic layer was washed with water and dried
- 30 (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (54mg). δ_H (CDCl₃) 1.74 (1H, dd, J 10.0 & 7.5 Hz), 1.85 (1H, m), 1.95 (1H, m), 2.3-2.8 (5H, m), 5.21 (2H, s), 5.56 (1H, d, J 6.6 Hz), 6.57 (1H, d, J 6.6 Hz), 7.0-7.5 (12H, m) ppm. ESMS MH⁺ 456.

Example 22**N-(2'-mercaptomethyl-4'-phenylbutanoyl)-p-(p-carboxy)-benzyloxy-D-phenylglycine (Diastereoisomer A)**

The diastereoisomer A methyl ester (37mg, 0.066mmol) from Description 37 was
 5 suspended in methanol (3ml) and treated with a solution of sodium sulphide nonahydrate
 (158mg, 0.66mmol) in water (2ml). The suspension was stirred under argon for 3 hours.
 The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (10
 drops) and diluted with ethyl acetate. The organic layer was washed with water and dried
 (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (34mg).
 10 δ_H (MeOD) 1.85 (2H, m), 2.5-2.8 (5H, m), 5.19 (2H, s), 5.44 (1H, s), 7.03 (2H, d, J 8.8
 Hz), 7.1-7.4 (6H, m), 7.56 (2H, d, J 8.2 Hz), 7.91 (1H, s), 8.04 (2H, d, J 8.2 Hz) ppm.

Example 23**N-(2'-mercaptomethyl-4'-phenylbutanoyl)-p-(p-carboxy)-benzyloxy-D-phenylglycine (Diastereoisomer B)**

The diastereoisomer B methyl ester (37mg, 0.066mmol) from Description 37 was
 suspended in methanol (3ml) and treated with a solution of sodium sulphide nonahydrate
 (158mg, 0.66mmol) in water (2ml). The suspension was stirred under argon for 3 hours.
 The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (10
 20 drops) and diluted with ethyl acetate. The organic layer was washed with water and dried
 (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (34mg).
 δ_H (MeOD) 1.84 (2H, m), 2.5-2.8 (5H, m), 5.19 (2H, s), 5.44 (1H, s), 7.0-8.0 (13H, m)
 ppm.

Example 24**2-[(5-Benzyl)thien-2-yl]-N-[2-(mercaptomethyl)-4-phenylbutyryl]glycine**

A solution of sodium sulphide nonahydrate (464mg) in water (3ml) was added to
 a stirred solution of 2-[(5-benzyl)thien-2-yl]-N-[2-(acetylthiomethyl)-4-
 phenylbutyryl]glycine ethyl ester (Description 40) (330mg) in methanol (3ml) under
 30 argon. Further portions of methanol (totalling 5ml) were added over 45 min. The
 mixture was stirred for a further 20 min. and then dilute hydrochloric acid (2ml) was
 added and the mixture partitioned between ethyl acetate and water. The organic phase
 was washed with water and brine, dried over magnesium sulphate and evaporated. The
 product (209mg) was isolated by column chromatography of the residue using gradient
 35 elution (Kieselgel: 5% going to 10% methanol in chloroform). ν_{max} (CHCl₃) 3423,
 3295, 1723 and 1674 cm⁻¹. δ (CD₃SOCD₃) 1.70-1.90 (2H, m), 2.43-2.70 (5H, m), 4.07
 and 4.09 (2H, two s's), 5.43 (1H, d, J 7.77Hz), 6.73-6.75 (1H, m), 6.88 and 6.91 (1H,

two d's, J 3.42Hz), 7.09-7.35 (10H, m). m/z 439 (M^+). [Found (HRMS): m/z 439.1282. Calc. for $C_{24}H_{25}NO_3S_2$; 439.1276].

Example 25

5 2-[(5-Benzyl)furan-2-yl]-N-[2-(mercaptomethyl)-4-phenylbutyryl]glycine

The title compound was prepared from 2-[(5-benzyl)furan-2-yl]-N-[2-(acetylthiomethyl)-4-phenylbutyryl]glycine ethyl ester (Description 43) by the procedure described in Example 24. ν_{\max} ($CHCl_3$) 3430, 3294, 1727, 1662 cm^{-1} . δ (CD_3SOCD_3) 1.70-1.80 (2H, m), 2.40-2.74 (5H, m), 3.90 and 3.94 (2H, two s's), 5.30-5.35 (1H, m),
10 5.99-6.02 (1H, m), 6.22 and 6.26 (1H, two d's, J 4.10Hz), 7.09-7.32 (10H, m), 8.48 (1H, d, J 6.98Hz). m/z 423 (M^+). [Found (HRMS): 423.1503. Calc. for $C_{24}H_{25}NO_4S$; 423.1504].

Example 26

15 2-[5-(Tetrahydrofuran-3-ylmethyl)thien-2-yl]-N-[2-(mercaptomethyl)-4-phenylbutyryl]glycine

The title compound was prepared from 2-[5-(tetrahydrofuran-3-ylmethyl)thien-2-yl]-N-[2-(acetylthiomethyl)-4-phenylbutyryl]glycine ethyl ester (Description 47) by the procedure described in Example 24 except that the eluent used was 10% methanol in
20 dichloromethane. ν_{\max} ($CHCl_3$) 3409, 3293, 1648 and 1603 cm^{-1} . δ (CD_3SOCD_3) 1.44-1.61 (1H, m), 1.70-1.82 (1H, m), 1.85-2.03 (1H, m), 2.30-2.80 (8H, m), 3.29-3.40 (2H, m), 3.53-3.76 (3H, m), 5.13 and 5.25 (1H, two d's, J 6.55Hz), 5.70 and 5.77 (1H, two s's), 6.64 (1H, d, J 3.23Hz), 6.74-6.84 (1H, m), 7.11-7.31 (5H, m), 7.87 and 8.12 (1H, two d's, J 6.68Hz).

25

Example 27

2-[5-(1-Tetrazolylmethyl)thien-2-yl]-N-[2-(mercaptomethyl)-4-phenylbutyryl]glycine

The title compound was prepared from 2-[5-(1-tetrazolylmethyl)thien-2-yl]-N-[2-(acetylthiomethyl)-4-phenylbutyryl]glycine ethyl ester (Description 52) by the procedure described in Example 24, except that the eluent used was 20% methanol in
30 dichloromethane. ν_{\max} (nujol), 3290, 1603 cm^{-1} . δ (CD_3SOCD_3) 1.68-1.86 (2H, m), 2.44-3.00 (6H, m), 5.25-5.31 (1H, m), 5.85 (2H, s), 6.88-7.31 (7H, m), 8.20-8.30 (1H, m), 9.49 (1H, s).

35

Example 28**2-[5-(2-Tetrazolylmethyl)thien-2-yl]-N-[2-(mercaptomethyl)-4-phenylbutyryl]glycine**

The title compound was prepared from 2-[5-(2-tetrazolylmethyl)thien-2-yl]-N-[2-(acetylthiomethyl)-4-phenylbutyryl]glycine ethyl ester (Description 54) using the procedure described in Example 24 except that the eluent used was 10% methanol in dichloromethane. ν_{\max} (CHCl₃) 3294 and 1646cm⁻¹. δ (CD₃SOCD₃) 1.68-1.81 (2H, m), 2.42-2.73 (5H, m), 5.74-5.83 (1H, m), 6.09 (2H, s), 6.88-6.96 (1H, m), 7.05-7.31 (6H, m), 8.20-8.31 (1H, m), 8.94 and 8.98 (1H, two s's). m/z 430 (M-H)⁻.

Example 29**2-[5-(1,2,3-Triazol-1-ylmethyl)thien-2-yl]-N-[2-(mercaptomethyl)-4-phenylbutyryl]glycine**

The title compound was prepared from 2-[5-(1,2,3-triazol-1-ylmethyl)thien-2-yl]-N-[2-(acetylthiomethyl)-4-phenylbutyryl]glycine ethyl ester (Description 57) by the procedure described in Example 24 except that the eluent used was 20% methanol in dichloromethane. ν_{\max} (CHCl₃) 3292, 1731, 1648 and 1602cm⁻¹. δ (CD₃SOCD₃) 1.70-1.82 (2H, m), 2.46-2.74 (5H, m), 5.22 (1H, d, *J* 6.85Hz), 5.72 (2H, s), 6.85-7.31 (7H, m), 7.68 and 7.72 (1H, two s's), 8.11 and 8.14 (1H, two s's).

Example 30**2-[5-(1,2,3-Triazol-2-ylmethyl)thien-2-yl]-N-[2-(mercaptomethyl)-4-phenylbutyryl]glycine**

The title compound was prepared from 2-[5-(1,2,3-triazol-2-ylmethyl)thien-2-yl]-N-[2-(acetylthiomethyl)-4-phenylbutyryl]glycine ethyl ester by (Description 59) the procedure described in Example 29. ν_{\max} (CHCl₃) 3289 and 1621cm⁻¹. δ (CD₃SOCD₃) 1.68-1.83 (2H, m), 2.44-2.73 (5H, m), 5.20 (1H, d, *J* 6.87Hz), 5.73 (2H, s), 6.83-6.94 (2H, m), 7.10-7.30 (5H, m), 7.74 and 7.78 (2H, two s's), 8.10 (1H, d, *J* 7.07Hz). m/z 431 (MH⁺).

Example 31**2-[5-(Imidazolidin-2,4-dion-3-ylmethyl)thien-2-yl]-N-[2-(mercaptomethyl)-4-phenylbutyryl]glycine**

The title compound was prepared from 2-[5-(imidazolidin-2,4-dion-3-ylmethyl)thien-2-yl]-N-[2-(acetylthiomethyl)-4-phenylbutyryl]glycine ethyl ester (Description 62) by the procedure described in Example 27. ν_{\max} (KBr) 3391, 1714 and 1638cm⁻¹. m/z 479 (MNH₄⁺).

Example 32**2-[5-(4-methoxybenzyl)thien-2-yl]-N-[2-(mercaptomethyl)-4-phenylbutyryl]glycine**

- The title compound was prepared from 2-[5-(4-methoxybenzyl)thien-2-yl]-N-[2-(acetylthiomethyl)-4-phenylbutyryl]glycine ethyl ester (Description 66) by the procedure described in Example 24. ν_{\max} (CHCl₃) 3423, 1724 and 1674cm⁻¹. m/z 469 (M⁺).
5 [Found (HRMS): m/z 469.1373. Calc. for C₂₅H₂₇NO₄S₂; 469.1382].

Example 33**2-[(5-Benzyl)furan-2-yl]-N-[2-(mercaptomethyl)-3-phenylpropionyl]glycine**

- The title compound was prepared from 2-[(5-benzyl)furan-2-yl]-N-[2-(acetylthiomethyl)-3-phenylpropionyl]glycine ethyl ester (Description 67) by the procedure described in Example 24. ν_{\max} (CHCl₃) 3433, 1728 and 1675cm⁻¹. m/z 409 (M⁺). [Found (HRMS): m/z 409.1352. Calc. for C₂₃H₂₃NO₄S; 409.1347].

Example 34**2-[(5-Benzyl)thien-2-yl]-N-[2-(mercaptomethyl)-4-phenylbutyryl]glycine diastereomeric pairs**

- The title compounds were separated as racemic diastereomeric pairs from the product of Example 24 by high pressure liquid chromatography.

Example 35**2-[5-(4,5-Dicarboxytriazol-1-ylmethyl)thien-2-yl]-N-[2-(mercaptomethyl)-4-phenylbutyryl]glycine**

- A solution of sodium sulphide nonahydrate (1.09g) in water (6ml) was added to a stirred solution of 2-[5-{4,5-di(methoxycarbonyl)triazol-1-ylmethyl}thien-2-yl]-N-[2-(acetylthiomethyl)-4-phenylbutyryl]glycine ethyl ester (Description 71) (400mg) in methanol (6ml). The mixture was stirred for 0.5h and then 5N hydrochloric acid (2ml) was added and the mixture partitioned between ethyl acetate and water. The organic phase was washed with water and brine, dried over magnesium sulphate and evaporated. The residue was crystallised by trituration with ether and ethyl acetate, and the solid filtered off and washed with ether then dried under vacuum to give the title compound (92mg). ν_{\max} (nujol) 3294, 1732, 1643cm⁻¹. m/z (M-H⁻).

Example 36

2-[5-(4-Carboxamidotriazol-1-ylmethyl)thien-2-yl]-N-[2-(mercaptomethyl)-4-phenylbutyryl]glycine

The title compound was prepared from 2-[5-(4-Carboxamido-1,2,3-triazol-1-ylmethyl)thien-2-yl]-N-[2-(acetylthiomethyl)-4-phenylbutyryl]glycine ethyl ester (Description 74) by the procedure described in Example 35. ν_{\max} (tetrahydrofuran) 3277, 3202, 1741 and 1692 cm^{-1} . δ (CD_3SOCD_3) 1.65-1.78 (2H, m), 2.42-2.71 (5H, m), 5.53-5.57 (1H, m), 6.06 (2H, s), 6.95-7.28 (7H, m), 7.89 (1H, s), 8.240 and 8.246 (1H, two s's), 8.28 (1H, s), 8.88 (1H, d, J 7.13Hz), 13.04 (1H, br s).

Example 37

2-[5-(4-Carboxytriazol-1-ylmethyl)thien-2-yl]-N-[2-(mercaptomethyl)-4-phenylbutyryl]glycine

The title compound was prepared from ethyl 2-[5-(4-methoxycarbonyl)triazol-1-ylmethylthien-2-yl]-N-[2-(acetylthiomethyl)-4-phenylbutyryl]glycine ethyl ester (Description 77) by the procedure described in Example 35. ν_{\max} (tetrahydrofuran) 1743, 1679 cm^{-1} . δ (CD_3SOCD_3) 1.70-1.88 (2H, m), 2.42-2.72 (6H, m), 5.57-5.63 (1H, m), 5.82 (2H, s), 6.98-7.29 (7H, m), 8.74 and 8.76 (1H, two s's), 8.87-9.10 (1H, m), 13.16 (1H, br s).

Example 38

2-[5-(5-Carboxytriazol-1-ylmethyl)thien-2-yl]-N-[2-(mercaptomethyl)-4-phenylbutyryl]glycine

The title compound was prepared from 2-[5-(5-methoxycarbonyl)triazol-1-ylmethyl)thien-2-yl]-N-[2-(acetylthiomethyl)-4-phenylbutyryl]glycine ethyl ester (Description 79) by the procedure described in Example 35. ν_{\max} (tetrahydrofuran) 3286, 1740 and 1679 cm^{-1} . δ (CD_3SOCD_3) 1.62-1.82 (2H, m), 2.40-2.72 (3H, m), 5.54-5.59 (1H, m), 6.04 (2H, s), 6.94-7.27 (7H, m), 6.81 and 8.23 (1H, two s's), 8.80-9.03 (1H, m), 13.16 (1H, br s).

Example 39

N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*p*-(*p*-methoxy)-benzyloxy-D-phenylglycine (Diastereoisomer A)

The diastereoisomer A methyl ester (21mg, 0.04mmol) from Description 80 was suspended in methanol (3ml) and treated with a solution of sodium sulphide nonahydrate (38mg, 0.16mmol) in water (2ml). The suspension was stirred under argon for 3 hours.

The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (10 drops) and diluted with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (19mg). δ_H (CDCl₃) 1.36 (1H, dd, J 9.2 and 8.3 Hz), 1.85 (1H, m), 2.0 (1H, m), 2.3-2.8 (5H, m), 3.82 (3H, s), 4.97 (2H, s), 5.54 (1H, d, J 6.4 Hz), 6.45 (1H, d, J 6.4 Hz), 6.9 (4H, overlapping d), 7.1-7.4 (9H, m) ppm. EIMS [M-H]⁻ 478.1690. Calculated for C₂₇H₂₉NO₅S 478.1688.

Example 40

10 N-(2'-mercaptomethyl-4'-phenylbutanoyl)-p-(p-methoxy)-benzyloxy-D-phenylglycine (Diastereoisomer B)

The diastereoisomer B methyl ester (24mg, 0.045mmol) from Description 80 was suspended in methanol (3ml) and treated with a solution of sodium sulphide nonahydrate (43mg, 0.18mmol) in water (2ml). The suspension was stirred under argon for 3 hours. 15 The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (10 drops) and diluted with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (21mg). δ_H (CDCl₃) 1.74 (1H, dd, J 10.0 and 7.5 Hz), 1.85 (1H, m), 2.0 (1H, m), 2.3-2.8 (5H, m), 3.81 (3H, s), 4.98 (2H, s), 5.55 (1H, d, J 6.6 Hz), 6.54 (1H, d, J 6.6 Hz), 6.9 (4H, overlapping d), 7.1-7.4 (9H, m) ppm. EIMS [M-H]⁻ 478.1695. Calculated for C₂₇H₂₉NO₅S 478.1688.

Example 41

25 N-(2'-mercaptomethyl-4'-phenylbutanoyl)-(3''-dibenzofuranyl) glycine (Diastereoisomer A)

The diastereoisomer A methyl ester (15mg, 0.03mmol) from Description 82 was suspended in methanol (2ml) and treated with a solution of sodium sulphide nonahydrate (30mg, 0.12mmol) in water (2ml). The suspension was stirred under argon for 3 hours. The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (10 drops) and diluted with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (12mg). 30 δ_H (CDCl₃) 1.35 (1H, t, J 8.8 Hz), 1.85 (1H, m), 2.0 (1H, m), 2.3-2.8 (5H, m), 5.77 (1H, d, J 6.4 Hz), 6.71 (1H, d, J 6.4 Hz), 7.1-7.6 (10H, m), 7.89 (1H, d, J 7.0 Hz), 8.04 (1H, s) ppm. EIMS M⁺ 433.1355. Calculated for C₂₅H₂₃NO₄S 433.1348.

35

Example 42**N-(2'-mercaptomethyl-4'-phenylbutanoyl)-(3''-dibenzofuranyl) glycine.****(Diastereoisomer B)**

- The diastereoisomer B methyl ester (16mg, 0.033mmol) from Description 82 was suspended in methanol (2ml) and treated with a solution of sodium sulphide nonahydrate (30mg, 0.13mmol) in water (2ml). The suspension was stirred under argon for 3 hours. The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (10 drops) and diluted with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (14mg).
- 10 δ_H (CDCl₃) 1.73 (1H, dd, J 10.0 and 7.6 Hz), 1.85 (1H, m), 2.0 (1H, m), 2.3-2.8 (5H, m), 5.78 (1H, d, J 6.6 Hz), 6.72 (1H, d, J 6.6 Hz), 7.0-7.6 (10H, m), 7.91 (1H, d, J 7.9 Hz), 8.03 (1H, s) ppm. EIMS M⁺ 433.1347. Calculated for C₂₅H₂₃NO₄S 433.1348.

Example 43

- 15 **N-(2'-mercaptomethyl-4'-phenylbutanoyl)-p-(2''-furanylmethoxy)-D-phenylglycine**
(Diastereoisomer A)

- The diastereoisomer A methyl ester (27mg, 0.055mmol) from Description 83 was suspended in methanol (2ml) and treated with a solution of sodium sulphide nonahydrate (53mg, 0.22mmol) in water (2ml). The suspension was stirred under argon for 3 hours.
- 20 The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (10 drops) and diluted with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (24mg). ESMS [M-H]⁻ 438.

25 **Example 44**

N-(2'-mercaptomethyl-4'-phenylbutanoyl)-p-(2''-furanylmethoxy)-D-phenylglycine.
(Diastereoisomer B)

- The diastereoisomer B methyl ester (30mg, 0.06mmol) from Description 83 was suspended in methanol (2ml) and treated with a solution of sodium sulphide nonahydrate (58mg, 0.24mmol) in water (2ml). The suspension was stirred under argon for 3 hours.
- 30 The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (10 drops) and diluted with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (27mg).
- 35 δ_H (CDCl₃) 1.72 (1H, dd, J 10.0 and 7.6 Hz), 1.85 (1H, m), 2.0 (1H, m), 2.3-2.8 (5H, m), 4.98 (2H, s), 5.54 (1H, d, J 6.6 Hz), 6.4 (2H, m), 6.54 (1H, d, J 6.6 Hz), 7.0-7.5 (10H, m) ppm. ESMS [M-H]⁻ 438.

Example 45**N-(2'-mercaptomethyl-4'-phenylbutanoyl)-p-(p-hydroxy)-benzyloxy-D-phenylglycine (Diastereoisomer A)**

The diastereoisomer A methyl ester (79mg, 0.14mmol) from Description 84 was
5 suspended in methanol (2ml) and treated with a solution of sodium sulphide nonahydrate (168mg, 0.70mmol) in water (2ml). The suspension was stirred under argon for 3 hours. The reaction mixture was then washed with ethyl acetate and the aqueous layer acidified by addition of 5M hydrochloric acid solution (10 drops) and then extracted with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). Removal of the
10 solvent afforded the desired product as a crisp foam (49mg). δ_H (CD₃OD) 1.85 (2H, m), 2.4-2.8 (5H, m), 4.91 (2H, s), 5.38 (1H, m),), 6.7-6.9 (4H, m), 7.1-7.4 (9H, m) ppm. ESMS MH⁺ 466.

Example 46**N-(2'-mercaptomethyl-4'-phenylbutanoyl)-p-(p-hydroxy)-benzyloxy-D-phenylglycine (Diastereoisomer B)**

The diastereoisomer B methyl ester (65mg, 0.115mmol) from Description 84 was
suspended in methanol (2ml) and treated with a solution of sodium sulphide nonahydrate (138mg, 0.58mmol) in water (2ml). The suspension was stirred under argon for 3 hours.
20 The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (10 drops) and diluted with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (40mg). δ_H (CD₃OD) 1.8 (2H, m), 2.4-2.8 (5H, m), 4.93 (2H, s), 5.45 (1H, s),), 6.7-6.8 (4H, overlapping d), 7.1-7.4 (9H, m) ppm. ESMS MH⁺ 466.

25

Example 47**N-(2'-mercaptomethyl-4'-phenylbutanoyl)-p-(p-dimethylamino)-benzyloxy-D-phenylglycine (Diastereoisomer A)**

The diastereoisomer A methyl ester (33mg, 0.06mmol) from Description 85 was
30 suspended in methanol (3ml) and treated with a solution of sodium sulphide nonahydrate (58mg, 0.24mmol) in water (2ml). The suspension was stirred under argon for 3 hours. The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (10 drops) and diluted with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (27mg,
35 93%). δ_H (CD₃OD) 1.85 (2H, m), 2.4-2.8 (5H, m), 2.90 (6H, s), 4.91 (2H, s), 5.38 (1H, s),), 6.7-7.3 (13H, m) ppm. EIMS M⁺ 492.

Example 48

N-(2'-mercaptomethyl-4'-phenylbutanoyl)-p-(p-dimethylamino)-benzyloxy-D-phenylglycine (Diastereoisomer B)

The diastereoisomer B methyl ester (55mg, 0.10mmol) from Description 85 was suspended in methanol (2ml) and treated with a solution of sodium sulphide nonahydrate (96mg, 0.40mmol) in water (2ml). The suspension was stirred under argon for 3 hours. The reaction mixture was then washed with ethyl acetate and the aqueous layer acidified by addition of 5M hydrochloric acid solution (10 drops) and then extracted with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (25mg). δ_H (CD₃OD) 1.8 (2H, m), 2.4-2.8 (5H, m), 2.93 (6H, s), 4.91 (2H, s), 5.38 (1H, s), 6.7-7.3 (13H, m) ppm. EIMS M⁺ 492.

Example 49

N-(2'-mercaptomethyl-4'-phenylbutanoyl)-p-(m-carboxy)-benzyloxy-D-phenylglycine (Diastereoisomer A)

The diastereoisomer A methyl ester (47mg, 0.08mmol) from Description 86 was suspended in methanol (3ml) and treated with a solution of sodium sulphide nonahydrate (100mg, 0.42mmol) in water (2ml). The suspension was stirred under argon for 3 hours. The reaction mixture was then washed with ethyl acetate and the aqueous layer acidified by addition of 5M hydrochloric acid solution (10 drops) and then extracted with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (36mg). δ_H (CDCl₃) 1.29 (1H, t, J 8.9 Hz), 1.78 (1H, m), 1.94 (1H, m), 2.23 (1H, m), 2.5-2.8 (4H, m), 5.05 (2H, s), 5.45 (1H, d, J 6.6 Hz), 6.42 (1H, d, J 6.6 Hz), 6.82 (2H, d, J 8.7 Hz), 7.2-7.4 (8H, m), 7.56 (1H, d, J 7.7 Hz), 7.94 (1H, d, J 7.7 Hz), 8.02 (1H, s) ppm. APCI [M-H]⁻ 492.

Example 50

N-(2'-mercaptomethyl-4'-phenylbutanoyl)-p-(m-carboxy)-benzyloxy-D-phenylglycine (Diastereoisomer B)

The diastereoisomer B methyl ester (64mg, 0.11mmol) from Description 86 was suspended in methanol (3ml) and treated with a solution of sodium sulphide nonahydrate (136mg, 0.57mmol) in water (2ml). The suspension was stirred under argon for 4 hours. The reaction mixture was then washed with ethyl acetate and the aqueous layer acidified by addition of 5M hydrochloric acid solution (10 drops) and then extracted with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (34mg). δ_H (CDCl₃) 1.65 (1H, dd, J

10.0 and 7.7 Hz), 1.78 (1H, m), 1.94 (1H, m), 2.26 (1H, m), 2.5-2.8 (4H, m), 5.07 (2H, s), 5.46 (1H, d, J 6.5 Hz), 6.43 (1H, d, J 6.5 Hz), 6.83 (2H, d, J 8.7 Hz), 7.2-7.4 (8H, m), 7.56 (1H, d, J 7.7 Hz), 7.94 (1H, d, J 7.7 Hz), 8.02 (1H, s) ppm. APCI [M-H]⁻ 492.

5 **Example 51**

N-(2'-mercaptomethyl-4'-phenylbutanoyl)-p-(3,4-dihydroxy)-benzyloxy-D-phenylglycine (Diastereoisomer A)

The diastereoisomer A methyl ester (81mg, 0.13mmol) from Description 87 was suspended in methanol (2ml) and treated with a solution of sodium sulphide nonahydrate (250mg, 1.04mmol) in water (2ml). The suspension was stirred under argon for 3 hours. The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (10 drops) and diluted with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (67mg). δ_H (CD₃OD) 1.85 (2H, m), 2.4-2.8 (5H, m), 4.91 (2H, s), 5.38 (1H, m), , 6.7-6.9 (4H, m), 7.1-7.4 (9H, m) ppm. ESMS MH⁺ 466.

Example 52

N-(2'-mercaptomethyl-4'-phenylbutanoyl)-p-(3,4-dihydroxy)-benzyloxy-D-phenylglycine (Diastereoisomer B)

The diastereoisomer B methyl ester (65mg, 0.115mmol) from Description 87 was suspended in methanol (2ml) and treated with a solution of sodium sulphide nonahydrate (138mg, 0.58mmol) in water (2ml). The suspension was stirred under argon for 3 hours. The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (10 drops) and diluted with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (40mg). δ_H (CD₃OD) 1.8 (2H, m), 2.4-2.8 (5H, m), 4.93 (2H, s), 5.45 (1H, s), , 6.7-6.8 (4H, overlapping d), 7.1-7.4 (9H, m) ppm. ESMS MH⁺ 466.

Example 53

N-(2'-mercaptomethyl-4'-phenylbutanoyl)-p-(p-nitro)-benzyloxy-D-phenylglycine (Diastereoisomer A)

The diastereoisomer A methyl ester (68mg) from Description 88 was suspended in methanol (3ml) and treated with a solution of sodium sulphide nonahydrate (120mg, 0.5mmol) in water (2ml). The suspension was stirred under argon for 3 hours. The reaction mixture was then washed with ethyl acetate and the aqueous layer acidified by addition of 5M hydrochloric acid solution (10 drops) and then extracted with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). Removal of the

solvent afforded the desired product as a crisp foam (7mg). δ_H (CDCl₃) 1.35 (1H, m), 1.85 (1H, m), 2.00 (1H, m), 2.30 (1H, m), 2.5-2.8 (4H, m), 5.16 (2H, s), 5.55 (1H, d, J 6.5 Hz), 6.48 (1H, d, J 6.5 Hz), 6.94 (2H, d, J 8.7 Hz), 7.1-7.4 (7H, m) 7.58 (2H, d, J 8.7 Hz), 8.25 (2H, d, J 8.7 Hz) ppm. APCI [M-H]⁻ 493.

5

Example 54

N-(2'-mercaptomethyl-4'-phenylbutanoyl)-p-(p-nitro)-benzyloxy-D-phenylglycine (Diastereoisomer B)

The diastereoisomer B methyl ester (43mg, 0.08mmol) from Description 88 was suspended in methanol (4ml) and treated with a solution of sodium sulphide nonahydrate (75mg, 0.31mmol) in water (2ml). The suspension was stirred under argon for 3 hours. The reaction mixture was then washed with ethyl acetate and the aqueous layer acidified by addition of 5M hydrochloric acid solution (10 drops) and then extracted with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (21mg). δ_H (CDCl₃) 1.72 (1H, dd, J 9.9 and 7.7 Hz), 1.85 (1H, m), 1.90 (1H, m), 2.32 (1H, m), 2.5-2.8 (4H, m), 5.16 (2H, s), 5.55 (1H, d, J 6.5 Hz), 6.54 (1H, d, J 6.5 Hz), 6.9-7.4 (9H, m) 7.58 (2H, d, J 8.7 Hz), 8.25 (2H, d, J 8.7 Hz) ppm. APCI [M-H]⁻ 493.

20 **Example 55**

N-(2'-RS-mercaptomethyl-4'-phenylbutanoyl)-p-(4-pyridylmethoxy)-D-phenylglycine (Diastereoisomers A and B)

The mixture of diastereoisomeric methyl esters (92mg, 0.18mmol) from Description 89 was suspended in methanol (2ml) and treated with a solution of sodium sulphide nonahydrate (174mg, 0.73mmol) in water (2ml). The suspension was stirred under argon for 2 hours. The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (10 drops) and diluted with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (66mg). δ_H (CDCl₃) 1.32 and 1.65 (1H, dd), 1.82 (1H, m), 2.0 (1H, m), 2.32 (1H, m), 2.4-2.8 (4H, m), 5.14 (2H, s), 5.52 (1H, overlapping d), 6.8-7.7 (11H, m) 8.51 (2H, d, J 6.0 Hz) ppm. APCI [M-H]⁻ 449.

35 **Example 56**

N-(2'-RS-mercaptomethyl-4'-phenylbutanoyl)-p-(2-pyridylmethoxy)-D-phenylglycine (Diastereoisomers A and B)

The mixture of diastereoisomeric methyl esters (83mg, 0.16mmol) from Description 90 was suspended in methanol (2ml) and treated with a solution of sodium

5 sulphide nonahydrate (157mg, 0.65mmol) in water (2ml). The suspension was stirred under argon for 1 hours. The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (10 drops) and diluted with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (67mg). δ_H (CDCl₃ containing MeOD) 1.82 (1H, m), 2.0 (1H, m), 2.32 (1H, m), 2.4-2.8 (4H, m), 5.18 (2H, s), 5.49 (1H, overlapping d), 6.9-7.4 (10H, m) 7.5 (1H, d, J 7.8 Hz), 7.73 (1H, m), 8.56 (1H, d, J 4.9 Hz) ppm. ESMS [M-H]⁻ 449.

Example 57

10 N-(2'-RS-mercaptomethyl-4'-phenylbutanoyl)-p-(3-pyridylmethoxy)-D-phenylglycine (Diastereoisomers A and B)

The mixture of diastereoisomeric methyl esters (104mg, 0.20mmol) from Description 91 was suspended in methanol (2ml) and treated with a solution of sodium sulphide nonahydrate (197mg, 0.80mmol) in water (2ml). The suspension was stirred
15 under argon for 1.5 hours. The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (10 drops) and diluted with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (67mg). δ_H (CDCl₃) 1.32 and 1.65 (1H, dd), 1.82 (1H, m), 2.0 (1H, m), 2.32 (1H, m), 2.4-2.8 (4H, m), 5.08 (2H, s), 5.54 (1H, overlapping d), 6.8-7.6
20 (10H, m) 7.85 (1H, d, J 8.0 Hz), 8.58 (2H, m) ppm. ESMS [M-H]⁻ 449.

Example 58

25 N-(2'-RS-mercaptomethyl-4'-phenylbutanoyl)-p-(p-acetamido)-benzyloxy-D-phenylglycine (Diastereoisomers A and B)

The mixture of diastereoisomeric methyl esters (101mg, 0.18mmol) from Description 92 was suspended in methanol (2ml) and treated with a solution of sodium sulphide nonahydrate (173mg, 0.72mmol) in water (2ml). The suspension was stirred under argon for 2 hours. The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (10 drops) and diluted with ethyl acetate. The organic layer
30 was washed with water and dried (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (91mg). δ_H (DMSO-d₆) 1.73 (2H, m), 2.04 (3H, s), 2.25 (1H, m), 2.4-2.8 (4H, m), 5.02 (2H, s), 5.30 (1H, overlapping d), 6.8-7.6 (11H, m) 8.64 and 8.69 (1H, d) ppm. ESMS [M-H]⁻ 505.

Example 59**N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*m*-(*m*-carboxy)-benzyloxy-D-phenylglycine (Diastereoisomer A)**

The diastereoisomer A methyl ester (31mg, 0.06mmol) from Description 94 was suspended in methanol (2ml) and treated with a solution of sodium sulphide nonahydrate (66mg, 0.28mmol) in water (2ml). The suspension was stirred under argon for 3 hours. The reaction mixture was then washed with ethyl acetate and the aqueous layer acidified by addition of 5M hydrochloric acid solution (10 drops) and then extracted with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (30mg). δ_H (CDCl₃) 1.37 (1H, t, J 8.9 Hz), 1.82 (1H, m), 1.98 (1H, m), 2.33 (1H, m), 2.5-2.8 (4H, m), 5.06 (2H, s), 5.60 (1H, d, J 6.6 Hz), 6.61 (1H, d, J 6.6 Hz), 6.9 - 7.6 (10H, m), 7.98 (2H, overlapping), 8.08 (1H, s) ppm. APCI [M-H]⁻ 492.

Example 60**N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*m*-(*m*-carboxy)-benzyloxy-D-phenylglycine (Diastereoisomer B)**

The diastereoisomer B methyl ester (33mg, 0.06mmol) from Description 94 was suspended in methanol (2ml) and treated with a solution of sodium sulphide nonahydrate (70mg, 0.29mmol) in water (2ml). The suspension was stirred under argon for 3 hours. The reaction mixture was then washed with ethyl acetate and the aqueous layer acidified by addition of 5M hydrochloric acid solution (10 drops) and then extracted with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (17mg). δ_H (CDCl₃) 1.69 (1H, dd, J 10.0 and 7.7 Hz), 1.80 (1H, m), 1.96 (1H, m), 2.3-2.8 (5H, m), 5.07 (2H, s), 5.59 (1H, d, J 6.5 Hz), 6.6-8.0 (13H, m), 8.08 (1H, s) ppm. APCI [M-H]⁻ 492.

Example 61**N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*m*-(*p*-carboxy)-benzyloxy-D-phenylglycine (Diastereoisomer A)**

The diastereoisomer A methyl ester (30mg, 0.06mmol) from Description 95 was suspended in methanol (2ml) and treated with a solution of sodium sulphide nonahydrate (64mg, 0.27mmol) in water (2ml). The suspension was stirred under argon for 4 hours. The reaction mixture was then washed with ethyl acetate and the aqueous layer acidified by addition of 5M hydrochloric acid solution (10 drops) and then extracted with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (28mg). δ_H (CDCl₃ + MeOD) 1.82

(1H, m), 1.98 (1H, m), 2.4-2.8 (5H, m), 5.11 (2H, s), 5.54 (1H, m), 6.9 - 7.5 (11H, m), 8.05 (2H, overlapping), ppm. ESMS [M-H]⁻ 492.

Example 62

5 N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*m*-(*p*-carboxy)-benzyloxy-D-phenylglycine (Diastereoisomer B)

The diastereoisomer B methyl ester (30mg, 0.06mmol) from Description 95 was suspended in methanol (2ml) and treated with a solution of sodium sulphide nonahydrate (79mg, 0.33mmol) in water (2ml). The suspension was stirred under argon for 4 hours.

10 The reaction mixture was then washed with ethyl acetate and the aqueous layer acidified by addition of 5M hydrochloric acid solution (10 drops) and then extracted with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (24mg). δ_H (CDCl₃+ MeOD) 1.85 (1H, m), 1.93 (1H, m), 2.3-2.7 (5H, m), 5.10 (2H, s), 5.54 (1H, m), 6.9-7.5 (11H, m),

15 8.05 (2H, m) ppm. ESMS [M-H]⁻ 492.

Example 63

N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*p*-(*m*-amino)-benzyloxy-D-phenylglycine (Diastereoisomer A)

20 The diastereoisomer A methyl ester (36mg, 0.07mmol) from Description 96 was suspended in methanol (2ml) and treated with a solution of sodium sulphide nonahydrate (66mg, 0.28mmol) in water (2ml). The suspension was stirred under argon for 3 hours. The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (10 drops) and diluted with ethyl acetate. The organic layer was washed with water and dried

25 (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (30mg). δ_H (CHCl₃ + CD₃OD) 1.85 (1H, m), 1.95 (1H, s), 2.4-2.8 (5H, m), 4.98 (2H, s), 5.47 (1H, m), ., 6.7-7.3 (13H, m) ppm. ESMS M-H 463.

Example 64

30 N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*p*-(*m*-amino)-benzyloxy-D-phenylglycine (Diastereoisomer B)

The diastereoisomer B methyl ester (30mg, 0.06mmol) from Description 96 was suspended in methanol (2ml) and treated with a solution of sodium sulphide nonahydrate (55mg, 0.23mmol) in water (2ml). The suspension was stirred under argon for 3 hours.

35 The reaction mixture was then washed with ethyl acetate and the aqueous layer acidified by addition of 5M hydrochloric acid solution (10 drops) and then extracted with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). Removal of the

solvent afforded the desired product as a crisp foam (24mg). δ_H ($CHCl_3$ + CD_3OD) 1.9 (2H, m), 2.4-2.8 (5H, m), 5.00 (2H, s), 5.48 (1H, m), 6.7-7.3 (13H, m) ppm. ESMS M-H 463.

5 Example 65

N-(2'-mercaptomethyl-4'-phenylbutanoyl)-p-(p-dimethylamino)-phenethyloxy-D-phenylglycine (Diastereoisomer A)

The diastereoisomer A methyl ester (26mg, 0.05mmol) from Description 97 was suspended in methanol (3ml) and treated with a solution of sodium sulphide nonahydrate (44mg, 0.19mmol) in water (2ml). The suspension was stirred under argon for 4 hours. The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (10 drops) and diluted with ethyl acetate. The organic layer was washed with water and dried ($MgSO_4$). Removal of the solvent afforded the desired product as a crisp foam (27mg). δ_H ($CHCl_3$) 1.32 (1H, m), 1.82 (1H, m), 2.00 (1H, s), 2.3-2.8 (5H, m), 3.00 (8H, s), 4.13 (2H, m), 5.48 (1H, d, J 6.5 Hz), 6.68 (1H, d, J 6.5 Hz), 6.79 (2H, d, J 8.5 Hz), 7.3 (1H, m) ppm. ESMS MH^+ 507.

Example 66

N-(2'-mercaptomethyl-4'-phenylbutanoyl)-p-(p-dimethylamino)-phenethyloxy-D-phenylglycine (Diastereoisomer B)

The diastereoisomer B methyl ester (48mg, 0.09mmol) from Description 97 was suspended in methanol (2ml) and treated with a solution of sodium sulphide nonahydrate (82mg, 0.34mmol) in water (2ml). The suspension was stirred under argon for 4 hours. The reaction mixture was then washed with ethyl acetate and the aqueous layer acidified by addition of 5M hydrochloric acid solution (10 drops) and then extracted with ethyl acetate. The organic layer was washed with water and dried ($MgSO_4$). Removal of the solvent afforded the desired product as a crisp foam (27mg). δ_H ($CHCl_3$) 1.7 (1H, m), 1.8 (2H, m), 2.4-2.6 (3H, m), 2.8-3.0 (4H, m), 2.92 (6H, s), 4.17 (2H, m), 5.50 (1H, d, J 6.5 Hz), 6.60 (1H, d, J 6.5 Hz), 6.7-7.3 (13H, m) ppm. ESMS MH^+ 507.

Example 67

N-(2'-RS-mercaptomethyl-4'-phenylbutanoyl)-p-(N-methyl-3-pyridiniummethoxy)-D-phenylglycinate (Diastereoisomers A and B)

The mixture of diastereoisomeric methyl esters (110mg, 0.17mmol) from Description 98 was suspended in methanol (2ml) and treated with a solution of sodium sulphide nonahydrate (163mg, 0.68mmol) in water (2ml). The suspension was stirred under argon for 1.5 hours. The reaction mixture was adjusted to pH 6.5 by the addition of

1M hydrochloric acid and the solvent removed under reduced pressure to afford the desired product as a yellow solid (contaminated with sodium chloride). δ_H (DMSO- d_6) *inter alia* 4.38 (3H, s), 5.33 (2H, s), 5.38 (1H, m), 6.76 (1H, m), 8.15 (1H, m), 8.62 (1H, m), 9.00 (1H, m), 9.17 (1H, s) ppm.

5

Example 68

N-(2'-mercaptomethyl-4'-phenylbutanoyl)-p-(p-benzyloxy)-benzyloxy-D-phenylglycine (Diastereoisomer A)

The diastereoisomer A methyl ester (48mg, 0.08mmol) from Description 99 was
10 suspended in methanol (3ml) and treated with a solution of sodium sulphide nonahydrate (75mg, 0.31mmol) in water (1ml). The suspension was stirred under argon for 3 hours. The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (10 drops) and diluted with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (44mg).
15 δ_H (CDCl₃) 1.36 (1H, dd, J 9.2 and 8.3 Hz), 1.85 (1H, m), 2.0 (1H, m), 2.3-2.8 (5H, m), 4.93 (2H, s), 5.06 (2H, s), 5.54 (1H, d, J 6.4 Hz), 6.48 (1H, d, J 6.4 Hz), 6.9 (4H, – overlapping d), 7.1-7.4 (14H, m) ppm. ESMS [M-H]⁻ 554.

Example 69

20 **N-(2'-mercaptomethyl-4'-phenylbutanoyl)-p-(p-benzyloxy)-benzyloxy-D-phenylglycine (Diastereoisomer B)**

The diastereoisomer B methyl ester (48mg, 0.08mmol) from Description 99 was
suspended in methanol (3ml) and treated with a solution of sodium sulphide nonahydrate (75mg, 0.31mmol) in water (1ml). The suspension was stirred under argon for 3 hours.
25 The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (10 drops) and diluted with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (44mg).
 δ_H (CDCl₃) 1.74 (1H, m), 1.85 (1H, m), 2.0 (1H, m), 2.3-2.8 (5H, m), 4.91 (2H, s), 5.03 (2H, s), 5.51 (1H, d,), 6.50 (1H, d), 6.9 (4H, overlapping d), 7.1-7.4 (14H, m) ppm.
30 EIMS [M-H]⁻ 554.

Example 70

N-(2'-mercaptomethyl-4'-phenylbutanoyl)-p-(p-trifluoromethoxy)-benzyloxy-D-phenylglycine (Diastereoisomer A)

35 The diastereoisomer A methyl ester (60mg, 0.10mmol) from Description 100 was suspended in methanol (4ml) and treated with a solution of sodium sulphide nonahydrate (98mg, 0.41mmol) in water (2ml). The suspension was stirred under argon for 3 hours.

The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (10 drops) and diluted with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (50mg).

5 δ_H (CDCl₃) 1.34 (1H, t, J 8.8 Hz), 1.85 (1H, m), 2.0 (1H, m), 2.3-2.8 (5H, m), 5.02 (2H, s), 5.55 (1H, d, J 6.4 Hz), 6.55 (1H, d, J 6.4 Hz), 6.94 (2H, d, J 8.6 Hz), 7.2-7.4 (1H, m) ppm. ESMS [M-H]⁻ 532.

Example 71

10 N-(2'-mercaptomethyl-4'-phenylbutanoyl)-p-(p-trifluoromethoxy)-benzyloxy-D-phenylglycine (Diastereoisomer B)

The diastereoisomer B methyl ester (63mg, 0.11mmol) from Description 100 was suspended in methanol (4ml) and treated with a solution of sodium sulphide nonahydrate (103mg, 0.43mmol) in water (2ml). The suspension was stirred under argon for 3 hours. The reaction mixture was then acidified by addition of 5M hydrochloric acid solution (10 drops) and diluted with ethyl acetate. The organic layer was washed with water and dried (MgSO₄). Removal of the solvent afforded the desired product as a crisp foam (56mg).

15 δ_H (CDCl₃) 1.75 (1H, dd, J 9.9 and 7.7 Hz), 1.85 (1H, m), 2.0 (1H, m), 2.3-2.8 (5H, m), 5.04 (2H, s), 5.55 (1H, d, J 6.5 Hz), 6.53 (1H, d, J 6.5 Hz), 7.0-7.5 (13H, m) ppm. ESMS [M-H]⁻ 532.

20

BIOLOGICAL ACTIVITY

I₅₀ screen

The inhibitory activity of the compounds of the invention was measured in 25mM PIPES pH 7 buffer at 10 concentrations (1000, 333, 111, 37, 12.3, 4.1, 1.4, 0.46, 0.15 and 0.05 μ M) at 37°C using nitrocefin (91 μ M final concentration) as the reporter substrate. The assays were performed with a 5 minute preincubation of enzyme and inhibitor and were conducted in the presence of added zinc sulphate (Zn²⁺ 100 μ M; final concentration). the methodology is described in detail in the following references: Payne *et al* (1991), *J. Antimicrob. Chemother.*, 28:255; Payne *et al* (1994), *Antimicrob. Agents and Chemother.*, 38:767.

25
30

Results

Compounds of the Examples exhibit I₅₀ values against *B. fragilis* CfiA metallo- β -lactamase of <1000 μ M. The I₅₀ values for Examples 3, 4, 6-17, 19, 21, 24-33, 34 (more polar isomer) 35-38, 40-42, 44-46, 48, 50, 53, 55, 56, 58-64, 66, 67 and 69 were <1 μ M.

35

All compounds of the above Examples exhibited significant inhibition of the *Stenotrophomonas maltophilia* L-1 (formerly *Xanthomonas maltophilia* L-1) and *Bacillus cereus* II metallo- β -lactamases, with I_{50} values in the range 0.2-100 μ M.

5

Antibacterial activity of compounds of the invention in combination with the carbapenem antibiotic, meropenem, against the *Bacteroides fragilis* 262 strain, which produces CfiA metallo- β -lactamase:-

[MIC = minimum inhibitory concentration (μ g/ml)]

10


Antibacterial activity of meropenem was potentiated as follows:-

MIC (μ g/ml) of meropenem alone: >128

Inhibitor compound	MIC (μ g/ml) of compound alone	MIC (μ g/ml) of meropenem in the presence of 8 μ g/ml of compound
Example 4	>256	32
Example 24	>256	32
Example 26	>256	16

Claims


1. A compound of formula (I) or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof:




wherein:

R is hydrogen, a salt forming cation or an *in vivo* hydrolysable ester-forming group;

10 R_1 is selected from



(a)



(b)

in which A is a monocyclic aryl or heteroaryl ring and B is a monocyclic aryl, alicyclic or heterocyclic ring, C and D are independently $-Z_p-(CR_8CR_9)_q-$ or

15 $-(CR_8CR_9)_q-Z_p$ where p is 0 or 1, q is 0 to 3 provided that p + q in C is not 0, R_8 and R_9 are independently hydrogen or (C_{1-6}) alkyl or together represent oxo and Z is O, NR_{10} or $S(O)_x$ where R_{10} is hydrogen, (C_{1-6}) alkyl or aryl (C_{1-6}) alkyl and x is 0-2, and wherein C and D are linked ortho to one another on each of rings A and B in formula (b);

R_2 is hydrogen, (C_{1-6}) alkyl or aryl (C_{1-6}) alkyl;

20 R_3 is hydrogen, (C_{1-6}) alkyl optionally substituted by up to three halogen atoms, (C_{3-7}) cycloalkyl, fused aryl (C_{3-7}) cycloalkyl, (C_{3-7}) cycloalkyl (C_{2-6}) alkyl, (C_{2-6}) alkenyl, (C_{2-6}) alkynyl, aryl, aryl $-(CH_2)_m-X-(CH_2)_n$, heterocyclyl or heterocyclyl $-(CH_2)_m-X-(CH_2)_n$, where m is 0 to 3, n is 1 to 3 and X is O, $S(O)_x$ where x is 0-2 or a bond;

R_4 is hydrogen, or an *in vivo* hydrolysable acyl group; and

25 R_5 and R_6 are independently hydrogen and (C_{1-6}) alkyl or together represent $(CH_2)_r$ where r is 2 to 5.

2. A compound according to claim 1 wherein R_1 is formula (a) and ring A is selected from 2,5-thienyl, 2,5-furyl, 1,2-phenyl, 1,3-phenyl and 1,4-phenyl, ring B is selected from phenyl optionally substituted by one or two hydroxy or by methoxy,


30 dimethylamino, carboxy or nitro, 2-furyl, 2-, 3- or 4-pyridyl, 1-tetrazolyl, 2-tetrazolyl, 1-

- triazolyl, 2-triazolyl, 2 thienyl and imidazolin-2,5-dione-1-yl and C is selected from CH₂, O or OCH₂.
3. A compound according to claim 1 wherein R₁ is formula (b), rings A and B are both phenyl, C is O, CH₂ or NR₁₀ and D is a bond (p+q=0).
 - 5 4. A compound according to claim 1 wherein R₁ is selected from (5-benzyl)thien-2-yl, (5-benzyl)furan-2-yl, 5-(1-tetrazolylmethyl)thien-2-yl, 5-(2-tetrazolylmethyl)thien-2-yl, 5-(imidazolin-2,5-dione-1-ylmethyl)thien-2-yl, 5-(1-triazolylmethyl)thien-2-yl, 5-(2-triazolylmethyl)thien-2-yl, 3-phenoxyphenyl, 2-phenoxyphenyl, 4-phenoxyphenyl, 3-(4-hydroxybenzyl)phenyl, 3-(4-methoxybenzyl)phenyl, 4-benzyloxyphenyl, 4-(2-thienylmethyloxy)phenyl, 1-fluorenyl, 3-(N-ethylcarbazolyl) 4-hydroxybenzyloxy-4-phenyl, 4-methoxybenzyloxy-4-phenyl, 4-dimethylaminobenzyloxy-4-phenyl, 4-carboxybenzyloxy-4-phenyl, 3-carboxybenzyloxy-4-phenyl, (2-pyridyl)-methoxy-4-phenyl, (4-pyridyl)-methoxy-4-phenyl, 5-[1-(4-carbamoyltriazolyl)-methyl]-thien-2-yl, 5-[1-(4-carboxytriazolyl)-methyl]-thien-2-yl, (2-furyl)-methoxy-4-phenyl and
15 dibenzofuranyl.
 5. A compound according to claim 1 wherein R₁ is 4-benzyloxyphenyl 3- or 4-substituted in the benzyl group by a substituent selected from halogen, mercapto, (C₁₋₆)alkyl optionally substituted by 1-3 halo, phenyl, phenyl(C₁₋₆)alkyl, phenyl(C₁₋₆)alkoxy, (C₁₋₆)alkoxy optionally substituted by 1-3 halo, hydroxy(C₁₋₆)alkyl, mercapto(C₁₋₆)alkyl, hydroxy, CO₂R₇, N(R₇)₂ or CON(R₇)₂ where each R₇ is
20 independently hydrogen, (C₁₋₆) alkyl or (C₁₋₆) alkanoyl, OCONH₂, nitro, (C₁₋₆) alkylcarbonyloxy, (C₁₋₆)alkoxycarbonyl(C₁₋₆) alkyl, formyl and (C₁₋₆) alkylcarbonyl groups.
 6. A compound according to any preceding claim wherein R₂ is hydrogen, methyl
25 or benzyl.
 7. A compound according to any preceding claim wherein R₂ is hydrogen.
 8. A compound according to any preceding claim wherein R₃ is selected from methyl, isobutyl, phenyl-(CH₂)₁₋₅, phenoxyethyl, 1-indanyl, 3,4-dihydroxybenzyl, 4-hydroxycarbonyl-phenylethyl, 2-trifluoromethylquinolin-6-yl, 4-difluoromethoxy-phenylethyl and 3-methyl-2,4,5-tricarbonylimidazol-1-yl.
 - 30 9. A compound according to any preceding claim wherein R₄ is hydrogen and R₅ and R₆ are independently hydrogen or methyl.
 10. A compound according to any preceding claim wherein the stereochemistry at the carbon atom marked * is D-.
 - 35 11. A compound according to any preceding claim wherein the stereochemistry at the carbon atom marked (+) is S.

12. N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*m*-benzyl-phenylglycine
(Diastereoisomer A or B).
13. N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*m*-phenoxy-phenylglycine
(Diastereoisomer A or B).
- 5 14. N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*m*-(*p*-methoxybenzyl)-phenylglycine
(Diastereoisomer A or B)
15. N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*m*-benzyloxy-phenylglycine.
16. N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*m*-(*p*-hydroxybenzyl)-phenylglycine.
17. N-(2'-mercaptomethyl-4'-phenylbutanoyl)-(1-fluorenyl)glycine.
- 10 18. N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*o*-phenoxy-phenylglycine
(Diastereoisomer A or B).
19. N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*p*-phenoxy-phenylglycine
(Diastereoisomer A or B).
20. N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*m*-(*p*-methoxyphenoxy)-phenylglycine
15 (Diastereoisomer A or B).
21. N-(2'-mercaptomethyl-4'-phenylbutanoyl)-(N-Ethyl-3-carbazolyl)glycine
(Diastereoisomer A or B).
22. N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*p*-benzyloxy-D-phenylglycine
(Diastereoisomer A or B).
- 20 23. N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*p*-(2"-thienylmethoxy)-D-
phenylglycine (Diastereoisomer A or B).
24. N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*p*-(*p*-carboxy)-benzyloxy-D-
phenylglycine (Diastereoisomer A or B).
25. 2-[(5-Benzyl)thien-2-yl]-N-[2-(mercaptomethyl)-4-phenylbutyryl]glycine.
- 25 26. 2-[(5-Benzyl)furan-2-yl]-N-[2-(mercaptomethyl)-4-phenylbutyryl]glycine.
27. 2-[5-(Tetrahydrofuran-3-ylmethyl)thien-2-yl]-N-[2-(mercaptomethyl)-4-
phenylbutyryl]glycine.
28. 2-[5-(1-Tetrazolylmethyl)thien-2-yl]-N-[2-(mercaptomethyl)-4-
phenylbutyryl]glycine.
- 30 29. 2-[5-(2-Tetrazolylmethyl)thien-2-yl]-N-[2-(mercaptomethyl)-4-
phenylbutyryl]glycine.
30. 2-[5-(1,2,3-Triazol-1-ylmethyl)thien-2-yl]-N-[2-(mercaptomethyl)-4-
phenylbutyryl]glycine.
31. 2-[5-(1,2,3-Triazol-2-ylmethyl)thien-2-yl]-N-[2-(mercaptomethyl)-4-
35 phenylbutyryl]glycine.
32. 2-[5-(Imidazolidin-2,4-dion-3-ylmethyl)thien-2-yl]-N-[2-(mercaptomethyl)-4-
phenylbutyryl]glycine.

33. 2-[5-(4-methoxybenzyl)thien-2-yl]-N-[2-(mercaptomethyl)-4-phenylbutyryl]glycine.
34. 2-[(5-Benzyl)furan-2-yl]-N-[2-(mercaptomethyl)-3-phenylpropionyl]glycine.
35. 2-[(5-Benzyl)thien-2-yl]-N-[2-(mercaptomethyl)-4-phenylbutyryl]glycine.
- 5 36. 2-[5-(4,5-Dicarboxytriazol-1-ylmethyl)thien-2-yl]-N-[2-(mercaptomethyl)-4-phenylbutyryl]glycine.
37. 2-[5-(4-Carboxamidotriazol-1-ylmethyl)thien-2-yl]-N-[2-(mercaptomethyl)-4-phenylbutyryl]glycine.
38. 2-[5-(4-Carboxytriazol-1-ylmethyl)thien-2-yl]-N-[2-(mercaptomethyl)-4-phenylbutyryl]glycine.
- 10 39. 2-[5-(5-Carboxytriazol-1-ylmethyl)thien-2-yl]-N-[2-(mercaptomethyl)-4-phenylbutyryl]glycine.
40. N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*p*-(*p*-methoxy)-benzyloxy-D-phenylglycine (Diastereoisomer A or B).
- 15 41. N-(2'-mercaptomethyl-4'-phenylbutanoyl)-(3"-dibenzofuranyl) glycine (Diastereoisomer A or B).
42. N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*p*-(2"-furanylmethoxy)-D-phenylglycine (Diastereoisomer A or B).
43. N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*p*-(*p*-hydroxy)-benzyloxy-D-phenylglycine (Diastereoisomer A or B).
- 20 44. N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*p*-(*p*-dimethylamino)-benzyloxy-D-phenylglycine (Diastereoisomer A or B).
45. N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*p*-(*m*-carboxy)-benzyloxy-D-phenylglycine (Diastereoisomer A or B).
- 25 46. N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*p*-(3,4-dihydroxy)-benzyloxy-D-phenylglycine (Diastereoisomer A or B).
47. N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*p*-(*p*-nitro)-benzyloxy-D-phenylglycine (Diastereoisomer A or B).
48. N-(2'-*RS*-mercaptomethyl-4'-phenylbutanoyl)-*p*-(4-pyridylmethoxy)-D-phenylglycine.
- 30 49. N-(2'-*RS*-mercaptomethyl-4'-phenylbutanoyl)-*p*-(2-pyridylmethoxy)-D-phenylglycine.
50. N-(2'-*RS*-mercaptomethyl-4'-phenylbutanoyl)-*p*-(3-pyridylmethoxy)-D-phenylglycine.
- 35 51. N-(2'-*RS*-mercaptomethyl-4'-phenylbutanoyl)-*p*-(*p*-acetamido)-benzyloxy-D-phenylglycine.

52. N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*m*-(*m*-carboxy)-benzyloxy-D-phenylglycine (Diastereoisomer A or B).
53. N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*m*-(*p*-carboxy)-benzyloxy-D-phenylglycine (Diastereoisomer A or B).
- 5 54. N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*p*-(*m*-amino)-benzyloxy-D-phenylglycine (Diastereoisomer A or B).
55. N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*p*-(*p*-dimethylamino)-phenethyloxy-D-phenylglycine (Diastereoisomer A or B).
56. N-(2'-*RS*-mercaptomethyl-4'-phenylbutanoyl)-*p*-(N-methyl-3-pyridiniummethoxy)-D-phenylglycinate.
- 10 57. N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*p*-(*p*-benzyloxy)-benzyloxy-D-phenylglycine (Diastereoisomer A or B).
58. N-(2'-mercaptomethyl-4'-phenylbutanoyl)-*p*-(*p*-trifluoromethoxy)-benzyloxy-D-phenylglycine (Diastereoisomer A or B).
- 15 59. A process for the preparation of a compound according to claim 1, which comprises reacting a compound of formula (II)




20 with a compound of formula (III)



- wherein W is a leaving group, Y is Y' where Y' is R₄'S or a group convertible thereto and R₁₁ is H, or Y and R₁₁ together form a bond, R^X is R or a carboxylate protecting group, X¹ is N₃ or NHR₂' and R₁', R₂', R₃', R₄', R₅' and R₆' are R₁, R₂, R₃, R₄, R₅ and R₆ or groups convertible thereto, wherein R, R₁, R₂, R₃, R₄, R₅ and R₆ are as defined in claim 1, and thereafter, where Y and R₁₁ form a bond, reacting the product with a nucleophilic sulphur reagent Y'H, where necessary, converting Y' into R₄'S, R^X, R₁', R₂', R₃', R₄', R₅' and/or R₆' into R, R₁, R₂, R₃, R₄, R₅ and/or R₆ and optionally inter-converting R, R₁, R₂, R₃, R₄, R₅ and/or R₆.
- 25 60. A pharmaceutical composition comprising a compound according to claim 1 together with a pharmaceutically acceptable carrier.
61. A pharmaceutical composition according to claim 60 which additionally
- 30 62. A compound according to claim 1 for use in the treatment of bacterial infections.

63. The use of a compound according to claim 1, in the manufacture of a medicament for the treatment of bacterial infections
64. A method of treatment of bacterial infections in humans or animals which comprises administering, in combination with a β -lactam antibiotic, a therapeutically effective amount of a compound of claim 1.
65. A compound of formula (IV):



10

- wherein the variables are as defined in claim 59, provided that R^x is other than R when R_1' , R_2' , R_3' , R_4' , R_5' and R_6' are R_1 , R_2 , R_3 , R_4 , R_5 and R_6 and excluding:
- N*-[2'-Benzyl-3'-mercaptopropionyl]-3-hydroxyphenylglycine;
- N*-[S-Acetyl-2'-benzyl-3'-mercaptopropionyl]-3-hydroxyphenylglycine methyl ester;
- 15 *N*-[2'-Benzyl-3'-mercaptopropionyl]-4-hydroxy-D-phenylglycine;
- N*-[S-Acetyl-2'-benzyl-3'-mercaptopropionyl]-4-hydroxy-D-phenylglycine ethyl ester;
- N*-[2'-Benzyl-3'-mercaptopropionyl]-4-hydroxy-3-nitrophenylglycine;
- N*-[S-Acetyl-2'-benzyl-3'-mercaptopropionyl]-4-hydroxy-3-nitrophenylglycine methyl ester;
- 20 *N*-[2'-Benzyl-3'-mercaptopropionyl]-3,4-dihydroxy-D-phenylglycine; and
- N*-[S-Acetyl-2'-benzyl-3'-mercaptopropionyl]-3,4-dihydroxy-D-phenylglycine methyl ester.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 97/05709

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07C323/60 C07D209/86 C07D333/16 C07D333/24 C07D307/54
C07D409/06 C07D307/91 C07D307/12 C07D213/30 A61K31/195
A61K31/40 A61K31/38 A61K31/41 A61K31/415 A61K31/34

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07C A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	J.L. STANTON, ET AL.: "Angiotensin converting enzyme inhibitors: N-substituted monocyclic and bicyclic amino acid derivatives" JOURNAL OF MEDICINAL CHEMISTRY, vol. 26, no. 9, September 1983, WASHINGTON, DC, US, pages 1267-1277, XP002055899 cited in the application see table I --- -/-	1,60



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

17 February 1998

Date of mailing of the international search report

05.03.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

English, R

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 97/05709

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	M.-C. FOURNIE-ZALUSKI, ET AL.: "New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: rational design, bioavailability, and pharmacological response in experimental hypertension" JOURNAL OF MEDICINAL CHEMISTRY, vol. 37, no. 8, 15 April 1994, WASHINGTON, DC, US, pages 1070-1783, XP002019771 cited in the application see tables 2-7	1,60
P,A	--- WO 97 30027 A (SMITHKLINE BEECHAM) 21 August 1997 cited in the application see page 2 - page 3; examples 11,12,14,15 --- -/-	1,60-65



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

17 February 1998

Date of mailing of the international search report

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

English, R

INTERNATIONAL SEARCH REPORT

Intern. Application No

PCT/EP 97/05709

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FR 2 323 680 A (NOBEL HOECHST CHIMIE) 8 April 1977 see examples 5,7 ---	65
X	M. IHARA, ET AL.: "Synthesis of beta-lactam antibiotics by the sulpheno-cycloamination" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 105, no. 25, 14 December 1983, WASHINGTON, DC, US, pages 7345-7352, XP002055900 see compound 26 ---	65
X	H.H. WASSERMAN, ET AL.: "The synthesis of beta-lactams by the cyclisation of beta-halopropionamides" TETRAHEDRON LETTERS, no. 6, February 1979, OXFORD, GB, pages 549-552, XP002055901 see table II, 5th entry, compound 5 -----	65

INTERNATIONAL SEARCH REPORT

Int'l application No.
PCT/EP 97/05709

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/EP 97/05709

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

Claims Nos.: -

because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

Claim 65: The expressions "a carboxylate protecting group" and "groups convertible thereto" used in the definitions of the variables Rx, R1', R2', R3', R4', R5' and R6' (in Claim 59) are not explicit and it is impossible to determine what groups are meant by them. On the basis of the compounds excluded by name and Descriptions 32 and 93 in the description, the search for compounds of this claim in which R1' is not R1 has been directed towards compounds in which R1' is a hydroxyphenyl group.

Remark : Although claim 64 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 97/05709

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9730027 A	21-08-97	AU 1766997 A	02-09-97

FR 2323680 A	08-04-77	BE 843994 A	10-01-77
		CA 1066304 A	13-11-79
		CH 614928 A	28-12-79
		DE 2640615 A	17-03-77
		GB 1520824 A	09-08-78
		JP 52036644 A	22-03-77
		NL 7609939 A	15-03-77
		SE 7610064 A	13-03-77
		SE 7610065 A	13-03-77
		US 4105690 A	08-08-78
